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Abstract
Introduction: Individually randomised controlled trials (iRCTs) of complex interventions com-
monly induce clustered outcomes in the intervention arm only, termed partially nested trials
(pnRCTs). In addition, iRCTs are increasingly used to evaluate interventions delivered propor-
tionate to individual need. This can result in only some of the intervention arm having clustered
outcomes due to post randomisation allocation to clusters, termed within-arm pnRCTs.
Research question: What elements need to be considered in the design, analysis and reporting
of complex intervention trials with continuous outcomes, with a particular focus on proportionate
interventions and intervention induced clustering in one trial arm?
Methods: Firstly, a systematic review of trials of proportionate interventions was performed.
Simulation of pnRCTs and within-arm pnRCTs were used to investigate appropriate analysis
methods. Sample size formulae for such RCTs were identified and summarised. Finally, a review
of publicly funded iRCTs with clustering was undertaken.
Results: Proportionate interventions commonly induced within-arm partial nesting. Appropri-
ate analysis methods were identified and demonstrated for pnRCTs, although with few clusters,
small cluster sizes, and small intracluster correlation coefficient (ICC) there was no optimal
method. Accounting for non-random clustering in within-arm pnRCTs was not possible; how-
ever, under realistic scenarios ignoring clustering can provide valid statistical inference. Sample
size formulae for pnRCTs require an ICC estimate. From 15 publicly funded iRCTs the me-
dian healthcare provider ICC was 0.009. To improve transparency an additional Consolidated
Standards of Reporting Trials-nonpharmacologic treatments item related to reporting ICC is
suggested.
Conclusions: This thesis demonstrates the extent of clustering in both proportionate inter-
vention trials and publicly funded iRCTs. Appropriate analysis methods are demonstrated for
pnRCTs. For within-arm pnRCTs it is typically recommended to ignore the clustering. Sam-
5
ple size methods are summarised and empirical ICCs provided. This work provides practical
guidance for design, analysis and reporting for continuous outcomes in RCTs with intervention
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In recent decades there has been an increasing acceptance and emphasis on evidence based
healthcare, the aim of delivering and making informed healthcare decisions through the use of
sound research and evidence evaluation [1]. Resources for any healthcare system are limited,
consequently rational policies and decision making will ideally use these limited resources to
provide and implement interventions that have been proven to be both effective and cost-effective
through well designed research and evaluation.
Randomised controlled trials (RCTs) play a central role in building this evidence as they are gen-
erally considered the gold standard for evaluating the effectiveness of interventions in healthcare.
The term intervention defines an activity undertaken with the purpose of improving, assessing,
promoting or modifying health or health conditions. RCTs have been widely used to evaluate the
effectiveness of pharmacological interventions. There has also been a move in public health, pri-
mary care and educational research towards evaluating the effectiveness of non-pharmacological
complex interventions. Complex interventions are conventionally those that are made up of a
variety of interacting components [2]. For example, evaluating weight management groups for
obesity, surgical interventions, and delivery methods of a psychotherapy intervention.
Individually randomised controlled trials (iRCTs) of complex interventions commonly induce
clustered outcomes in the intervention arm only, termed partially nested trials (pnRCTs). RCTs
are also being used to evaluate the effectiveness of complex interventions delivered proportionate
to individual need. This can result in only some of the intervention arm having clustered
outcomes due to post randomisation allocation to clusters, termed within-arm pnRCTs.
Appropriate statistical design and analysis of RCTs are required to enable valid and useful
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conclusions to be made. The design and analysis of iRCTs evaluating complex interventions
are improving; however, there is need for improved understanding. The overarching research
question of this thesis is: what elements need to be considered in the design, analysis and
reporting of complex intervention trials with continuous outcomes, with a particular focus on
proportionate interventions and intervention induced clustering in one trial arm.
1.1 Chapter aims
This chapter aims to introduce a motivating example, the E-SEE trial design, providing a brief
overview of the trial in order to present the various complexities that can arise. The thesis
research question and research aims are then introduced. The chapter will conclude with an
overview of the thesis structure.
1.2 Motivating example: the E-SEE trial
Much of the motivation for this thesis originated from discussion regarding the design and anal-
ysis of the multi-centre E-SEE (Enhancing Social-Emotional health and wellbeing in the Early
years) trial. The E-SEE trial aims to evaluate the effectiveness of a community based implemen-
tation of the Incredible Years (IY) group-based parenting programme, delivered proportionate to
need [3]. The trial is funded through the National Institute for Health Research (NIHR) Public
Health Research programme call asking the research question “What are the effective and cost-
effective interventions to promote social and emotional wellbeing among children aged under 2
years?”. Figure 1.1 shows the NIHR call [4], focussing on proportionate universal interventions
[5] considering the impact on health inequalities.
The E-SEE trial aims to deliver IY as a proportionate universal intervention based on assessment
of need. The research question is: “Are the IY-Infant (IY-I) and IY-Toddler (IY-T) programmes,
when delivered in a dose proportionate to need, and when compared to services as usual, effective
and cost-effective in enhancing child social and emotional well-being at 20 months of age?”. At
the time of writing this thesis the E-SEE trial is still ongoing and this PhD has been running
in parallel with the trial.
Participants were randomised at the individual level to one of two trial arms: control arm (care
as usual) or IY intervention arm. The IY intervention arm consists of a proportionate delivery of
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Figure 1.1: NIHR PHR programme May 2013: 13/93 Social and Emotional Wellbeing in Early
Years
three levels of the IY intervention program. Within the IY intervention arm IY-Baby is issued
at the universal level to all. At two months, parents are offered the group based IY-Infant
if they are showing levels of stress or mild depression (PHQ-9 score of ≥5), comprised of 10
weekly parenting group sessions (2 -9 months). Parents are assessed again at nine months and
offered IY-Toddler if they show signs of stress or mild depression, comprised of weekly group
parenting sessions (9-18 months). The E-SEE trial is an individually randomised controlled
trial, with treatment induced clustering in one arm of the trial. Group sessions are delivered to
groups of parents in local centres by trained facilitators, delivered in a number of authorities,
with different facilitators at local centres. The clustering only occurs at certain stages of the
intervention (clustering by group based intervention at IY-Infant and IY-Toddler). Clustering
occurs in only one arm of the trial (partial nesting) and for only some individuals in that trial
arm (within-arm partial nesting).
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The original trial design aimed to evaluate the overall effectiveness of all three levels of the IY
programme and the individual effectiveness of each level being investigated. The E-SEE design
presents particular challenges for both the design and analysis of the trial and led to the initial
idea of exploring this in depth as a PhD. Further exploration of the wider topic informed the
generation and refining of the research objectives.
1.3 Research question
As highlighted above the focus of this thesis is to answer the research question: what elements
need to be considered in the design, analysis and reporting of complex intervention trials with
continuous outcomes, with a particular focus on proportionate interventions and intervention
induced clustering in one trial arm?
1.4 Research aims
The specific thesis aims to address the research question are:
1. To review current practice of how randomised trials of proportionate interventions are
designed and analysed and the extent of clustering in such trials.
2. To evaluate commonly used analysis methods for partially nested randomised trials and
within-arm partially nested randomised trials to establish which methods are most appro-
priate and why.
3. To identify and collate a comprehensive summary and resource for sample size methods
available for partially nested randomised trials.
4. To determine the extent and quality of reporting of clustering in iRCTs with intervention
induced clustering and provide empirical estimates of ICCs.
1.5 Thesis Structure
In this chapter the E-SEE trial has been presented as an example of the various complexities
that arise from randomised trials of complex interventions, focusing on the two key themes of
proportionate interventions and treatment induced clustering. The research objectives of this
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thesis are introduced. A description of the thesis structure and what each chapter includes
follows.
Chapter 2 provides a conceptual framework and background for this thesis reviewing the public
health and statistical literatures. Key terminology and concepts are defined, including complex
intervention, proportionate universalism and proportionate interventions. Randomised con-
trolled trial (RCT) designs are introduced including individual, cluster, partially nested, and
within-arm partially-nested RCTs. Implications for the precision of treatment effects are given
for statistical analyses and sample size, describing how the statistical analysis and reporting of
a trial needs to correspond to the features of the design. Aspects of clustering including, types
of clustering, quantifying clustering, and defining and calculating the intracluster-correlation
coefficient (ICC) are introduced.
The framework is used in chapter 3 to structure a systematic review to address the aim of
reviewing how randomised trials of proportionate interventions are designed and analysed in
practice and the extent of clustering in such trials. The systematic review identifies trials of
proportionate interventions, categorised as either stepped-care or optimal intervention strategy
studies. The search strategy and eligibility criteria for selecting the trials are provided. Data is
extracted and summarised on the therapeutic area, stages and decision rules of the intervention,
statistical analysis used, whether different intervention stages were analysed and the frequency
and treatment induced clustering. The most common therapeutic area is mental health and
treatment induced clustering is present in the majority of trials identified.
Chapters 4 and 5 address the aim of evaluating appropriate statistical methods for analysing
trials with nested outcomes in one trial arm. Chapter 4 summarises analysis models commonly
employed for pnRCTs and evaluates these through a simulation study. The literature to date
is considered, the issue of degrees of freedom, and the lack of clear guidance highlighted. The
simulation study emulates pnRCTs over various scenarios of cluster size, number of clusters,
ICC and both homoscedastic and heteroscedastic individual variances. Six analysis methods
are compared in terms of bias, Type I error, ICC estimation, and power. Recommendations
regarding the appropriate analysis method to use are presented in relation to the design of the
study. Model fitting code is presented for R, Stata and SAS. The simulation code is given in an
appendix.
Chapter 5 extends the case of pnRCTs to those similar to E-SEE and seen in the systematic
review in chapter 3. Randomised trials which introduce within-arm partial nesting are further
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introduced and potentially appropriate statistical analysis methods are presented and reviewed
using a simulation study. Again, the simulation study emulates within-arm pnRCTs over various
scenarios of cluster size, and number of clusters. Recommendations regarding the appropriate
analysis method to use are presented in relation to the design of the study, the expected pro-
portion of participants with clustered outcomes and expected ICC. The simulation study only
considers one clustered intervention stage, trials which evaluate interventions with numerous
clustered intervention stages are discussed and the limitations this may have on accounting for
clustering in the analysis.
Chapter 6 reviews and collates sample size formulae and relevant statistical software for the
design of trials with clustering in one arm. The sample size formulae are outlined, building up
from individually randomised trials to cluster trials and finally to pnRCTs. The issue of within-
arm clustering is discussed in the context of sample size calculations and guidance provided in
relation to the simulation results in chapter 5. Practicalities of obtaining the values required for
these sample size formulas are discussed.
Chapter 7 investigates the extent, reporting, and evidence of clustering and ICCs in individ-
ually randomised trials published in the Health Technology Assessment (HTA) Journal, as a
representative source of publicly funded and reported trials in the UK. Trials with potential for
treatment induced clustering are selected. Extent of clustering is reported alongside how it has
been recognised in the design, analysis, and reporting. Reporting is assessed with adherence
to key items of the CONSORT-non-pharmacological treatments checklist related to clustering.
Evidence of ICCs used in sample size and empirical estimates of ICCs from the trials are pre-
sented, with the aim of raising awareness and informing current trial design and required sample
size calculations.
A discussion of the thesis is found in chapter 8. This is structured according to the aims, placing





RCTs of complex interventions raise numerous challenges in the design and analysis stages.
The E-SEE trial was presented in chapter 1 as a means to introduce the key themes of this
thesis: proportionate interventions and intervention induced clustering. RCTs are essential
for evaluating the effectiveness of health interventions, however, clustering and proportionate
delivery introduce additional complexity to the analysis of the trial.
This chapter provides background for the understanding and definition of complex interventions
in health, introducing the motivation for proportionate universalism, proportionate interventions
and focusing on the complexities that arise from clustered of outcome data and proportionate
interventions.
2.2 Chapter aims
The chapter introduces key terminology and concepts, including complex intervention, pro-
portionate universalism and proportionate interventions. Various types of RCT designs are
introduced. Implications for the precision of treatment effects are given for statistical analy-
ses and sample size, describing how the statistical analysis and reporting of a trial needs to
correspond to the features of the design. Aspects of clustering including, types of clustering,




Many interventions aimed at improving healthcare can be defined as complex interventions, in
that they are made up of multiple interacting components [6]. Trials of such interventions often
present their own specific challenges [7]. Complex interventions are defined here based on the
Medical Research Council (MRC) guidance [6] and the more recent work by Kühne et al. [8].
The role the researcher takes in defining an intervention simple or complex is also considered
[9].
Complex interventions are defined as those that are made up of several interacting components,
they are generally non-pharmacological interventions. The complexity may arise through [6]:
 Number of components and interactions between components;
 Number of different groups/organisational levels targeted by the intervention;
 Variability of outcomes;
 The degree of flexibility/tailoring of intervention permitted.
An intervention component is any aspect of the intervention that could potentially have an
effect on the efficacy of the intervention. A component can be part of the intervention content,
features that promote adherence or fidelity of delivery. The multiple components may target
different levels of the social-ecological model, designed to affect change at these different levels
[10]. For instance, an intervention can be delivered to the individual patient such as the OCTET
trial of low intensity cognitive behavioural therapy and guided self-help for obsessive compulsive
disorder [11]. They can be delivered at the community level such as the PLEASANT trial of a
letter sent from General Practice (GP) aimed at reducing childhood asthma exacerbation levels
[12]. Some interventions are delivered to the healthcare professional. The intervention can also
be delivered at the family level, for example, the ‘Families for Health’ trial of family based
childhood obesity treatment delivered to the whole family [13]. To add to the complexity, a
combination of these different levels can also occur within one trial. The multiple components
can affect the efficacy, effectiveness, and cost-effectiveness of the intervention.
Evaluation of complex interventions can raise difficulties due to the inherent features of the inter-
vention itself. Datta and Petticrew [14, p.16] state that “the literature on complex interventions
is thick with descriptions of complex, challenging interventions, but thin on practical advice on
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how these should be dealt with”. RCTs of complex interventions are sometimes criticised as
being ‘black box’. It can be challenging to evaluate and understand both the effectiveness of
an intervention and how it works without examining underlying processes. This is something
the MRCs guidance [6, 15] on developing and evaluating complex interventions emphasises, the
importance of evaluating both the effectiveness of an intervention and how it works. These
guidelines breakdown the key elements of complex intervention framework into: development;
feasibility and piloting; evaluation; and implementation. Guidelines and frameworks for the
reporting of trials of complex interventions also exist [16, 17].
Petticrew [9] argues that there is not an easy divide between simple and complex interventions,
they are on a continuum and simple questions can be asked of complex interventions and vice
versa. These are considered pragmatic perspectives used by researchers and it is actually the
researchers perspective and research question that defines the simple and complex explanations of
an intervention. With this viewpoint a staged proportionate intervention (each stage a different
component), such as the IY intervention in the E-SEE trial, could be both simple and complex
dependent upon the analysis. A complex analysis may want to examine the effects of how and
whether the component parts work alone and together as well as the synergies between them.
A simpler analysis may focus on whether the intervention works as a whole package. It can be
difficult or impossible to identify whether it is a particular component of a complex intervention
that is causing the effect. In addition, some components may induce clustering in the outcome
due to the nature of the delivery of the intervention, for example, therapist led treatment or
group based treatment (this will be expanded upon in section 2.7). This is where the importance
of study design is key, to design a trial to answer the key research questions and to understand
how and for whom an intervention is working.
Multi-component interventions can be costly and resource intensive. Patient tailored or stratified
healthcare is becoming more common, and this principle can be applied to complex interventions.
The different components may not all be required or appropriate to individual need. One
approach to address this is the use of proportionate or adaptive interventions. Proportionate or
adaptive interventions are multi-component interventions given in a staged manner. In such an
approach participants receive a low intensity intervention, then individuals who do not respond
receive a more intense intervention component. Before explaining proportionate interventions,
the following section will discuss the origins and motivations of proportionate universalism which
was breifly introduced in chapter 1 through the E-SEE trial and the NIHR call [4].
29
2.4 Proportionate universalism
There are limits on healthcare funds, hence, proportionate universalism [5] is focussed on pro-
viding care for those who need it when they need it with the aim of reducing health inequalities.
The term proportion universalism originated from the Strategic Review of Health Inequalities
in England Marmot Review [5]. There is a strong case for local authorities to invest in tackling
health inequalities, benefits being both social and economic. Marmot et al. [5] writes:
“Focusing solely on the most disadvantaged will not reduce health inequalities suf-
ficiently. To reduce the steepness of the social gradient in health, actions must be
universal, but with a scale and intensity that is proportionate to the level of disad-
vantage. We call this proportionate universalism.” [5, p.15].
Marmot et al. [5] argued that universal healthcare has done little to reduce health inequalities.
Suggesting that consideration should be given to exploring different ways complex interventions
could be administered in order to reach those most in need, improve health, and reduce in-
equalities. In 2012 the National Institute for Health and Care Excellence (NICE) stated that
only 0.4% of public health research had been focussed on interventions aimed to improve health
inequalities [18]. Since the Marmot Review [5] there has been an increased interest in the im-
portance the social gradient in health can have throughout society, it does not just affect those
at the very low socio-economic statuses but is graded throughout the population [19].
Many standard interventions can actually increase health inequalities. The affluent often access
interventions with higher frequency than the more deprived, thus, though the interventions may
improve the health of those who receive the interventions they are actually leading to an increase
in health inequalities due to access to services and interventions [5]. The universal level of a
proportionate intervention is aimed at bringing the general health of the whole population of
interest up and then targeting additional stages of the proportionate intervention to those in
need.
Proportionate universalism may be interpreted in varying manners, from the development of
direct health interventions for those in most need to dose-response interventions with tailoring
of the intensity of interventions proportionate to need. A recent framework for the application of
proportionate universalism [20] argued that interventions in a proportionate universalist set-up
need to be applied to some degree to the whole population (the universal level), rather than
only to those most disadvantaged. Targeting specific groups risks labelling these groups and
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thus the associated stigmas that come with labelling. However, proportionate universalism will
incorporate a level of selectivism based on an individuals needs (the proportionate level) and in
turn this will require some targeting. Few systems or policies are truly universal; some argue that
the need for judgements restricts universalism through the decisions of who gets what service
[20].
The principle and terminology of proportionate universalism has been taken up largely in the
fields addressing parent [21, 22] and child health [19, 23–26], including mental health [26], all
focal in the Marmot Review [5]. The literature varies from narrative articles, qualitative studies,
to quantitative analyses of observational data identifying health inequalities.
A key focus of studies which mention proportionate universalism has been on promoting the
best start for a child in the early years, significant in developmental processes that shape the
rest of life [19]. Unequal access to services is central to the inequalities in child health and
development, these inequalities increase as a child grows up [19]. The studies pointed to a lack
of evidence on how to promote child health and development in an equitable way even though
there is a large amount of evidence and discourse of its importance [19, 27].
A number of reviews exist aiming to identify interventions that promote health equality for
children [23, 26]. The scoping review by Welsh et al. [26] focussed on interventions to promote
mental health well-being and reduce inequalities in children in high-income countries. Out of
more than 1000 potentially relevant interventions, none were understood to follow a propor-
tionate universalism framework, they were either targeted or universal. Some of the universal
programmes somewhat emphasised inequalities by benefiting the advantaged children more,
whereas others found stronger effect sizes for the most disadvantaged. This emphasizes the
importance of a proportionate universalism framework, providing appropriate healthcare for all,
not merely those at the top or bottom of the socio-economic scale. A systematic review by
Morrison et al. [23] identified 23 universal, targeted and proportionate parenting interventions
in European countries (1999-2013) which aimed to reduce inequalities in child health and de-
velopment. However, only two of the 23 interventions followed a proportionate universalism
principle, whilst the rest were targeted at those at higher risk or who were already showing signs
of a developmental problem. These reviews have identified a gap between the recommendations
of proportionate universalism and the available interventions.
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2.5 Proportionate interventions
One consequence of proportionate universalism as a motivation for intervention delivery is the
development and evaluation of proportionate complex interventions in RCTs. Proportionate
interventions comprise of various stages or different component parts. For example, everyone
receives the first stage of the intervention and their response to this stage determines if they
progress onto the next stage; it is delivered proportionate to the need of the individual. The
E-SEE trial aims to evaluate a proportionate delivery model of the IY parenting programme [3].
Proportionate universalism has two levels: the universal and the proportionate.
Proportionate universalism is a relatively new term, aiming not to increase inequalities by imple-
menting health interventions. However, the principle of adapting interventions proportionate to
need has been present for much longer. Proportionate universal interventions are closely linked
to other terminology, including:
 dynamic treatment regimens;
 adaptive treatment regimens;
 adaptive interventions;
 adaptive treatment strategies;
 stepped-care interventions;
 multi-level interventions.
The following defines what is meant by a proportionate intervention, using the literature on
adaptive interventions to motivate this work. A proportionate intervention or adaptive inter-
vention entails an individualised approach with numerous treatment sequences dependent upon
individual need as treatment is adapted dependent on need (for example, continue, augment,
switch, step-down) [28]. This may mimic how decisions are made in practice, thus guiding the
intervention process. These interventions have two main components: (a) individualised treat-
ment based on participants needs and (b) a time varying intervention that adapts in response to
participants changing need over time [29]. There are often a variety of questions to answer when
developing a proportionate intervention, including: when is the optimal time to assess respon-
siveness to treatment?; should non-responsive individuals be offered an augmented treatment
or an alternative treatment?; should the initial period of treatment be based on an individuals
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baseline characteristics?; could the decision to augment treatment be individualised based on
other outcomes?.
A proportionate intervention includes: (i) decision stages and at each decision stage: (ii) inter-
vention options; (iii) tailoring variable(s); (iv) a decision rule; (v) outcomes. The decision rule
utilises the tailoring variable(s) to decide upon the staged intervention an individual receives.
The tailoring variable is patient information. The decision rule cut-off should ideally be based on
previous research. The intervention may be individualised based on decision rules using dynamic
information about the individual that is likely to change due to intervention such as response
or adherence either singularly (only one decision) or sequentially (multiple decision stages).
Proportionate interventions are useful as individuals who require a step-up/down or switch in
treatment receive that and for those that are responding to the current treatment there are
no increased burdens such as side effects or invested time. Increased burden can lead to non-
adherence, which may in turn reduce positive intervention effects. In addition, all interventions
incur costs and as healthcare resources are limited, the ability to reduce costs of receiving
unnecessary further interventions whilst treating those in greatest need is an important goal.
Proportionate interventions may be particularly relevant for interventions with heterogeneous
responses. For example, interventions developed for mental health disorders often produce
heterogeneous responses due to the within person (over time) and between person differential
responses to intervention [30].
Developing and evaluating proportionate interventions in trials raises specific issues in the design
and analysis. Teams developing such complex intervention packages may want to evaluate the
effectiveness of the individual stages or the incremental benefits of each stage in addition to the
overall intervention. This presents fresh challenges for the design and statistical analysis of such
interventions. In general, trials randomise individuals or clusters to a whole treatment pathway
to assess effectiveness. However, a proportionate universalist design creates multiple treatment
pathways, each dependent upon outcomes at the previous stage of treatment.
In an RCT, an intention-to-treat (ITT) analysis provides an estimate of the average effect size
for those randomised to the intervention of interest. A per-protocol (PP) provides an estimate
of the average effect size for those who adhere to the protocol fully. In a staged or proportionate
intervention the intervention is delivered dependent upon the need of an individual, thus the
estimates of an average effect size may not be as relevant as they are in more standardised
interventions.
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Further complexities also arise from the clustering of outcomes in one or more stages of propor-
tionate interventions. For instance, in the E-SEE trial the first component of the IY intervention
is delivered at the individual level and the second and third components of the intervention are
delivered to groups of individuals. This will potentially induce treatment induced clustering
from both the group dynamics and the role of the group facilitator. This clustering is induced
by the nature of the intervention rather than randomisation to a cluster. Clustering in iRCTs
will be discussed in more detail in sections 2.6 and 2.7.
2.6 Randomised controlled trials
An RCT is a controlled experiment designed to evaluate the effectiveness of one or more in-
terventions to an appropriate comparator. The intervention may be: a drug or other form of
medical intervention such as surgery or therapy; or a method of organising or delivering health-
care such as a new system or training for care providers. This section provides a background
to some of the key types of RCTs used in health research and the corresponding requirements
for the design and analysis of such trials. More detailed information on power calculations and
sample sizes are given in chapter 6 and comparison of analysis methods given in chapters 4 and
5.
The main aim of an RCT is typically to obtain an unbiased and reliable estimate of the effec-
tiveness of the intervention being tested. In a parallel two arm trial individuals or units known
as clusters are randomised to either receive a control condition, often the standard of care, or an
experimental intervention condition. By using randomisation, all known and unknown factors
that could possibly confound the estimate of the intervention effect should be balanced on aver-
age between the two trial arms; this allows any difference between the two arms to be attributed
to the intervention. It is then possible to make statistical inference about the causal effectiveness
of an intervention by comparing the outcomes of the trial arms after a predetermined follow-up
period.
Drug trials are classified by phase, with four main stages and well defined guidelines for each of
phase I/II/III/IV purposes and scope. The same phases of development are not used for inter-
vention trials. However, there has been an increasing use and acceptance that clinical treatments
and public health decisions should be based on a comprehensive review of the evidence. This
evidence should be based on rigorously conducted studies, which evaluate both benefits and ad-
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verse events. The use of such evidence will ideally enable policy makers and healthcare services
to allocate resources accordingly to interventions which have been proven to be both effective
and cost-effective [31].
2.6.1 Superiority trials and hypothesis testing
A two-arm parallel RCT is commonly used to show one intervention is superior to another.
Individuals are randomly allocated to one of two arms and a statistical test is undertaken to
make inference about the intervention effect. This is referred to as a superiority trial.
Let’s define a null hypothesis (H0) and alternative hypothesis (HA). In a two-arm superiority
trial comparing intervention treatment t = 1 to control treatment t = 0 these are
 H0: ȳ0 = ȳ1, two treatments are the same
 HA: ȳ0 6= ȳ1, two treatments are different
where ȳ is the average outcome measure in the corresponding treatment arm.
An RCT only investigates a sample of the population; the outcome is an estimate of the true
population outcome. A hypothesis test can be used to test the significance of the difference
in outcome between the control and intervention group. A 0.05 cut-off level for statistical
significance is typically chosen, however, this is arbitrary and confidence intervals should be
reported alongside any p-value.
The use of a p-value cut-off results in a dichotomous decision, giving two possible errors, Type
I and Type II error summarised in Table 2.1. Type I error occurs when we reject the null-
hypothesis when it is true, a false positive (α = probability of Type I error) and is determined
in advance of a study. Type II error occurs when we fail to reject the null-hypothesis when it is
false, a false negative, and is dependent upon the sample size and the effect size of interest (β =
probability of Type II error). We more commonly report the power of a study (1− β) to detect
an effect size.
35
Table 2.1: Summary of Type I and Type II errors
H0 True H0 False
Do not reject H0 Correct decision Type II error
(1− α) (β)
Reject H0 Type I error Correct decision
(α) (1− β)
2.6.2 Continuous outcomes
This thesis considers continuous outcomes, these are commonly used in complex intervention
and public health research for example through the use of outcomes such as body mass index
(BMI) and Patient Health Questionnaire-9 (PHQ-9) and Quality of Life (QoL) outcomes such
SF-36, EQ5D, PHQ-9. Continuous outcomes were the most common primary endpoint in a
recent review of UK publicly funded trials (NIHR funded), 45.8% of trials published between
2006 and 2016 (49 of 107 RCTs published in the Health Technology Assessment journal) [32].
2.6.3 Individually randomised trial
RCTs can employ an individually randomised controlled trial (iRCT) design, where participants
are individually randomised to receive one of the investigative treatments. Figure 2.1 presents
a schematic of a two-arm parallel iRCT, they are commonly used in drug trials and other
types of individual therapies. In iRCTs we often assume that the outcomes from participants
are independent of one another and thus usual assumptions of independence of outcomes in
statistical analysis are met. The corresponding sample size calculations for such trials can use
standard calculations which assume independent outcomes [33].
Figure 2.1: Schematic of a two-arm parallel individually randomised trial where R represents













2.6.4 Cluster randomised trial
Using an iRCT is not always appropriate or feasible. Cluster randomised trials (cRCTs) may
be more suitable. Cluster randomisation occurs when an entire unit (for example GP practice,
school or hospital) known as clusters, are randomised to interventions [31]. Figure 2.2 presents a
schematic of a cluster trial with two arms, a control and an intervention arm. They are employed
for a number of reasons. The intervention may need to be applied to whole communities or it is
easier to administer it this way, for example, implementation of new procedures in a GP practice
or hospital where the intervention applies to the whole unit. Cluster randomisation helps reduce
the likelihood of contamination between intervention arms; it may not be realistic to offer the
intervention to one individual without others at the same cluster (hospital or GP practice) being
exposed to the intervention as well.
Figure 2.2: Schematic of a cluster trial where R represents randomisation (randomisation is at


































Clustering is defined in general for an RCT to be when outcomes are grouped together based
upon a common property, such as GP practice, school or hospital. Outcomes for subjects within
the same cluster are expected to be more similar than those from different clusters.
The implications of clustering in cRCTs are widely acknowledged [34]. Cluster trials generally
require larger sample sizes than individual trials designed to answer the same research question
(if an iRCT is possible) and should account for the correlation of outcomes in the analysis
method. Analysis methods are further discussed in section 2.8.2.
2.6.5 Individually randomised controlled trials with clustering
Where randomisation occurs at the individual level clustering may also occur, consequently,
clustering of outcomes can be present in iRCTs. For instance, clustering of participants’ out-
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comes due to receiving treatment as part of a group-based parenting intervention [35], treatment
in specialist clinics for the treatment of venous leg ulcers [36], or participants under the care of
a surgeon for comparison for hemostasis in elective benign thyroid surgery [37]. The clusters
in iRCTs are not necessarily the organisational unit, they are the care provider or intervention
group which may play a role in the causal pathway of the intervention effect. We might expect
a correlation of outcomes between individuals either in the same group or receiving treatment
from the same care provider. This clustering can be caused by care provider characteristics such
as level of experience, level of training, competence, or in a group trial through group dynamics
[38, 39].
When designing and analysing iRCTs with clustering we need to consider implications of the
potential lack of independence. Ignoring clustering in the analysis can lead to misleadingly
precise results and consequently incorrect conclusions [40].
There is increasing acknowledgement of clustering present in iRCTs, with a growing awareness
of the need to account for this clustering [41–46]. Consolidated Standards of Reporting Trials
(CONSORT) statement consists of a minimum set of reccomendations for reporting randomised
trials [16]. Extended CONSORT guidelines for the reporting of RCTs of nonpharmalogical in-
terventions (CONSORT-NPT) have drawn attention to the need, when applicable, to address
clustering by care provider and/or centre [17, 44]. However, studies still fail to account for
potential treatment induced clustering and a recent CONSORT extension for social and psy-
chological interventions (published July 2018) does not address the issue of potential clustering
though it is common in psychological interventions [47].
2.6.6 Nested and partially nested randomised controlled trials
Treatment induced clustering in iRCTs has been termed a nested randomised controlled trial
(nRCT) [48] and can occur in both arms of the trial as presented in Figure 2.3. In a similar
vain, an increasingly applied design in healthcare and education research is a partially nested
randomised controlled trial (pnRCT), where participants are individually randomised to trial
arms and clustering of outcomes occurs in only one arm of the trial [48, 49] (sometimes termed
partially clustered trials). A schematic of a pnRCT is presented in Figure 2.4. The STEPWISE
trial is an example of a pnRCT, assessing a structured lifestyle education programme aimed at
supporting weight loss for adults with schizophrenia and first episode psychosis in a community
mental health setting. Individuals were randomised to either an intervention arm of group-
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Figure 2.3: Schematic of a nested trial where R represents randomisation, there are k clusters


































Figure 2.4: Schematic of a partially nested trial where R represents randomisation, there are
























based lifestyle education sessions or a control arm receiving usual care at the individual level
[50]. In iRCTs with treatment induced clustering where clustering does not occur for all the
trial participants, analysis must be at the individual level.
The cluster sizes in nRCTs and pnRCTs are typically smaller than those in cRCTs. Cluster
size in a cRCT is often externally fixed, such as the number of individuals attending a clinic or
number of individuals in a GP practice. In contrast to cRCTs, there may be more researcher
control over cluster sizes in pnRCTs such as the number of patients treated by a care provider
or the group sizes. Although group sizes are typically decided by intervention developers; they
need to form a viable group for the intervention delivery and develop group dynamics. Limits
on care providers capacity will also lead to cluster size restrictions.
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2.6.7 Further complicated designs
The above sections have described some of the most commonly used RCT designs in complex
intervention research, though many others exist. One obvious extension from the above include
what Walwyn and Roberts [38] term crossed designs, where care providers treat patients in both
trial arms. A crossed design may result in contamination, for example, asking the same therapist
or physician to present two very different therapies to their patients could be impractical, the
therapist may get confused, and patients of the same therapist or physician might be acquainted
[51].
A second extension from the pnRCT design is seen in the E-SEE trial and trials of other
proportionate interventions. These are a more complex version of the pnRCT in which only
one arm has clustered outcomes and within that arm only some of the patients have clustered
outcomes, as not all receive the clustered intervention. For instance, in E-SEE only those who
step-up to the parenting groups will be clustered by group, the other participants receive only
the parenting book (their outcomes would not be expected to be clustered). For the remainder of
this thesis these types of trials are referred to as ‘within-arm partially nested trials’ (within-arm
pnRCTs) in which only some of the intervention arm have clustered outcomes.
Landau and Chalder [52] recommend “where feasible randomise participants to clusters that are
related to the delivery of treatment (therapists, groups)”. However, in trials such as E-SEE group
interventions are offered only to a subset of the intervention arm (those who meet some criteria
after the previous intervention stage). In addition, only one or two groups are to be delivered
in each location and group allocation is based on nearest available group. This type of trial
design will result in non-random allocation to groups, consequently it is likely that a potential
clustering effect occurs. For example, participants offered the group intervention are those with
more similar responses and people from the same catchment area may have similarities, such as
socio-economic class and health, adding to the potential clustering effect (if it is not possible to
fully adjust for the predictive characteristics using baseline covariates).
2.6.8 Multi-centre trials
All of the above designs have only considered either one or two-levels of hierarchy in the data, the
individual and a single cluster level variability. There are often more than two-levels, for instance
large public health research iRCTs are commonly run across multiple sites, such as geographical
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regions, NHS hospitals or mental health clinics. These trials are termed multi-centre studies,
participants are recruited across multiple centres, in order to achieve the required sample size
and to improve generalisability of findings. Participants from the same centre may be expected
to have similar outcomes implying a positive correlation and possibly the need to account for
the centre based clustering. Details of different types of clustering are presented in more detail
in section 2.7.2. A multi-centre iRCT design can result in three or more levels of hierarchy in the
data. For example, the SARAH: Stretching and Strengthening for Rheumatoid Arthritis of the
Hand study was a multi-centre iRCT evaluating the clinical and cost-effectiveness of an exercise
programme over and above usual care for Rheumatoid Arthritis. The trial included four levels
of data hierarchy: seventeen NHS trusts in England, comprising 21 rheumatology and therapy
departments, 48 hand therapists, and finally individual level variance [53].
2.7 Clustering
In the previous section different types of RCTs were introduced. This section goes into more
detail regarding the clustering of outcomes, provides a formal definition of clustering and sum-
marises the types of clustering that may occur in trials.
2.7.1 Defining clustering
Clustering in the context of RCTs can be defined as “when observations are grouped together
based upon common attributes” [54, p.2]. Consequently, outcomes from individuals within the
same cluster may be expected to be correlated to one another. The correlation of outcomes of
individuals from the same cluster results in a lack of independence of outcomes.
Two key reasons for correlation of outcomes within a cluster exist. Firstly, patients within the
same cluster may have similar characteristics, for example, patients from the same hospital may
have similar socio-economic status. Secondly, clusters themselves can influence the patients
outcome, for example, patients within the same hospital may have more similar outcomes due
to the quality of the hospital staff or hospital procedures or patients being treated by the same
therapist may have more similar outcomes due to the therapists’ experience [54].
The ‘clustering effect’ is commonly quantified using the intracluster correlation coefficient (ICC).
The ICC measures the extent to which outcomes from participants within the same cluster are
correlated to one another [40]. This correlation violates usual assumptions for sample size
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calculations and analysis methods of independent observations. If clustering is ignored and we
analyse results as if independent we assume we have more information than we actually do. An
estimate of the ICC is commonly used to calculate the variance inflation factor [55], also known
as the design effect. The design effect is used to adjust sample sizes to allow for clustering.
Further details regarding how we define and estimate the ICC are discussed in section 2.8.2 and
how to calculate sample sizes in chapter 6.
Clustering is defined by Kahan and Morris [54] as either pre- or post-randomisation. Pre-
randomisation clustering relates to when patients are grouped into clusters and then randomised,
for example when patients present to different hospitals and then are randomised upon presen-
tation. Post-randomisation clustering occurs when patients are randomised and subsequently
assigned to clusters, for example when patients are randomised to a type of therapeutic interven-
tion and then assigned a therapist. Whereas, if therapist were used as a stratification variable in
the randomisation procedure (patients are assigned to therapist and then randomised) it would
be defined as pre-randomisation clustering.
2.7.2 Types of clustering
Table 2.2 draws together and summarises the different clusters and associated clustering that
may be present in RCTs. These are centre in a multi-centre RCT, cluster in a cluster RCT, care
provider, and group treatment.
Table 2.2: Types of clustering in RCTs and associated clustering






Pre- and post-intervention outcomes due to being from the same
centre, possibly similar characteristics. Post-intervention outcomes





Pre- and post-treatment outcomes due to being from the same
cluster, possibly similar characteristics. Post-intervention outcomes





Post-intervention outcomes due to variability in care provider






Post-intervention outcome may be clustered due to group treatment
effects/dynamics.
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2.7.3 Clustering and randomised trials
Table 2.3 draws together section 2.6 and section 2.7.2 providing a summary of differences be-
tween individual, cluster, care provider, and group treatment RCTs (adapted from Roberts and
Roberts [48]). Many individual, care provider, and group treatment RCTs are also multi-centre
studies and thus need to consider the possibility of clustering by centre.
Table 2.3: Summary of differences between individual, cluster, care provider, and group treat-
ment RCTs




Randomisation Individual Individual/Cluster Individual/Cluster Individual/Cluster
Cluster size - Mean cluster size
















- Equal between arms Variable, based on
care providers
capacity









may be more than









ICC - Considered equal
between arms under
null hypothesis
Care provider effects Group dynamics
*Clustering may be present due to centre in multi-centre iRCT
2.8 Analysing and measuring clustered outcomes
In addition to obtaining sufficient power and accurate results, accounting for clustering enables
us to estimate the ICC. The following sections provide a description of the ICC, briefly introduce
analysis methods for clustered outcomes, and how to estimate the ICC. ICCs are important for
the interpretation of trial results where we may be directly interested in the group or thera-
pist effects. ICCs are also required when calculating sample sizes for RCTs with clustering to
maintain power and control Type I error rates [40]. Therefore, better reporting of ICCs in trial
results papers is vital for providing an evidence base of ICCs and improving the assumptions
used in trial design.
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2.8.1 Defining the ICC
The ICC (introduced in section 2.7.1) explains the extent of similarity between individual out-
comes within the same cluster.
The definition of the ICC comes from the expression for the correlation between outcomes from
two individuals [56]. The assumptions which underlie this definition are given by Eldridge et al.
[56] as:
1. any two responses from different clusters are independent, but pairs of responses within
clusters are correlated, and
2. the correlation is the same for all pairs of individuals from the same cluster.
Figure 2.5 presents formal proportion of variance definitions of the ICC, it is the ratio of the
between-cluster variance to the total variance (the sum of between and within cluster variance).
In a pnRCT the total variance refers to the variance in the clustered trial arm. There are
circumstances in which we may be interested in modelling the dependence of the correlation
on cluster characteristics. However, when considering a trial with one level of clustering, for
example care provider or parenting group, it is commonly assumed that there is a a single
common correlation ρ presented in equation 2.2, Figure 2.5.
Figure 2.5: Definitions of the ICC





∀i 6= l (2.1)
It is common to assume there is a single common correlation ρ which applies to all
clusters in a trial, also known as compound symmetry, or exchangeability assumption





∀i 6= l and ∀j. (2.2)
The true ICC will lie in the interval [− 1/(m− 1), 1], where m is the cluster size. The lower
bound of the ICC is − 1/(m− 1) if all the clusters are the same size. When cluster sizes vary the
lower bound becomes − 1/(mmax − 1), where nmax is the largest cluster size [56]. The closer to 1
the more correlated the outcomes within the same cluster are, and vice versa. However, it is
generally believed that ICCs in trials with clustering are unlikely to be negative [51] and under
the proportion of variance definition of the ICC the ICC is always positive. It is plausible that
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individuals treated by the same care provider, in the same group or from the same GP practice
are positively correlated to one another and unlikely that they will be negatively correlated.
However, negative correlation may arise in some instances. Individuals may respond to the same
therapist differently, some responding positively, some with no change and some deteriorate. A
negative ICC could occur if this increased variability occurs more within therapists than between
therapists. Negative ICCs could also occur if there is competition among individuals being
treated by the same therapist leading to an unequal distribution of limited therapist resources;
if lots of resources are used for one patient in a cluster then less will be available for another
patient in that cluster. For example, competition for attention from a therapist in a group
administered intervention or a therapist burning out toward the end of a trial [57].
2.8.2 Analysing clustered outcomes and calculating the ICC
Different analysis methods are available to analyse clustered outcomes and estimate ICCs from
both cRCTs and iRCTs with clustering. Model choice depends upon research goals, design and
type of outcome.
Two standard approaches for analysing clustered data exist: analysis at the cluster level and
analysis at the individual level. If statistical inference is aimed at the cluster level such as GP
practice then cluster level analysis may be appropriate. If statistical inference is aimed at the
individual level then individual level analysis is more suitable, and CONSORT [34] recommend
the use of models that analyse individual level data whilst controlling for clustering effect.
There are four common approaches used to analyse RCT data with a continuous outcome, whilst
adjusting for clustering [40]:
1. Cluster level analysis - analysis carried at the cluster or care provider level
2. Linear regression with cluster robust standard errors - analysis carried at the individual
level
3. Mixed effects models - analysis carried at the individual level
4. Marginal models - analysis carried at the individual level
We can account for clustering by including the cluster as a fixed effect in a regression model.
Though this method is simple to implement and has been used in practice in both cRCTs
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and iRCTs with clustering it is not recommended. This strategy can result in a Type I error
rate inflated above what would have occurred if we ignored the clustering altogether [43]. In
addition, using the fixed effects method has been argued to limit the results of the analysis to
the specific clusters used in a study (section 7.3.1.2 includes more discussion on this) and will
generally produce low estimates of the treatment effect variability as the cluster level variability
is removed [51].
For the following models define yij as a continuous outcome for individual i in cluster j, i =
1, . . . , N , j = 1, . . . , k, tij is the intervention indicator (0 = for control, 1 = for intervention), θ is
the treatment effect, β0 is an intercept term, and εij errors represents individual level variation
and uj represent cluster level varaition.
2.8.2.1 Cluster level analysis
Analysis at the cluster level can be conducted using a two-stage process in which we create
a summary measure of the individual outcomes for each cluster (for example proportion of
individuals who quit smoking or the mean of a continuous outcome). The cluster level summaries
are then analysed using an appropriate statistical test, commonly an independent two-samples
t-test or a non-parametric test such as the Wilcoxon’s rank sum test [31]. Randomisation ensures
the cluster summary measures are statistically independent.
Cluster level analysis is often not the most efficient analysis approach. Firstly, when clusters
are of differing sizes this can violate the assumptions of the independent samples t-test (that
cluster summary measures are Normally distributed within each arm and that the there are
equal variances across arms) [51]. Secondly, cluster level analysis is not suitable for trials in
which clustering of outcomes only occurs for some individuals and not others, for example in
pnRCTs only those in one trial arm belong to clusters and those in the other trial arm are
independent of one another. Finally, cluster-level analysis does not provide an estimate of the
ICC.
2.8.2.2 Individual level analysis
This section explains the three individual level analysis methods.
Linear regression with cluster robust standard errors
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It is possible to use linear regression with robust cluster variance estimators. Robust standard
errors gives regression coefficients that are more robust to violations of the underlying assump-
tions. The concept of robust variance estimates have been extended to cover the situation of
clustering of outcomes [58]. These will be discussed in more detail in chapter 5.
Mixed effects model
Mixed effects models can be used to analyse individual level outcome data whilst accounting
for both the between- and within- cluster variation. They represent the different levels in data
(cluster, individual, repeated measures level) and the residual variance constitutes variance
components for the different levels. They also allow multiple levels of clustering and nested data
to be accounted for by adding additional random effects, such as therapists nested within sites.
Mixed effects models for clustered data typically comprise: a constant, the fixed effects (which
include the intervention effect), individual residuals and a random effect representing cluster-
specific effects. These models estimate the cluster specific effect of the intervention on the
endpoint, the variance of the distribution of cluster means is estimated (between-cluster variance)
(σ2u) and within-cluster variance (σ
2
ε ). The random effects refer to uj and are assumed to be
taken at random from a population of clusters. This is also referred to as the random intercept
model. The fixed part of the model states an overall regression line representing the population
average outcome and the random effect uj moves this regression line up or down according to
each cluster. It is typically assumed that the cluster residuals uj are Normally distributed.
If we consider the simple case of a randomised trial with two levels of data hierarchy for all indi-
viduals: everyone belongs to a cluster resulting in cluster level variability and there is individual
level variability. The following mixed effects model can be defined for a continuous outcome for
individual i in cluster j, i = 1, . . . , N , j = 1, . . . , k,
yij =β0 + θtij + uj + εij , (2.3)
uj ∼N(0, σ2u),
εij ∼N(0, σ2ε )
where the random intercept term uj represents between cluster variation and εij the individual
residuals. The above model assumes the effect of every cluster j is to add a random effect uj to
outcomes. The parameters of the mixed effects model are commonly estimated using maximum
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likelihood estimation (MLE) or restricted maximum likelihood methods (REML), with the latter
shown to produce less biased results particularly when there are a small number of clusters [40].
The statistical significance of the parameters are usually assessed using the likelihood-ratio,
Score or Wald statistics.
In mixed effects models parameters of additional levels will be harder to estimate, for each
additional level (or each additional random effect) more data is required, especially for the
variance-covariance parameters of the higher levels. Convergence diagnostics may become an
issue if there are a large number of levels. However, mixed effects models allow fitting of complex
models such as the inclusion of covariates, stratification variables and longitudinal outcome data
and their handling of missing data by incorporating all available data therefore, these are the
focus of this work.

















where σ2u is the component of outcome variance related to differences between clusters, the
between-cluster variation and σ2ε is the component of outcome variance related to differences
between individuals within clusters, the within cluster variation. The total variance of the
clustered outcomes is σ2 = σ2u + σ
2
ε , hence, ρh is the proportion of variance explained by the
between-cluster variation [31]. The variance components cannot be negative, resulting in the
positivity constraint of ρh (ρh lies between 0 and 1).
Marginal models using generalised estimating equations
Marginal models provide an alternative method of analysis for individual level data to estimate
regression coefficients. They provide population averaged rather than cluster specific estimates
[31]; the term population averaged comes because we can estimate θ by averaging over the
clusters treating the correlation as nuisance parameters. The population averaged or marginal
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model can be written as
yij = β0 + θtij + vij (2.5)
where the error term vij is regarded as random error, correlated within clusters. The error term
is considered a nuisance term which is accounted for in the estimation procedure (there are
no additional terms in the model that estimate cluster specific effects as in the mixed effects
models).
The GEE method, developed by Liang and Zeger [59], can be used to estimate the regression
coefficients in marginal models, estimating the intervention effect and its precision are carried
out separately. The residuals are assumed to be correlated, with Corr(vij , vlj) = ρ(tij , tlj ;<).
A working correlation matrix R is used to estimate the correlation matrix < and different
correlation structures can be assumed to model the clustering of individuals in the same cluster.
An exchangeable correlation structure is commonly assumed, the same correlation within each
cluster this common correlation ρ is the ICC.
GEEs typically use robust standard errors of the parameter estimates to allow for clustering
which are derived from the observed variability in the data (as opposed to an underlying prob-
ability model). The significance of the intervention effect estimate is then determined using a
Wald test statistic using the robust variance estimate [59]. The robust standard error estimate
is consistent even when correlation structure is misspecified, however, when there are only a
small number of clusters in the intervention arm it has been shown to be underestimated [31].
A number of methods have been proposed to address the limits of the robust standard error
estimator.
2.8.2.3 Small numbers of clusters
The individual analysis methods are based on asymptotic theory, with the assumption that there
are a large number of clusters. When there are only a small number of clusters the methods may
be unreliable. Various minimum numbers of clusters for trials with continuous outcomes have
been suggested in order to maintain Type I error rates at for example 5%. Hayes and Moulton
[31] suggest that more than 30 clusters (15 clusters per arm) are required to use mixed effects
models or GEEs. Additionally, a minimum of 30-40 clusters have been suggested for mixed
effects models and 40-50 for GEEs [51]. However, performance of models is also affected by how
other model assumptions are met, the size of clusters and variability of cluster sizes. Mixed
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effects models have been shown to be less biased than GEEs when there are a small number of
clusters [42, 51, 60]. The feasibility of running trials with large number of clusters is key to the
problem. Partial nesting may add to this issue, there may be a smaller number of clusters due
to clustering only occurring in one trial arm.
A number of small sample corrections have been developed to circumvent the problem of having
only a small number of clusters. It is not always possible to design trials with a large number of
clusters, particularly in iRCTs with clustering when the number of clusters may be limited by
the number of care providers available to deliver the intervention. The corrections work in one
of two ways: increasing the estimated standard error of the intervention effect or altering the
degrees of freedom used to calculate confidence intervals and/or p-values for the intervention
effect. Leyrat et al. [61] undertook a recent comparison of analysis methods for cRCTs with small
numbers of clusters (40 or fewer). They found that unweighted and variance-weighted cluster-
level analysis, mixed effects models with degree of freedom corrections (Satterthwaite), and GEE
with a small-sample correction provided Type I error rate at or below 5% in most scenarios,
down to as few as six or eight clusters, whereas uncorrected approaches lead to inflated Type
I error rates. Consequently, where individual level analysis is required and there are a small
number of clusters it is recommended to use small sample corrections for degrees of freedom
(for example Satterthwaite) where possible. Small sample corrections relevant to this thesis are
discussed in more detail in chapter 4 section 4.4.6.
2.8.2.4 Methods for ICC estimation
Analysis at the individual level allows estimation of the ICC as shown in equation 2.4. In addition
to mixed effects models and GEEs, analysis of variance (ANOVA) can be and is commonly used
to calculate the ICC. This can be done using a one-way ANOVA with the cluster level variable
as a random factor. ANOVA estimates the mean squares between and within clusters, referred
to as MSB and MSW, respectively. MSW estimates the within-cluster variance (estimating σ2u)
and MSB estimates the mean square between clusters which varies due to between- and within-
cluster variance (estimating mσ2r + σ
2
u, mis number of individuals per cluster). The ANOVA
proportion of variance estimation interpretation of the ICC is estimated using
ρA =
MSB −MSW
MSB + (m− 1)MSW (2.6)
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The ICC estimate from equation 2.6, ρA, can be negative. If cluster sizes are unequal the cluster











where k is the number of clusters, Ns is the total number of individuals, and mj is the number of
individuals in cluster j. Ukoumunne et al. [62] explain that the above weighted average cluster
size is used in place of the arithmetic mean cluster size because the between-cluster variance can
be underestimated when using the arithmetic mean.
Table 2.4 briefly summarises and compares the three different methods for estimating ICCs.
Most methods will give similar ICC results unless the data are very extreme, for instance contain
outliers and unbalanced cluster sizes [40].
Table 2.4: Methods to estimate ICCs
Method Advantages Disadvantages




can give zero and
negative ICC estimates.
Less suited with varying cluster sizes and when








Positivity constraint, for small ICCs the ICC





Treats clustering as nuisance parameter,
underestimates standard error of intervention
effect when the number of clusters is small [64].
2.9 Summary
The motivation for this thesis originated from difficulties in the design and analysis of staged
interventions such as those evaluated in the E-SEE trial. This prompted work to understand
the aims of the proportionate universalism framework and proportionate interventions, how this
framework fits into the wider context of complex intervention trials in public health and any
particular challenges in such trials. The first aim of this thesis is to review current practice
of how randomised trials of proportionate interventions are designed and analysed and the
extent of clustering in such trials. This is addressed in the following chapter using a systematic
review of trials. An initial scoping search and discussions around the E-SEE trial identified
proportionate interventions as likely to present particular issues relating to the hierarchical data
structures. Consequently this thesis investigates design, analysis and reporting of trials with
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partial clustering of outcomes, starting with the simpler case of pnRCTs and building up to the
more complex case of a within-arm pnRCTs. This chapter outlined the different trial designs,
complexities that arise through clustered outcomes and relevant terminology which will be used
throughout the thesis.
The next chapter presents a systematic review of trials of proportionate intervention trials
addressing the aim to review current practice of how randomised trials of proportionate inter-
ventions are designed and analysed and the extent of clustering in such trials.
52
Chapter 3




In chapter 2, proportionate universalism was introduced and the move towards evalutating
proportionate interventions in RCTs and a few of the subsequent challenges discussed. The
proportionate universal framework has been discussed in NICE guidelines [18], National Health
Service (NHS) documents [65], charities [66] and by public health authorities [67]. However, there
is little written in academic literature on how to actually implement proportional universalism
in practice or how to assess effectiveness of these interventions. A recent framework for the
application of proportionate universalism has been published [20] with the aim of filling the
gap between principle and practice. The framework provides an approach for governments and
policy makers but does not extend to how to best evaluate which proportionate interventions
are effective in practice. This chapter presents a systematic literature review of published trials
of proportionate interventions.
The current review addresses the first research aim of this thesis, to review current practice of
how trials of proportionate interventions are designed and analysed and the extent of intervention
induced clustering in such trials. Particular interest is given to whether any trials evaluated the
effectiveness of the different components of these interventions to understand the process or
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treated them as a whole. The presence of intervention induced clustering in the trials included
in this systematic review are also reviewed.
In addition to my supervisors, the chapter acknowledges the collaborative support of Tracey
Bywater, researcher at the University of York. Tracey contributed to the search strategy design.
The work was led and carried out by myself and has been submitted to Trials journal [68].
3.2 Chapter aims
This chapter reviews current practice of how randomised trials of proportionate interventions
are designed and analysed and the extent of intervention induced clustering in such trials. A
systematic review is conducted to address this aim the specific objectives of this systematic
methodological review are to:
1. explore how trials evaluating proportionate interventions are being conducted and re-
ported;
2. review the type of statistical design and analysis methods being implemented in randomised
trials involving staged proportionate interventions;
3. review whether trials of proportionate interventions are being analysed differently to more
conventional non-proportional intervention trials and if the component parts and clustering
of outcomes are considered in the analysis.
3.3 Methods
Details of the protocol for this systematic review were registered on PROSPERO (www.crd.
york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016033781).
3.3.1 Literature search
Proportionate interventions evaluated in a randomised trial between 2010 and 2015 were sought.
A scoping study was undertaken to identify relevant search terms with guidance provided by a
systematic reviewer regarding search terms, databases and making full use of truncation. Advice
regarding search terms was also sought from PhD supervisors and external expert collaborator
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Tracey Bywater. The objective related to whether intervention induced clustering of outcomes
was considered in the analysis was added to the protocol after further consideration of the
motivation for this review and findings from the scoping search identified many trials with
potential clustering.
Electronic searches were undertaken using the databases: MEDLINE (OvidSP), Web of Science
(Core Collection), and PsycINFO. The following search terms were used in the title or abstract:
‘proportionate universalism’, ‘proportionate intervention’, ‘proportionate treatment’, ‘staged in-
tervention’, ‘staged treatment’, ‘adaptive treatment regimen’, ‘adaptive intervention’, ‘adaptive
treatment strategy’, ‘dynamic treatment regimen’, ‘multi-level intervention’, or ‘stepped care’.
The final search combined search terms with the Boolean operator ‘OR’ and the Boolean oper-
ator ‘AND’ to combine them with the randomised trial search strategy. The randomised trial
search strategy was based on the Cochrane Highly Sensitive Search Strategies for identifying
randomized trials [69]. The start date of the six year time frame was chosen based on the
2010 publication date of the Marmot review [5] (it was anticipated no trials would use the term
proportionate universalism prior to this).
The final search was conducted on 16th March 2016 (after piloting of the search strategy and
refining). See Figure 3.1 for the MEDLINE search strategy. It was intended to provide a
thorough overview of the types of trials evaluating proportionate interventions being used in
practice and not be exhaustive, therefore, additional hand searching or searching of clinical
trials registers was not incorporated.
Figure 3.1: MEDLINE search strategy
1. (randomi#ed controlled trial OR controlled clinical trial).pt. OR
randomi#ed.ab. OR placebo.ab. OR clinical trial as topic.sh. OR ran-
domly.ab. OR trial.ti.
2. limit 1 to yr=”2010 -2015”
3. (proportionate universalism OR proportionate intervention$ OR propor-
tionate treatment$ or staged intervention$ or staged treatment$ OR multi-
level intervention$ OR multi-level program$ OR multi-level system$ OR
multi-level treatment$ OR stepped care).ab,ti.
4. (adaptive treatment$ OR adaptive treatment regime$ OR adaptive
intervention$ OR adaptive treatment strateg$ OR dynamic treatment
regime$).ab,ti.
5. 3 OR 4
6. 1 AND 5
7. 2 AND 6
8. limit 7 to English language
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3.3.2 Eligibility criteria
All results that were trials or pilot studies (including protocols) which evaluated interventions
delivered proportionate to need were eligible. An intervention was defined as proportionate when
there was a variation in the intervention dependent upon either an intermediate or primary out-
come measured prior to the study endpoint. The intervention included decision stages and at
each stage there were intervention options based on tailoring variables and pre-defined decision
rules. Interventions which were tailored without decision rules were excluded from this review.
Observational studies were excluded and the review was restricted to English language results
only. Where more than one article for a single study was found, the main published results
articles were included if present and superseded any protocol or cost-effectiveness study. All
therapeutic areas were considered and no restrictions imposed on the types of participants/de-
mographics.
3.3.3 Quality control
No quality assessment of the identified studies was used as the purpose of this review was to
understand the extent of studies evaluating proportionate interventions and how they are being
designed and analysed.
3.3.4 Study selection
Searches were conducted and all duplicates removed. Study selection based on the eligibility
criteria was performed by myself to identify relevant results from the search strategy. At the
initial screening stage, titles and abstracts were assessed to identify eligible studies. The full
articles of studies meeting review criteria were inspected to identify relevant studies that fulfil
the inclusion criteria.
3.3.5 Data extraction and analysis
A dedicated data extraction tool was developed for this review in an Excel spreadsheet. The
data extraction tool was discussed and finalised amongst three reviewers, myself and two thesis
supervisors, to agree on data extraction fields. Data were not double-extracted for the purpose
of this review. However, to quality check agreement, clarity of eligibility criteria, and the
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data extraction tool two second reviewers (thesis supervisors) reviewed a random sample of
ten results each. After the quality check, a small clarification to the eligibility criteria was
made but no changes to the data extraction were deemed necessary. For a small number of
studies a second opinion was sought from thesis supervisors where inclusion was not clear. The
review evaluated designs and methods used in proportionate intervention trials, therefore, there
was no meta-analysis undertaken. The data extraction included: publication year, location of
study (country), therapeutic area, type of study (trial results, protocol or secondary analysis),
design type, aim, eligibility criteria, intervention, tailoring variable and decision rules, number of
decision stages, control intervention, final study follow-up period, sample size, primary outcome,
overall statistical model, whether analysis of different stages was undertaken, and intervention
induced clustering.
PRISMA guidelines for reporting systematic reviews were followed where relevant [70]. A
PRISMA checklist was completed to reflect the manuscript submitted to Trials based on this
the work from this chapter.
The review results were presented using summary statistics and a narrative synthesis, providing
a description of any similarities and differences across the included studies. Studies were grouped




Figure 3.2 presents the selection of studies in this systematic review. Of the 531 unique records
identified from the database search, 44 eligible studies were identified. The narrative synthesis
is split into two subcategories by type of study design, stepped-care and optimal intervention
strategy. Inclusion of a control was not required for eligibility. Due to the nature of assessing
proportionate interventions some results did not include a control, for instance if the study
objective was to identify an optimal intervention strategy.
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Figure 3.2: PRISMA study flow diagram, representing the number of records identified, included
and excluded during the literature search
Records identified through database searching (n=856)
Records after duplicates removed (n=531)
Records screened (n=531)
Records excluded (n=435)
Full-text records assessed for eligibility (n=96)
Full-text records excluded (n=52)
- Intervention not adapted to need (n=13)
- No or undefined decision stages/rules n=27)
- Unavailable (n=1)
- Protocol, preliminary, or
study already included (n=10)
- Abstract only (n=1)
Studies included in data synthesis (n=44)
- Stepped-care (n=37)
- Optimal treatment strategy (n=7)
3.4.2 Study characteristics
Table 3.1 presents an overview of included studies. There were 18 studies based in the United
States, 16 in The Netherlands, two in each of Australia, England and Scotland, Norway, and
Sweden, and three based in other countries (India, Nigeria and a multi-site study across France,
Hungary, Romania and Slovakia).
The median number of decision stages (points at which the intervention was adapted according
to need based on predefined decision rules) was 2 (interquartile range (IQR) 1-3). The median
length of trial follow-up was 12 months (IQR 6-12 months) and the median sample size was 236
(IQR 150 to 387).
Measures were taken at baseline, at each decision stage and after the end of the final intervention
stage. Generally, follow-up measures were also taken a number of months after completion of
interventions. There were both individually and cluster randomised trials included in the results.
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There were a variety of reasons given for adopting a proportionate intervention, including costs,
resources, and providing interventions appropriate to individuals.
Table 3.1: Overview of studies included in the systematic review
First Author Datea Therapeutic area Country Follow-upb N
Ell [71] 2010 Depression and anxiety United States 12 387
Van’t
Veer-Tazelaar [72]
2010 Depression and anxiety The Netherlands 12 170
Braamse [73] 2010 Distress after autologous stem cell
transplantation
The Netherlands 10 286
Patel [74] 2010 Depression and Anxiety India 12 2796
Gilliam [75] 2010 Obsessive compulsive disorder United States 3 14
Kay-Lambkin [76] 2010 Depression among metham-
phetamine users
Australia 5 8
Richter [77] 2011 Blood pressure France, Hungary,
Romania, Slovakia
6 256
Weissd [78] 2011 Prescription opioids dependence United States 6 653
Mitchell [79] 2011 Bulimia nervosa United States 12 293
Seekles [80] 2011 Depression and anxiety The Netherlands 6 120
Tolin [81] 2011 Obsessive compulsive disorder United States 3 34
van der Leeden
[82]
2011 Anxiety in children The Netherlands 6 133
Apil [83] 2012 Depression The Netherlands 12 136
Karp [84] 2012 Depression and chronic pain United States 12 250
Shortreed d [85] 2012 Schizophrenia United States 18 1460
Dozeman [86] 2012 Depression and anxiety The Netherlands 10 185
Nordin [87] 2012 Stress management of cancer pa-
tients
Sweden 12 300
Jakicic [88] 2012 Weight loss United States 18 363
Wangd [89] 2012 Oncology United States 7 150
Pommer [90] 2012 Depression and anxiety in patients
with asthma or COPD
The Netherlands 24 160
Lamb [91] 2012 Whiplash injuries England and Scotland 12 3851
Krebber [92] 2012 Distress in head and neck and lung
cancer patients
The Netherlands 12 176
Borsari [93] 2012 Alcohol consumption United States 9 598
Rosed [94] 2013 Smoking cessation United States 6 606
Watson [95] 2013 Alcohol consumption England and Scotland 12 529
Oosterbaan [96] 2013 Common mental disorders The Netherlands 8 163
van Dijk [97] 2013 Depression among patients with
diabetes and/or coronary heart
disease
The Netherlands 12 236
Arving [98] 2013 Stress management of cancer pa-
tients
Norway 24 300
Mattsson [99] 2013 Depression and anxiety Sweden 24 200
Carels [100] 2013 Weight loss United States 4 52
van der Aa [101] 2013 Depression and anxiety The Netherlands and
Belgium
24 230
Kasari d [102] 2014 Communication for minimally ver-
bal children with autism
United States 8 61
Muntingh [103] 2014 Panic and anxiety The Netherlands 12 180
Kilbourne d [104] 2014 Mood disorder United States 24 1600
Hamall [105] 2014 Families living with childhood
chronic illness
Australia 6 1050
Gureje [106] 2015 Depression Nigeria 12 1190
Stoop [107] 2015 Depression and anxiety in patients
with diabetes, asthma or COPD
The Netherlands 18 46
Stam [108] 2015 Impairment in older dizzy people The Netherlands 12 300
Lock [109] 2015 Anorexia nervosa United States 6 45
Schuurhuizen
[110]
2015 Distress in patients with
metastatic colorectal cancer
The Netherlands 11 715
Haug [111] 2015 Panic and anxiety Norway 12 173
Salloum [112] 2015 Post-traumatic stress in children United States 3 53
Wud [113] 2015 Bipolar disorder United States 3 365
Painter [114] 2015 Depression in HIV patients United States 12 249
a Publication date, b Primary follow-up post baseline in months, N = Sample size, d Optimal-intervention strategy subcategory
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3.4.3 Stepped-care
Table 3.3 presents a summary of the included studies categorised as stepped-care. A total of 84%
(37 of 44) of the studies followed a stepped-care model for the intervention. The stepped-care
model is recommended by NICE [115] for the provision of services for common mental health
disorders. In a stepped-care model the least intensive intervention, or level of intervention, is
delivered first to all patients, and patients step up or down the stepped-care pathway dependent
upon their response to the previous intervention step.
Figure 3.3 represents the flow of patients through an example of a typical stepped-care trial with
three intervention steps. The key principles of stepped care are: to provide the most appropriate
and best intervention according to need; reduce the burden on patients by providing only the
intervention required; and improve cost-effectiveness by providing the level of intervention re-
quired for a positive outcome [115]. The reduction of costs for those who respond to lower level
intensity interventions can free up resources for those who require more intensive intervention
[116].
Figure 3.3: Example of a stepped-care trial with three steps and the option to rejoin treatment















The majority of stepped-care studies, 73% (27 of 37) were focussed on the therapeutic areas
of depression, anxiety, stress, or some form of mental health disorder. Other therapeutic areas
targeted included: weight loss [88, 100], alcohol consumption [95, 117], eating disorders [79, 109],
whiplash injuries [91], blood pressure control [77], resilience and wellbeing of families living with
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childhood chronic illness [105], and impairment in older dizzy people [108].
The intervention often involved some form of watchful waiting period for the first step followed
by regular monitoring at pre-defined follow-up times of an outcome measure (either secondary
or primary). Based on this outcome measure, decisions were made whether to progress to the
next step or not, this process continued for however many steps were included in the interven-
tion. Each decision stage comprised of either a choice of interventions, continued treatment,
augmented treatment, or to discontinue the treatment all together for the following step based
on an individuals’ outcome. The progression of treatment steps for interventions aimed at
mental health disorders commonly included a watchful waiting period or bibliotherapy/guided
self-help, psychotherapy sessions (either individual or group based), with possible progression
to medication (for example, antidepressants).
Control conditions were generally usual care or enhanced usual care with others being assessment
only [105], waitlist control [93], or the active intervention delivered in a non-stepped model [81,
100, 118]. Four of the stepped-care trials included no explicit control [75, 77, 82, 87]. The lack
of control was argued by [82, p.70] as “partially inherent to the stepped care design, since it
would be unethical to assign children to a waiting list after a first treatment phase if they needed
further treatment”. This suggests a confusion in how to evaluate proportionate interventions as
it would have been ethical to randomise at baseline to a control arm of care as usual. Nordin
et al. [87] did not include a comparator for step one intervention, however, after step one those
who continued to report stress symptoms were randomised to a group or individual format of
intervention deliver (step two a or b) thus a comparison of delivery method was possible.
A variety of statistical analysis methods were used dependent upon the outcome measures and
main aims. Longitudinal data were incorporated into many of the analyses. Mixed effects mod-
els, containing both fixed and random effects, were used as the statistical analysis method in
38% of studies (14 of 37), see Table 3.3. They were used to account for both longitudinal data
and the clustering effects of NHS trusts, therapists, and other health professionals. Repeated
measures ANOVA was used in three studies [75, 92, 99], however, this method does not success-
fully deal with missing values. In contrast the mixed effects model assume data are missing at
random and allows for imbalance or missing observations within patient [60].
Six stepped-care studies included or planned some form of analysis of the different intervention
stages. These included: summaries of outcome measures presented per intervention step [77];
analysis of outcomes after step one and step two [96]; analysis at the end of each step and the
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end of the whole intervention as well as a comparison of differences in outcomes and patient
characteristics (weight loss and self-monitoring characteristics) between those who were stepped
down and those who remained in treatment in the stepped-care arm [100]; analysis comparing
patient demographic characteristics of those who agree to participate in step two/three compared
to those who decline (for eligible patients) [105]; percentages of children free of any anxiety
disorder after each treatment phase and by intervention [82]; analysis of outcomes after step one
and analysis of outcomes after step two adjusting for intervention received in step one and any
interactions between step one and two interventions [91].
The objectives of the study by Lamb et al. [91] were to evaluate the effectiveness of step one, step
two, and the combined effects of the interventions together. This was made possible by designing
two linked, pragmatic, RCTs. In step one emergency departments were cluster randomised to
The Whiplash Book or usual care, and individual consent was not sought at this stage. In step
two participants who received either of the step one interventions and were eligible after step
one (persistent symptoms at three weeks) were individually randomised at step two to either
one physiotherapist advice session or up to six physiotherapist advice sessions.
Table 3.2: Abbreviations for Table 3.3
Abbreviation Description
BAI Beck Anxiety Inventory
CBT Cognitive behavioural therapy
CES-D Epidemiologic Studies Depression scale
CGI Clinical Global Impression
CGI-S Clinical Global Impression – Severity scale
CIDI Composite International Diagnostic Interview
DSM-IV Diagnostic and Statistical Manual of Mental Disorders
EORTC-QLQ-C30 European Organization for Research and Treatment of Cancer QLQ-C30 quality of
life questionnaire
GAD-7 Generalised Anxiety Disorder-7
GHQ-12 12-item General Health Questionnaire
HADS Hospital Anxiety and Depression Scale
HADS-A Hospital Anxiety and Depression Scale – Anxiety
HADS-D Hospital Anxiety and Depression Scale – Depression
ICD-10 International Statistical Classification of Diseases and Related Health
Problems-10th revision
IDS Inventory of Depressive Symptomatology
IES Impact of Events Scale
MASC Multidimensional Anxiety Scale for Children
MINI Mini International Neuropsychiatric Interview
PHQ-9 Patient Health Questionnaire
PST Problem solving treatment
SCL-20 20-item Symptom Checklist Depression Scale
STAI State-Trait Anxiety Inventory
WSAS Work and Social Adjustment Scale
Y-BOCS Yale-Brown Obsessive-Compulsive Scale
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Table 3.3: Characteristics of included stepped care studies
First
Author
Intervention Tailoring variable and de-
cision rules (response un-
less otherwise stated)
Primary outcome Statistical analysis Analysis
of
stages
Ell [71] Stepped-care, 3 steps: 1) based on patient preference, pa-
tients start PST or antidepressant medication 8 weeks, 2)
a different antidepressant medication or the addition of an-
tidepressant medication or PST 4 weeks, 3) considered for
additional PST, augmentation of low-dose Trazodone for in-
somnia, and referral to speciality mental health care.
50% SCL-20 reduction Depression remission was as-
sessed by SCL-20<0.5 or
PHQ-9<5
Logistic regression model to








Stepped-care, 4 steps: 1) watchful waiting, 2) bibliotherapy,
3) PST and 4) antidepressant medication. Stages were in 3
month cycles.
CES-D<16 MINI/DSM-IV diagnostic
status of depressive and
anxiety disorders
Incremental effectiveness computed
as the difference in the probability





Stepped-care, 2 steps: 1) internet based self-help program,
2) contracting, individual face-to-face counselling, medica-
tion, or referral to other services.
PHQ-9≤10 and/or HADS<8
and/or STAI < 40.
Psychological distress using
HADS and physical role func-
tion using EORTC-QLQ-C30.
ANOVA No
Patel [74] Stepped-care, 4 steps: 1 ) psychoeducation, 2) antidepres-
sants, 3) interpersonal psychotherapy in addition to antide-
pressants or an alternative to antidepressants for those who
did not respond to them, 4) referral to psychiatrist.
Varying ICD-10 diagnosis Chi-square and t-test. Mixed effect




Stepped-care, 2 steps: 1) short therapist sessions and bib-
liotherapy, 2) longer therapist directed sessions.
Y-BOCS reduction≥5 points
plus a post-treatment score of
≤13
Y-BOCS total score and the
clinician’s CGI severity rat-
ing.




Stepped-care, 4 steps: 1) brief integrated CBT/motivational
interview (MI) intervention one session, 2) 4 CBT/MI ses-
sions: 3) 4 CBT/MI sessions, 4) 4 CBT/MI sessions.
Varying Depression and metham-
phetamine use.





Stepped-care, 6 steps: incremental therapy included the
following add-on therapies at 4-week intervals: aliskiren
150–300 mg once daily, hydrochlorothiazide 12.5–25 mg once
daily, and finally amlodipine 5–10 mg once daily, as needed.
Meet the target blood pres-
sure at 4-week intervals.
Estimated cumulative proba-
bility of patients achieving BP
target
Probability of reaching the BP
target, assessed by estimating
control rates of patients who reached
target per visit using life-table
survivor estimates at each visit.
Summaries presented of change in




Stepped-care, 3 steps, 1) therapist assisted self-help for 18
weeks, 2) fluoxetine until 1 year follow-up, 3) full CBT for
6 months.
70% or more reduction in fre-
quency of purging by the end
of session six.
Recovery (no binge eating or
purging behaviours in the past
28 days). Remission (no
longer meeting DSM–IV crite-
ria).





Stepped-care, 4 steps: 1) watchful waiting 4 weeks, 2) guided
self-help, 3) short face-to-face PST 5 sessions, 4) pharma-
cotherapy and/or specialised mental health care.
IDS<14 and HADS<8 and
WSAS<6
IDS and HADS t-tests No
Tolin [81] Stepped-care, 2 steps: 1) bibliotherapy 6 weeks, 2) therapist
directed ERP sessions.
Y-BOCS decreased by ≥5 and
≤13.
Y-BOCS and cost Mixed effects model No
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Stepped-care, 4 steps: 1) randomised to group or individual
CBT sessions for children and parents, 2) five manual-based
Parent-Child Treatment for Anxiety (PCTA) sessions, 3) ad-
ditional five PCTA sessions.
Children diagnosed with an
anxiety disorder and/or who
scored below the cut-off of the
MASC
Change in proportion of chil-
dren with any DSM-IV anxi-
ety disorder
Percentages of children free of any
anxiety disorder after each
treatment phase and by intervention
(step 1 only, 1-2, and 1-2-3, and all
combined). Mixed effects models for
changes on continuous variables.
Yes
Apil [83] Stepped-care, 4 steps: 1) watchful waiting 6 weeks, 2) bib-
liotherapy self-help booklet 6 weeks, 3) individual CBT 12
weekly sessions, 4) referral to physician or psychotherapist
for any indicated treatment.
CES-D ≤16 Incidence of new depressive
episode
Feasibility evaluated descriptively.
Chi-square used to test if selective
drop-out biased results on incidence
of a new depressive episode.
No
Karp [84] Stepped-care, 2 steps: 1) 6 weeks open treatment with ven-
lafaxine xr 150 mg/day and supportive management (SM),
2) 14 weeks in which non-responders are randomised to high-
dose venlafaxine xr (up to 300 mg/day) with PST for De-
pression and Pain or high-dose venlafaxine xr and continued
SM.
PHQ-9 of ≤5 for 2 weeks
and at least 30% improvement
in the average numeric rating
scale for pain.
Univariate pain and depres-
sion response and both ob-
served and self-report disabil-
ity.
Number needed to treat between 2
interventions. Repeated measures
mixed-effect models for self-reported
and observed physical disability





Stepped-care, 4 steps: 1) watchful waiting 3 months, 2)
activity-scheduling 3 months, 3) life review and consulta-
tion with GP 3 months, 4) consultation with GP discuss
further treatment 3 months.
Improvement of ≥5 points on
the CES-D.
Incidence of major depressive
disorder or anxiety disorder
using MINI
Incidence rate ratio using an
unadjusted and adjusted Poisson
regression analysis of the
MINI/DSM-IV depressive and
anxiety cumulative incidence
(1=developed a disorder, and





Stepped-care, 2 steps: 1) low intensity stress-management
intervention given to all patients, 2a) more intensive group
stress management treatment, 2b) more intensive individual
stress management treatment .
A decrease in stress related
symptoms measured by IES
and/or HADS from clinical
levels to normal results.
Subjective distress (intrusion









Stepped-care, 6 steps: 1) monthly group intervention session
+ weekly mailed lessons and submission of self-monitoring
diaries, 2) continue step 1 + 10-minute monthly telephone
contact, 3) step 2 + a second 10-minute telephone contact
each month, 4) step 3 + 1 individual in-person intervention
contact per month, 5) step 4 + provided meal replacement
shakes and bars to replace 1 meal and 1 snack per day, 6)
step 5 + replace 1 of the telephone contacts with a second
individual session per month. Modified based on weight loss
achievement at 3 month intervals.
Weight loss goals 5% at 3
months, 7% at 6 months, 10%
at 9 months, and remained at
10% at 12, 15, and 18 months.
Change in weight over 18
months
t-test to compare mean weight loss
between groups. Mixed effects




Stepped-care, 3 steps: 1) 4 sessions of extensive psycho-
education, 2) a course on coping with depression and/or
anxiety, 10 consultations, 3) coaching (6 booster sessions on
top of step 2) complemented with optional anti-depressant
and/or anxiolytic medication.
PHQ-9<7 and/or GAD-7<8. PHQ-9 & GAD-7 & MINI Chi-square and t-test. Mixed effect
models for longitudinal data.
No
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Lamb [91] Stepped-care, 2 steps: 1) The Whiplash Book advice/active
management advice, 2a) single session of physiotherapist ad-
vice or 2b) up to six sessions of physiotherapy.
Non-response if persistent
symptoms 3 weeks after emer-
gency department attendance
(WAD grades I–III).
Neck Disability Index (NDI) Mixed effects model (accounts for
clustering effects from NHS trusts




Stepped-care, 4 steps: 1) watchful waiting 2 weeks, 2) guided
self-help via internet or booklet 5 weeks + 6 phone/email
coaching sessions, 3) PST administered by a specialised
nurse, 4) specialised psychological intervention or antide-
pressant medication chosen in cooperation between patient
and care co-ordinator.
HADS-A or HADS-D ≤7 HADS Repeated measures ANOVA
(continuous outcomes). GEEs used




Stepped-care, 2 steps: 1) brief advice session, 2a) brief mo-
tivational intervention, 2b) assessment only.
Non-response if student
has heavy episodic drinking
(HED) ≥4 and/or alcohol-
related consequences ≥5 in
the past month they were
randomised to receive step 2
or control (assessment only).
HED and peak blood alcohol
content
Comparison of outcomes at 3, 6 and
9 months between those assigned to






Stepped-care, 3 steps: 1) behavioural change counselling 1
session, 2) motivational enhancement therapy, 3 sessions, 3)
local specialist alcohol services .
AUDIT–Consumption (3-
item) (AUDIT–C) < 5
Average drinks per day Mixed effects model (accounts for





Stepped-care, 2 steps: 1) self-help course, 2) CBT in combi-
nation with antidepressant medication.
CGI-S<3 % of patients responding to
and remitting after treatment
measured using CGI-S
Logistic mixed effects models.




Stepped-care, 4 steps: 1) watchful waiting, 2) guided self-
help, 3) PST, 4) referal to GP.
PHQ-9≥6 Cumulative incidence of
DSM-IV major depressive
disorder using MINI
Logistic mixed effects models. No
Arving
[98]
Stepped-care, 2 steps: 1) low-intensity stress-management
consisting of 2 counselling sessions over 6 weeks, 2) more in-
tensive stress-management treatment consisting of 4-7 ses-
sions.
IES and/or HADS score at 6
week assessment not clinically
significant.







Stepped care, 2 steps: 1) Self-help material, chat forum and
FAQ section, 2) CBT.
HADS subscale<7 at 1, 4, or
7 months after inclusion.









Stepped-care, 3 steps: 1) group-based behavioural weight
loss programme 6 weeks, 2a) behavioural weight loss pro-
gramme 6 weeks or 2b) self-help, 3a) behavioural weight
loss programme 6 weeks or 3b) self-help.
Meet the 3% weight loss tar-
get.
% weight loss Repeated measures ANOVA
(continuous variables) and
Chi-square test (categorical
variables) to compare differences
between treatment groups at the





Stepped-care, 4-steps: 1) watchful waiting, 2) guided self-
help, 3) PST, 4) referral to GP.
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Muntingh
[103]
Stepped-care, 4 steps: 1) guided self-help, 2) CBT 6 sessions,
3) antidepressant medication prescribed by GP, 4) optimiza-
tion of medication in primary care or referal to secondary
care.
50% reduction in BAI score
and BAI≤11
BAI score Difference in gain BAI gain scores
from baseline. Inverse probability
weighting used, accounts for




Stepped-care, 3 steps: 1) family resilience and well-being
fact-sheet, 2) family resilience and well-being activity book-
let, 3) family resilience information support group or waitlist
control.
Step 2: parents eligible if have
a child attending one of 4 se-
lected outpatient clinics at the




ters Family Assessment De-
vice, FAD). Social connect-
edness (Medical Outcomes
Study Social Support Survey,
MOSSSS). Family beliefs.
Descriptive statistics used for Step
1. ANOVA for effect of booklet
intervention for all participants in
Step 2 and sustained change tested
using a repeated measures mixed
effects model for the participants
who did not move into Step 3.
ANOVA to examine additional effect
of the information support group




Stepped-care, 3 steps: 1a) 8 weekly psychoeducation & PST
sessions, 1b) 8 weekly weekly psychoeducation & PST ses-
sions + doctors advice on treatment, 2a) 4 monthly weekly
psychoeducation & PST sessions, 2b) 8 weekly weekly psy-
choeducation & PST sessions, 2c) consult doctor + 8 weekly
weekly psychoeducation & PST sessions, 3a) 4 monthly
weekly psychoeducation & PST sessions, 3b) consult doc-
tor + 8 weekly weekly psychoeducation & PST sessions.
Step 1: 1a) if PHQ-9 11-14 ,
1b) if PHQ-9≥18. Step 2: 2a)
PHQ-9<11, 2b) PHQ-9 11-17,
2c) PHQ-9≥18. Step 3: 3a)
PHQ-9<11, 3b) PHQ-9≥11.
Recovery of depression at 12
months as shown by a PHQ-
9≤6
Mixed effects model. No
Stoop
[107]
Stepped-care, 3 steps: 1) 4 weekly psychoeducation individ-
ual meetings, 2) 10 weekly individual meetings covering the
coping with depression/anxiety course, 3) advice to meet
GP to discuss optional medication and 6 booster sessions
during 6 months. Followed by monitoring of symptoms of
depression or anxiety in case of remission.
PHQ-9<7 and/or GAD-7<8. Symptoms of anxiety and de-
pression after 12-months in-
tervention and 6 months post
intervention.
ANCOVA and clinical significance




Risk factor guided intervention including: 1) medication
adjustment in case of three or more prescribed fall-risk-
increasing drugs, 2) stepped care in case of anxiety disorder
and/or depression, and 3) exercise therapy in case of im-
paired functional mobility. Those eligible for more than one
intervention start them at the same time. Stepped-care, 4
steps: 1) watchful waiting 6 weeks, 2) guided self-help treat-
ment 6 weeks, 3) problem-solving treatment max 6 sessions,
4) referral to GP.
GAD-7<10, a PHQ-9<10, or
a positive PHQ-PD score.
Dizziness-related impairment,
assessed using the Dizziness
Handicap Inventory (DHI).
Mixed effects models for
longitudinal data to compare
intervention and control group,
regardless of number of
interventions. Subgroup analysis for
3 groups separately that received 1
of 3 interventions.
No
Lock [109] Adaptive intervention, Intensive Family Coaching, consist-
ing of family-based treatment (FBT)/Intensive Parental
Coaching (IPC): 4 sessions of FBT + 3 session of IPC.
Weight gain≥2.3kg after
FBT, proceed to IPC.
Retentions and treatment use,
suitability and expectancy,
clinical outcomes, changes in
parental self-efficacy.
Feasibility and acceptability
compared across the randomised
groups (FBT vs. FBT/IPC) using
chi-square test and t-test.
No
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Schuurhuizen
[110]
Targeted selection by a nurse (HADS≥13 and/or
“Lastmeter”≥5), enhanced care (treatment process man-
aged by a trained nurse) and stepped-care. Stepped-care,
4 steps: 1) watchful waiting 3 weeks, 2) a guided self-help
program 5-7 weeks max 6 sessions in 10 weeks, 3) face to
face PST, 4) psychotherapy, medication or a referral to
other services (e.g. social work).
HADS<13 Psychological distress mea-
sured by HADS.
ANCOVA for difference between
groups. Time patients entered
stepped-care and the response to
treatment (progression or not) are




Stepped care, 3 steps: 1) short psychoeducation, 2) 10 weeks
Internet-based self-help program, 3) 12 weeks individual
CBT.
Two out of three of the fol-
lowing criteria: 1) loss of pri-
mary diagnosis (SCID-I), 2)
CSR≤ 3 and reduced by at
least two points, and 3) for
PD, BSQ≤2.5, and for SAD
SPS≤25.
Clinicians’ Severity Rating
(CSR) a 0-8 severity rating of
the primary anxiety diagnosis
Multiple regression analyses. No
Salloum
[112]
Stepped-care, 2 steps, 1) 3 therapist-led sessions, 11 par-
ent–child meetings at home over 6 weeks using a workbook,
weekly brief phone support, online psychoeducation infor-
mation and video demonstrations, 2) 9 trauma focussed
CBT sessions.
PTS≤3, or a Trauma Symp-
tom Checklist for Young Chil-
dren PTS score ≤39, and an
IE Clinical Global Impression-
Improvement rating of 3, 2, or
1.
Trauma Symptom Checklist
for Young Children - post-
traumatic stress subscale
(TSCYC-PTS).
Linear mixed effects models
(continuous outcomes). Generalised






Stepped-care, 5 steps: 1) watchful waiting, 2) depression
care team treatment suggestions (counselling or pharma-
cotherapy, considering participant preference), 3) pharma-
cotherapy suggestions after review of treatment history ,4)
combination pharmacotherapy and speciality mental health
counselling, 5) referral to speciality mental health.




report of severe adverse effect,
increase in PHQ-9 from base-
line by ≥5, or <50% decrease
from enrolment PHQ-9.
Quality-adjusted life years
and percentage of participants
with depression treatment
response
Generalised linear models to
calculate predicted expenditure for
each participant to determine
incremental cost. Logistic regression
models to compare the odds of
achieving clinically meaningful
improvement (SCL-20 improved by
≥50%) between groups.
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3.4.4 Optimal intervention strategy
A summary of the studies categorised as optimal intervention strategy is presented in Table 3.5.
A total of 16% (7 of 44) of the review studies were aimed at finding an optimal intervention
strategy when interventions consist of more than one stage. Unlike the majority of stepped-
care studies, randomisation occured more than once and there was often no true control arm
as the different proportionate intervention strategies were compared to one another. Six of the
studies were explicitly defined as sequential multiple assignment randomised trials (SMARTs)
with the other study based on a two phase trial design evaluating an adaptive smoking cessation
intervention stratgey [94].
The optimal intervention strategy studies included three trial results studies [78, 94, 102], three
secondary analyses of trials [85, 89, 113], and one trial protocol [104]. All seven studies were
based in the United States, where the SMART design was developed [119, 120]. Therapeutic
areas covered, include: oncology [89], schizophrenia [85], depression and anxiety [104], bipo-
lar disorder [113], patients dependent on prescription opioids [78], smoking cessation [94], and
communication for minimally verbal children [102].
The SMART study design has been developed to inform the development of an optimal inter-
vention strategy. SMARTs compare groups of experimental conditions and provide the evidence
to choose the intervention options at different stages. They enable the investigation of the inter-
vention effects of different stages as part of a sequence rather than standalone interventions. The
aim of a SMART is typically to develop an optimal adaptive intervention, it is recommended
that the developed optimal adaptive intervention is then evaluated using a further randomised
confirmatory trial comparing it to an alternative [120]. However, some SMART trials have also
been run as confirmatory trials with control arms for comparison.
Five of the optimal intervention strategy studies were based on two stages of intervention and
two studies used a three stage design [89, 104]. A measurement at the end of each stage was
used to assess response and thus progression to the next stage. Participants were generally
randomised to stage one interventions and if they were classified as responders to stage one they
continued this treatment and non-responders were randomised to the following stage treatments,
an example design is represented in Figure 3.4. The number of treatments at each randomisation
stage varied greatly between studies, at stage one there were between two and six treatments
randomised (two treatments [78, 102, 104], three treatments [113], four treatments [89], or five
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treatments [85]). No control group was used in four of the studies [85, 89, 102, 104], one study
used placebo in stage one [113], and usual care was used in another [78].
Figure 3.4: Example of SMART design with second randomisation dependent upon an interme-
diate outcome response status (R, Randomise; B, C and D, treatments; B+, enhanced treatment














In general, more complex analysis methods were used for the optimal proportionate intervention
strategy category compared to the stepped-care trials. Inverse probability weighting methods
were used to estimate the outcome means associated with each of the two-stage dynamic treat-
ment regimes [89]. A comparison of two treatment conditions was done using the stage two
endpoint and GEEs (to account for correlation among measurements of patients from the same
site) [78]. Other methods to estimate optimal intervention strategy included mixed effects mod-
els [102, 104] and Q-learning [113] .
The studies generally aimed to estimate the optimal proportionate intervention strategy as
a whole rather than considering the effects of each treatment stage. Different stages of the
interventions were considered in some studies. Weiss et al. [78] measured participants who
responded after stage one and randomised those who did not respond to stage two. Weighted
regression was used by Kasari et al. [102] to compare outcomes between the three embedded
proportionate interventions including an indicator for stage one and stage two treatment and
accounting for the probability of a participant following their assigned sequence of treatments
based on randomisation sequence.
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Table 3.4: Additional abbreviations for Table 3.5.
Abbreviation Description
EF External facilitator
EMT Enhanced milieu teaching
IF Internal facilitator
JASP Joint attention symbolic play enagagement and regulation
PANSS Positive and Negative Syndrome Scale
PSA Prostate-specific antigen
QOL Quality of life
REP Replicating Effective Programs
SF-12 12-Item Short Form Health Survey
SGD Speech-generating device
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Intervention Tailoring variable and deci-
sion rules (response unless
otherwise stated)





2 stage intervention. Stage 1: buprenorphine-naloxone in-
duction, 2 weeks of stabilization, a 2-week taper, and 8 weeks
of follow-up. Stage 2: 12 weeks of buprenorphine-naloxone
stabilization, a 4-week taper, and 8 weeks of follow-up. In
each phase, patients randomised to (1) standard medical
management (SMM) or (2) SMM plus individual drug coun-
seling
Stage 1: self-reported opioid use
on ≤4 days in a month, absence of
2 consecutive opioid-positive urine
test results, no additional sub-
stance use disorder treatment, and
≤1 missing urine sample. Stage
2: abstaining from opioids during
week 12 and during ≥2 of the pre-
vious 3 weeks.
Composite measures indicating
minimal or no opioid use based
on urine test–confirmed self- re-
ports
Compare 2 treatment conditions
using the stage 2 endpoint. GEEs





2 stage intervention. Initially randomised to newer atypical
antipsychotics or to perphenazine. Patients randomised at
stage 1 to perphenazine who discontinue were randomised
to a newer atypical antipsychotic. Patients randomised at
stage 1 to newer atypical antipsychotic who discontinue were
given the choice of 2 randomisation arms, including, ziprasi-
done, olanzapine, risperidone, or quetiapine, excluding their
previous treatment or either clozapine, olanzapine, risperi-
done, or quetiapine, again excluding their previous treat-
ment. Dissatisfied patients could opt to switch treatment
again, at this stage treatment was neither randomised nor
blinded.
Non-response if patient discontin-
ues treatment and then eligible for
randomisation to next stage.
12-month PANSS score and 12-
month QOL score.
Marginal structural modelling us-
ing a weighted analysis to com-
pare treatment regimes, the al-
ways atypical antipsychotic regime





3 stage intervention. Stage 1: randomised to 1 of 4 combina-
tion chemotherapies. Stage 2: 2a) responders receive second
course of same chemo, 2b) non-responders, randomised to
second-line treatment. Stage 3: After 2a, 3a) responders re-
ceive second course of same treatment, 3b) if not treatment
finished. After 2b, 3c) if overall success finish treatment, 3b)
if not randomised to second treatment and process repeated
once more. After 3a, finish treatment.
Response defined as: Prostate-
specific antigen (PSA) decline of at
least 40% from baseline, objective
regression (of any magnitude) of
any measurable disease, improve-
ment in any cancer-related symp-
toms, and no new lesions or new
cancer-related symptoms. Success
defined as: a PSA decline of at
least 80% from baseline, resolution
of all cancer-related symptoms, an
objective tumour regression of at
least 50% from baseline for all
measurable lesions, and no new le-
sions or cancer-related symptoms.
Long term survival using log sur-
vival time. Efficiency in dimin-
ishing disease burden over 32
weeks using three specific scor-
ing functions defined as func-
tions of toxicity and efficacy tak-
ing values in the interval [0,1].
Inverse probability weighting
methods to estimate the mean
of counter-factual outcome for
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Rose
[94]
2 stage intervention. Stage 1: all received nicotine patch
treatment 2 weeks before quit date. Responders continue
nicotine patch treatment. Non-responders randomised to 1)
control (nicotine patch), 2) nicotine patch and bupropion, or
3) verenicline alone. Stage 2: for precessation nicotine patch
responders, nonlapsers continue nicotine patch and for those
who lapsed in the first week after quit date randomised to
1) control (nicotine patch), 2) nicotine patch and buprpion,
or 3) verenicline alone.
Ad lib smoking (expired car-
bon monoxide levels) decreased by
>50% after 1 week
Continuous smoking abstinence
at end of treatment
Logistic regression compared each





2 staged intervention. Stage 1: sessions of a) JASP+EMT or
b) JASP+EMT+SGD. Stage 2: early responders continue
stage 1 treatment. Slow responders from 1a) randomised to
receive intensified stage 1 treatment or augmented stage 1.
Slow responders from 1b) receive intensified stage 1 treat-
ment.
After stage 1 if child demonstrated
25% or greater change on at least
half of the variables (7 out of 14),
then the participant was consid-
ered an early responder.
Total spontaneous, communica-
tive utterances coded from a
standardised Natural Language
Sample
Mixed effects models compared
outcome between stage 1 treat-
ments. Secondary aim analysis
used a weighted regression to com-
pare mean outcomes between the
3 embedded adaptive intervention,
including an indicator for stage 1




SMART design for adaptive implementation strategy. Run-
in phase: sites offered REP to implement life goals (LG) for
patients with mood disorders. Sites not initially responding
to REP are randomised to receive additional support from
an EF or both EF/IF. Additionally, sites randomised to EF
and still not responsive will be randomised to continue with
EF alone or to receive EF/IF.
<50% patients receiving ≥3 evi-
dence based practice sessions
SF-12 mental health-related
quality of life and PHQ-9 scores
Mixed effects models. Compare
interventions in non-responding
sites beginning with REP +
EF/IF versus interventions begin-
ning with REP + EF on longitu-
dinal patient-level change in num-
ber of LG sessions received. Com-
pare whether continuing REP +
EF vs. augmenting with REP +
EF/IF leads to changes in out-
comes, among sites who are non-





2 staged intervention. Stage 1: patients randomised to
Bupropion, Paroxetine, or placebo. Stage 2: non-responders
assigned 2nd intervention. If receive Buporopion or Paroxe-
tine at stage 1, current doses increased. If placebo at stage
1, Bupropion or Paroxetine.
≥50% improvement over initial
Scale to Assess Unawareness of
Mental Disorders and not meeting
DSM-IV criteria for hympomania
or mania
Scale to Assess Unawareness of
Mental Disorders




3.4.5 Intervention induced clustering
Any potential intervention induced clustering was identified in studies included in this review.
Table 3.6 presents a summary of intervention induced clustering of the trials, including the
clustering type (therapist or group), the clustered intervention/s and which intervention stages
had the potential for intervention induced clustering. Of the 44 trials in this review, 37 (84%)
were identified as having some form of potential intervention induced clustering.
Of the stepped-care trials 95% (35 of 37) described interventions which were identified as having
possible intervention induced clustering. Of the optimal treatment strategy trials 43% (3 of 7)
described interventions which were identified as having possible intervention induced clustering.
Though there were only a small number of these types of trials included in this review. Of the
37 studies 42% (16), 30% (11) and 27% (10), had clustering at one, two and three or more stages
of the intervention, respectively. Furthermore, of these 37 studies, 54% (20), 68% (25) and 62%
(23), had potential clustering at stage one, stage two, and stage three (and possibly subsequent
stages) of the intervention, respectively.
Clustering was accounted for in the analysis of some trials. When cluster randomisation by
site was undertaken this type of clustering was generally taken account of in both the design
and analysis. Intervention induced clustering was accounted for in the analysis of two trials
included in this review [91, 95]. Lamb et al. [91] ran a two stage trial with a cRCT for step one
(randomisation unit was the NHS trust), evaluating The Whiplash Book versus usual advice,
and an iRCT for step two, comparing physiotherapy versus reinforcement of advice given in
emergency departments. The analysis used random effects to adjust for clustering of NHS trusts
at step one and clustering of NHS trusts and of therapists within NHS trusts at step two. ICCs
were reported for different outcomes and different follow-up times for both NHS trusts and NHS
therapists. The AESOPS trial [95] involved clustering at step one of the intervention included
(20-minute counselling session by a practice/research nurse) and at step two (three 40-minute
motivational enhancement therapy sessions by a therapist such as an alcohol health worker,
clinical nurse manager or drug and alcohol counsellor). The analysis reported that where the
data allowed, the therapist/nurse identification in the AESOPS trial was added as a random
effect, including three levels of data hierarchy: participant within therapist within practice [95].
In the majority of sites, step one and two were delivered by a different care provider. The same
care provider delivered the interventions and steps one and two in four sites. However, the
final model used was a two-level mixed model with participants nested within GP practice as
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the three-level model (including nurse/therapist) resulted in a model that failed to converge.
Both trials that reported to adjust for intervention induced clustering were reported in the HTA
Journal (AESOPS [95] is also included in the HTA review in chapter 7).
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Table 3.6: Summary of intervention induced clustering in trials included in systematic review.
indicates potential intevention induced clustering in that stage of intervention.
First author Clustering
type
Clustered intervention/s Clustering stage
Stage 1 Stage 2 Stage 3 +




Therapist PST (stage 3)
Braamse [73] Therapist counselling (stage 2) -
Patel [74] Therapist Psycotherapy (stage 3), psychiatrist
(stage 4)
Gilliam [75] Therapist therapist sessions (stage 1 & 2)
Kay-Lambkin
[76]
Therapist CBT/MI sessions (stage 1, 2 3, & 4)
Weiss [78]d Therapist Counselling (stage 1 & 2) -
Mitchell [118] Therapist Psychoeducation (stage 1),
depression/anxiety course (stage 2),
coaching (stage 3)
Seekles [80] Therapist PST (stage 3)
Tolin [81] Therapist Therapist sessions (stage 1 & 2)
Van der Leeden
[82]
Therapist Group or individual CBT (stage 1),
parent-child sessions (stage 2 & 3)
Apil [83] Therapist CBT (stage 3), psycotherpy (stage 4)
Dozeman [86] Therapist Life review (stage 3) & consultation with
GP (stage 3 & 4)
Nordin [87] Therapist &
Group
Individual or group stress management
(stage 2)
-
Jakicic [88] Therapist &
Group
Group session (stage 1 - 6), individual
session (stage 6)
Pommer [90] Therapist Psychoeducation (stage 1),
depression/anxiety course (stage 2),
coaching (stage 3)
Lamb [91] Therapist Pysiotherapy advice (stage 2a & 2b)
Krebber [92] Therapist PST (stage 3), psychological intervention
(stage 4)
Borsari [93] Therapist Advice session (stage 1), motivational
intervention (stage 2)
Watson [95] Therapist Counselling (stage 1), therapy (stage 2)
Oosterbaan [96] Therapist CBT (stage 2)
Van Dijk [97] Therapist PST (stage 3)
Arving [98] Therapist Counselling (stage 1 & 2)
Carels [100] Therapist Group programme (stage 1-3b)
Van der Aa [101] Therapist PST (stage 3)
Kasari [102]d Therapist &
Group
Speech clinician, special educator or
child psychologist sessions (phase 1,
children only & phase 2, children &
parents)
Muntingh [103] Therapist CBT (stage 2)
Kilbourne [104]d Therapist Life goals program (LG) provider
Hamall [105] Group Support group (stage 3)
Gureje [106] Therapist Psychoeducation & PST sessions (stage
1-3)
Stoop [107] Therapist Psychoeducation (stage 1),
depression/anxiety course (stage 2),
coaching (stage 3)
Stam [108] Therapist PST (stage 3)




Therapist PST (stage 3), psychotherapy (stage 4)
Haug [111] Therapist Psychoeducation (stage 1), CBT (stage
3)
Salloum [112] Therapist Therapist sessions (stage 1), CBT (stage
2)
Painter [114] Therapist Counselling (stage 2 & 4)
d Optimal-intervention strategy subcategory. Stage is used interchangeably with step, but as a more generic term




The results suggest that trials are being designed in various therapeutic areas that fit the pro-
portionate universal framework. Most studies were conducted in developed countries. The term
proportionate universalism was not used within the identified studies, other terminology used
included: stepped-care, proportionate intervention strategy, dynamic treatment regimen, and
SMARTs. In the review eligible studies fell into two main subcategories of designs: trials using
the stepped-care design (to provide treatment dependent on need) or trials aimed at identify-
ing an optimal intervention strategy (when more than one intervention was available at various
stages and administered dependent upon need).
The stepped-care model begins with a lower level of intervention at the first step and treatment
is only administered at further steps to those in need, randomisation generally only occurs at
baseline. The optimal intervention strategy trials inform decisions on how and when to alter
treatment, they generally involved randomisation at each stage dependent upon response at the
end of the previous stage.
Mental health disorders were the most common therapeutic area of research in this review.
This is most likely because a large majority of the results were stepped-care trials, which is a
NICE recommended pathway for mental health care [115]. Reasoning for using a proportionate
intervention was mainly based around costs and providing the level of care required by an
individual. This is particularly relevant in mental health and complex interventions due to the
sometimes resource intensive interventions (both in terms of time and costs).
Statistical methods used varied greatly based on the outcome measures, though longitudinal
data is generally a feature of trials of proportionate interventions. The trials need to update
and measure the changing needs of patients during delivery of the intervention, resulting in
the collection of longitudinal data. ANOVA and repeated measures ANOVA were used in a
number of analyses. However, these are not recommended as a general approach for longitudinal
data due to the limitations in not being able to deal with missing data, failing to model the
covariance among repeated measures and the use of a repeated measures ANOVA assumes an
exchangeable auto-correlation structure between any two observations on the same individual
[60]. More complex analysis methods were employed in the SMART studies which aimed to find
the optimal intervention strategy.
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Findings highlight that the nature of proportionate interventions commonly results in a com-
plex hierarchical structure of data, with hierarchical clustering introduced by both intervention
and/or centre, in addition to longitudinal data. If outcomes are correlated, not accounting for
this in the analysis methods will result in an inflation in standard errors. The majority of trials
in this systematic review were identified as potentially resulting in some form of intervention
induced clustering.
A minority of studies considered the different stages of the interventions. Some stepped-care
studies used an intention to treat analysis to compare the intervention group to the control
group after each step individually and after the whole intervention period. Only one study
explicitly evaluated the effectiveness of the different components as a key objective [91]. Without
consideration of the separate component parts of a proportionate intervention the assumption is
that each component will in itself be effective. Though this may be true, the effectiveness of the
components might alter as they are incorporated with one-another. By design, the population
size of a stepped-care trial on an intervention decreases as the trial progresses through the steps.
This makes any comparisons between stages to be either impossible or very difficult without
consideration at the design phase to account for this because of insufficent power. It is possible
to evaluate the effectiveness of each stage of a proportionate intervention, as done by Lamb
[91], by randomising patients who are eligible to the active or control treatment, regardless of
the treatment they received at the previous stage. However, this requires large sample sizes
and strong assumptions about response rates (hopefully relatively accurate) based on decision
stages and rules to ensure there are enough patients to randomise at later stages of the trial. In
certain scenarios it would be unethical or impossible to withhold the next stage treatment of a
proportionate intervention if a patient were eligible. For example, if an unstaged version of the
active treatment being tested was used as the control treatment or if each stage builds upon the
previous stage in the following stage.
3.5.2 Limitations
Due to the resource limitations of this review it was not possible to supplement the database
searching with reference list checking or trial registries. Only articles published in English were
included. The studies included were mainly stepped-care, this may suggest limitations in the
search criteria or eligibility criteria to identify other types of studies that were also trials of
proportionate interventions. The review was limited to articles published after 1 January 2010,
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however, this was with the aim to reflect current practice.
3.5.3 Wider context
Proportionate interventions have a role to play in the overarching goal of proportionate univer-
salism, both in reducing health inequalities and providing care to those in need. If the use of
early stage low intensity interventions provides similar outcomes to more intense interventions
then costs are reduced and health interventions less onerous on both patients and health pro-
fessionals. Increased intensity of treatments does not necessarily lead to increased effectiveness.
Some patients are expected to respond to lower intensity interventions.
In broad terms proportionate interventions fit within the overarching goals of personalised
medicine: to make decisions appropriate to an individual patient, decisions that lead to the
best outcomes for the patient, and to formalise clinical decision-making and make it evidence
based. Personalised medicine aims to assign individuals to interventions based on their individ-
ual characteristics and target interventions to patients likely to benefit. This requires evidence
on what types of patients will benefit from different interventions, which is not always available
[121]. In contrast, proportionate interventions can be self correcting with individuals failing to
benefit from lower intensity interventions stepping up to more intense interventions.
The recommendation from the Marmot review for interventions to follow a proportionate univer-
salism framework has not been supported by an evidence base on how to evaluate or implement
such interventions [5]. This review provides examples of the types of interventions that fit under
the proportionate universalism framework and the trial designs used to evaluate these at present.
3.5.4 Implications and recommendations
There have been recent developments in proportionate intervention strategies, trial designs now
exist to develop optimal intervention strategies (SMARTs). Designs also exist to evaluate the
effectiveness of stepped-care interventions as a whole. Further research considering how to
design and analyse trials of proportionate interventions would benefit from considering when
quantifying the effectiveness or the incremental effectiveness of each stage is necessary and how
this may be implemented. This depends upon whether the separate stages have been evaluated
in a trial before as well as the interactions between them, is the interaction of the different
component parts expected and of interest? Without this aspect it may be unclear how all
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components work and how they interact with one another.
Trialists need to consider the impact that multiple hierarchical levels (often present in propor-
tionate interventions) have on the design and analysis. More complex mixed effects models
accounting for the various correlations may be necessary. These may consider and build on
methods for iRCTs with intervention induced clustering [48, 122]. Many proportionate inter-
ventions identified in this review were an extension of a partially nested trial, with intervention
induced clustering often at different stages of the intervention.
Of the 52 studies excluded based on the full texts, 27 were excluded due to lack of or undefined
nature of the decision stages or rules in the intervention. This lack of clarity was occasionally due
to the decision rule being based on a health professionals opinion. However, lack of clarity was
also repeatedly due to limited information in the articles’ explanation of what the intervention
actually entailed. For any trials to provide fully usable information and interventions replicable
they require a clear explanation of the decision stages and rules, readers can then understand
the reasoning and the process can either be implemented in a different setting or in a further
trial.
When reporting trials it is important to follow both the relevant CONSORT guidelines checklist
[16] and the template for intervention description and replication (TIDieR) checklist [123]. The
CONSORT-NPT [17] statement also explicitly instructs authors to, where applicable, report
details of whether and how clustering by care providers or centres was addressed in the sample
size and statistical methods, and results (participant flow). Both CONSORT and TIDieR state
that interventions must be reported with sufficient detail to allow replication, including how and
when they were administered. This is particularly pertinent in proportionate interventions such
as stepped-care as the how and when are often multifaceted.
3.6 Summary
The increasing demand on healthcare services has driven the move for proportionate universal-
ism as well as the move towards fairer and more effective personalised medicine; appropriate
treatment and service provision according to individual need is key. The proportionate univer-
salism framework enables individuals to receive the care they require and reduces the burden of
treatment on an individual whilst reserving resources for those most in need. This review has
identified various contexts and therapeutic areas in which trials of proportionate intervention
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are being designed and implemented in, mainly in the treatment of mental health disorders.
Potential intervention induced clustering was identified in the majority of the studies included
in this review. The term proportionate universalism was not used in any of the studies identi-
fied, though analogous terms will be used including the stepped-care model, adaptive treatment
strategy, and dynamic treatment regimen. The two key types of study designs found in this
review included stepped-care studies and SMART studies. The effectiveness of different stages
was considered in a minority of studies and often only as a simple analysis using summary
statistics.
The findings from this review are used to inform investigations of methods to analyse trials of
proportionate interventions which result in within-arm nesting in chapter 5. The next chapter






Clustering of any form needs to be considered in trial design and analysis, it can result in
a reduction in statistical efficiency and if ignored standard errors and p-values for intervention
effects are typically underestimated [31]. Chapter 2 introduced pnRCTs (clustering of individuals
in only one arm of the trial), highlighting that these often arise in trials of complex interventions
and are likely to occur in trials of proportionate interventions. Bauer et al. [49] undertook a
literature review of RCTs published in four public health and clinical research journals; out of 94
RCTs, they identified 32% as pnRCTs, 40% as iRCTs and 27% as cRCTs. A lack of awareness
for the need to account for the dependence of observations in the clustered arm of the pnRCTs
was identified. Specific statistical methods need to be used for analysing pnRCTs, this chapter
uses a simulation study to evaluate analysis methods for pnRCTs with continuous outcomes.
In theory, the mixed-effects models can be formulated for analysis of pnRCTs so that they do not
model clustering in the control arm. However, when running these models in statistical software
packages it is necessary to impose some form of clustering in the control arm. Although there
is literature on the topic of analysing pnRCTs [42, 45, 48, 49, 122, 124], the analysis models
have not been evaluated in a systematic manner. Research to date is lacking in addressing the
best way to treat the non-clustered control arm when running the models in statistical software,
using scenarios of relevance in the field of public health with small clusters and small ICCs [45,
125], and estimating the effect of the variance ratio of the residuals on the model fit.
In this chapter, a series of simulations are used to evaluate the statistical analysis models for
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two-arm parallel pnRCTs with continuous outcomes. This follows on from work of Flight et
al. [45], a range of scenarios are evaluated including the effect of ICC, heteroscedasticity of
individual level variance across trial arms, cluster size and the number of clusters. In pnRCTs
there may be small numbers of clusters, for instance only seven therapists treated patients in
the intervention arm of the Accupuncture for lower back pain trial [126], thus the simulations
evaluate the impact of the number of clusters on statistical inference and if statistical inference
remains valid using mixed effects models with a small number of clusters.
In addition to my supervisors, this chapter acknowledges the collaborative support of the fol-
lowing researchers: Munya Dimairo; Laura Flight; Laura Mandefield; and Stephen J Walters,
ScHARR Statisticians. They contributed during the simulation conception and design for qual-
ity control and to ensure simulation scenarios where chosen of relevance to real world trials. The
work was led and implemented by myself (including set-up and running of all simulations and
write-up) and has been published in BMC Medical Research Methodology journal [68].
4.2 Chapter aims
This chapter addresses the research aim to evaluate commonly used analysis methods for pn-
RCTs to establish which methods are most appropriate and why. The specific objectives are to
explore:
1. where mixed effects models are necessary,
2. methods of specifying the clusters in the non-clustered arm when fitting a model and the
impact these have on the analysis,
3. the impact of cluster sizes and the number of clusters on statistical inference and,
4. the impact of heteroscedastic individual variance between trial arms on statistical inference.
4.3 Literature on pnRCTs
Table 4.1 presents a summary of the key literature on the analysis of pnRCTs. Literature was
identified using an updated literature search of the one undertaken by Flight et al. [45] for more
recent work and findings. Sample size calculations for pnRCTs have been addressed elsewhere
[127–131] and are discussed in chapter 6.
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Analysis methods for pnRCTs have mainly focussed on using mixed effects models [45, 48, 49,
122, 132–135]. These allow us to control for baseline covariates and represent the different levels
in the data, including cluster, individual, and repeated measures (where applicable) and estimate
the ICC as part of the primary analysis.
The cluster inducing intervention may result in a decrease or increase of the individual level vari-
ability. Consequently, in addition to accounting for the clustering, it might be expected that the
variance of the individual errors to differ between trial arms in pnRCTs, termed heteroscedastic
variance [48]. When an intervention arm with clustering is compared to a non-clustered control
arm the between-cluster variation in the intervention arm is not present in the control arm.
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Table 4.1: Summary of relevant literature on analysis of pnRCTs
Author Relevant themes Range of values* Findings
Schweig
[135]
Describe and compare models for pnRCTs
with non-compliance using a simulation
study.
Simulation for two levels of
clustering, exact cluster sizes (m)
unclear in paper, cschool = 37,
cclass = 177, λB = 2, 8,
ρschool = 0.005, 0.05, 0.15,
ρclass = 0.0004, 0.10, 0.25, and
θ = 0.087.
Clustering and non-compliance may have a substantial impact on statistical
inference about intention-to-treat effects. Provide methods that may accommo-
date pnRCT with non-compliance, recommend using complier average causal
effect estimate (CACE) and scaling by the proportion of compliers. No mention
of degrees of freedom, assumed they used default degrees of freedom method
available in R lme packages.
Flight
[45]
Compare models applied to four examples
of pnRCTs. Compare three different meth-
ods for classifying the non-clustered control
arm in pnRCTs, including: singleton clus-
ters, one large cluster and pseudo clusters.
Examples with
{m, c} = {36, 8; 24, 7; 14, 8; 5, 6},
and estimated
ρ̂ =< 0.0001, 0.02, 0.007.
Recommend use of the heteroscedastic model, recommendations based only on
re-analysis of case studies. Methods for classifying the non-clustered control
arm in pnRCTs had a large impact in fully clustered mixed effects models and
no measurable impact in partially nested mixed effects models. ICCs in four
examples were found to be small.
Sterba
[124]
Review of modelling developments for pn-
RCTs, focused on those particularly rele-
vant to psychotherapy trials.
Recommend the inclusion of cluster variability in analysis model as it pro-
vides insight into treatment process (rather than treating it as a nuisance).
Annotated Mplus commands for models.
Lohr
[133]
Report presenting a guide to design and
analysis issues for pnRCTs in education re-
search, using example trials. Discussion of
degrees of freedom issue in Appendix.
Guidance document, defines pnRCT in context of education research and show




Compare models for pnRCTs using a simu-
lation study, investigate misspecification for
the estimation of the parameters and their
standard errors.
Simulation study with m = 5,
c = 10, 30, 50, 100,
ρ = 0.05, 0.1, 0.2, λA = 1, d = 0.3.
All models perform comparably with respect to fixed effect estimates. Recom-
mend use of partially nested mixed effects model. Simulations were under null
hypothesis and ICC was always greater than zero. No mention of degrees of
freedom, assumed default degrees of freedom used from MLwiN software, and
homoscedasticity was assumed for individual variances between the two arms.
Sanders
[134]
Compare models for pnRCTs using simu-
lation study in terms of Type I error and
power.
Simulation study with
{m, c} = {2, 10; 4, 4; 5, 4; 10, 2},
ρ = 0, 0.1, 0.2, 0.3, 0.4, 0.5, λA = 1,
and ω2 = 0, 0.01, 0.059, 0.138.
Type I error rate increased as ICC increased, Satterthwaite degrees of freedom
had better control than Kenward-Roger degrees of freedom. Found using mixed
effects model for pnRCT when ICC is zero likely leads to never detecting
intervention effects, observed Type I error rates nearly non-existent under all
scenarios with ICC equal to zero. Recommend to evaluate if ICC is significantly
different from zero prior to selecting analysis method. Homoscedasticity was
assumed for individual variances between the two arms.
86
Table 4.1 – Continued from previous page
Baldwin
[122]
Compare analysis models for pnRCT sim-
ulation study, comparing three degrees of
freedom calculations, and a pnRCT exam-
ple.
Simulation for m = 5, 15, 30,
c = 2, 4, 8, 16,
ρ = 0, 0.05, 0.1, 0.15, 0.3,
λB = 0.25, 1, 4, and d = 0, 0.5.
Recommend pnRCTs take account of heteroscedasticity. Satterthwaite and
Kenward-Roger degrees of freedom control Type I error rate. The heteroscedas-
tic model provides an unbiased estimate and little reduction in power compared
to the homoscedastic model. Argue that using a partially nested mixed effects
model only a problem for statistical inference when the number of clusters is
small. The number of clusters has greater impact on power in pnRCTs. At
least eight, preferably 16 clusters, to maintain Type I error rate.
Bauer
[49]
Review of RCTs to ascertain the prevalence
of pnRCTS in four public health and clinical
research journals. Analysis models for pn-
RCTs extended to include pre-test measures
as covariates, individual and group level co-
variates, and example of pnRCT
Example with clustering in one
arm c = 41, m = 9, and estimated
ρ̂ = 0.02.
Out of 94 RCTs, 32% were pnRCTs, 40% iRCTs and 27% cRCT. None used
methods specific to pnRCTs. Example pnRCT data could be analysed using
mixed effects models. Argue pnRCTs “often increase external validity at the
expense of internal validity” (p.20).
Roberts
[48]
Examine the case of pnRCTs, heterogeneity,
comparison of analysis methods for simula-
tion study and present an example.
Simulation for m = 6,
c = 8, ρ = 0, 0.1, 0.2, 0.3,
λA = 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2
and d = 0.
Recommend pnRCTs take account of heteroscedasticity. Satterthwaite unequal
variances t-test gave robust to heteroscedasticity. The heteroscedastic model
gives slightly inflated test size for large ρ: suggest Satterthwaite degrees of
freedom as a solution.
Lee [41,
42]
Describe analysis models for iRCTs with
clustering and apply to two examples (us-
ing Bayesian approach)




Statistical tests for RCTs with clustering
that differ across trial arms.
Example with clustering in both
arms with m = 7− 12, c = 3.
Provide an adjustment for the independent samples t-test for pnRCTs. Sta-
tistical impact of heterogeneity effect increases as the cluster size increases,
and as heterogeneity increases. The test does not allow for the inclusion of co-
variates, multiple treatments, baseline measures, or non-normally distributed
outcomes.
*m = cluster size, c = number of clusters, ρ= ICC, d = standardised effect size, ω2= Omega Squared effect size percent of variability accounted for by treatment condition, λA = ratio of total
variance in control arm compared to clustered, λB= ratio of individual variance in control arm compared to clustered arm. Ordered by year of publication.
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During research of the literature I found an error in the description of the simulation study in
Baldwin et al. [122] paper, they had simulated a ratio of standard deviations as opposed to a
ratio of variances. Following contact with the corresponding author a correction was made to
this paper.
4.4 Analysis methods for partially nested trials
As discussed in chapter 2, it is not recommended to analyse clustered trial data using a fixed effect
for each individual cluster in the model. This section provides more information on the main
modelling approaches currently available and used for pnRCTs, including ignoring clustering
altogether, imposing clustering in the non-clustered control arm, and explicitly modelling the
partially nested design by modelling clustering only in the intervention arm.
Define y as a continuous outcome, i is the individual participant indicator, j is the cluster
indicator, tij is the intervention indicator (0 = control, 1 = intervention), θ is the intervention
effect, β0 is an intercept term. Error terms are defined depending on the model procedure,
represented using ε, u, and r.
4.4.1 Linear regression model
One approach, and the one often taken in pnRCTs, is to ignore the clustering altogether. Linear
regression analysis ignores the grouping and uses analysis for non-clustered trials, assuming
independence between individuals regardless of whether they are in the same cluster. The
outcome for the ith individual ignoring any group level variation is given by the model
yi = β0 + θti + εi, (4.1)
εi ∼ N (0, σ2ε ).
This infers that the conditional variance of y in both the treatment and control arms is equal.
Ordinary least squares (OLS) is a method to estimate parameters in linear regression model
which minimises the residual (differences between observed and predicted responses) sum of
squares. An important assumption of the linear regression model is that the outcomes are
independent, if the outcomes of individuals in the same cluster are correlated, the independence
assumption is violated and standard errors of the intervention effect are underestimated when
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using the linear regression model in equation 4.1 [40].
4.4.2 Fully nested mixed effects model
We can use a fully clustered mixed effects model which includes the cluster as a random effect
as in equation 4.2; this includes variability at both the individual and cluster level. The mixed
effects model with imposed clustering of the control arm requires the estimation of a random
cluster effect for both intervention and control arms. Some options for the imposed clustering in
the control arm are given in Table 4.2. Here, the random intercept term uj represents between
cluster variation, this can model the cluster level variation and εij is the individual level variation
for the ith individual in the jth cluster. The outcome for the ith individual and the jth cluster
is given by the model
yij =β0 + θtij + uj + εij , (4.2)
uj ∼N(0, σ2u),
εij ∼N(0, σ2ε ).
The variance of the control arm and intervention arm are assumed to be the same (homoscedas-
tic). When the variance is believed to differ between control and intervention arm equation 4.2
is not appropriate as it does not account for heteroscedasticity [48]. Adding random coefficients
at individual and group level to equation 4.2 can account for between treatment heterogeneity.
Again the clustering in the control arm must be specified.
4.4.3 Partially nested mixed effects models
Alternatively the cluster effect can be applied to the clustered arm only, defined as partially
nested models which accurately reflects the design of the study [48, 49, 122, 131, 135, 137].
Individuals in the non-clustered arm are assumed independent.
4.4.3.1 Homoscedastic model
In the partially nested homoscedastic model, the random effect uj is applied to the clustered
treatment arm only, between-cluster variability is only present for the intervention arm. The
outcome for the ith individual and the jth cluster is given by the partially nested homoscedastic
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model
yij = β0 + θtij + tijuj + εij , (4.3)
uj ∼ N (0, σ2u),
εij ∼ N (0, σ2ε ).
Equation 4.3 equates to a random intercept model for each cluster in the intervention arm,
yij |(tij = 0) = β0 + εij ,
yij |(tij = 1) = β0 + θ + uj + εij .
Mutual independence of the random components uj ⊥ εij is assumed. The ICC in the treatment




ε ). There is no ICC for the control arm as there is no estimate of between





Equation 4.3 is homoscedastic as the variance of the individual errors, εij , between arms is the
same, in practice this may differ between trial arms. It makes the assumption that the variance
in the intervention arm is greater than the control arm which will not necessarily always be
the case. The clustered intervention may result in a decrease or increase of the individual level
variability.
4.4.3.2 Heteroscedastic model
The variance of the individual errors may differ between trial arms [48]. Therefore, equation
4.3 is extended to a partially nested heteroscedastic model in equation 4.4. This allows for
differing individual errors between intervention and control arms but does not constrain the
form of heteroscedasticity. For instance, in a pnRCT with a therapist led treatment in the
intervention arm we might expect the individual level variance to differ between participants of
the intervention and control arms. The partially nested heteroscedastic model is given by
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yij = β0 + θtij + tijuj + (1− tij)rij + tijεij , (4.4)
uj ∼ N (0, σ2u),
rij ∼ N (0, σ2r ),
εij ∼ N (0, σ2ε )
where εij are the individual level residuals in the clustered arm and rij are the individual level
residuals in the unclustered arm. Equation 4.4 gives,
yij |(tij = 0) = β0 + rij ,
yij |(tij = 1) = β0 + θ + uj + εij .





thus accounting for heteroscedasticity and not assuming the variance in treatment arm is always






It is possible to use a mixed effects model to analyse pnRCT data with a fixed treatment slope
and a random intercept related to cluster level residuals as in equations 4.3 and 4.4. Theoretically
in such models, the residual cluster variance is only estimated for the clustered intervention arm.
We may consider that there are two ICC values in such a pnRCT trial: the ICC in the whole
dataset which we can use to calculate how correlated the outcome is in relation to all participants








As no individual has both εij and rij the above ICC is likely to be an underestimate of the true
ICC. The ICC in the clustered intervention arm only (how correlated the outcome is in relation







In a sense, inference is based on overall ICC although the source of clustering is driven by one
arm. On the other hand, if we assume the ICC in the unclustered arm is zero then one approach
when designing a pnRCT is to inflate the sample size only in the clustered treatment arm using
arm specific ICC. The assumption of zero ICC in the unclustered arm may be questionable and
trial dependent considering what the control arm receives. The second approach for estimating
ICC is used in this study.
4.4.5 Impose clustering in the control arm
Regardless of whether or not the model assumes clustering in one or both arms, there is still
a need to create artificial clusters in the non-clustered arm to fit the model and within the
statistical software package a decision must be made about how to code the cluster indicators
in the control arm. One method is to impose clusters for all individuals, including those in the
control arm, and use analysis for cRCTs with clustering in both arms.
Table 4.2 represents the different options for imposing clustering, j, in the control arm, l is
the number of individuals in the control arm and k is the number of arbitrary clusters in the
control group. Option one treats the control group as one single cluster; option two treats each
individual in the control arm as their own cluster of size one (singleton clusters) giving j = l
clusters in the control arm. ICC estimation can be problematic with options one and two, in
theory, it is not possible to estimate between-cluster variability in option one, or estimate within
cluster variability in the control group using option two [138]. Option three imposes artificial
pseudo-random clusters in the control group to overcome the problem of estimating within or
between-cluster variability. The number of arbitrary clusters, k, needs to be considered. In this
work it was chosen to be equal across treatment arms. In addition, option three will likely result
in a lower ICC estimation due to the assumed independence of control participants.
Table 4.2: Options for imposing clustering of controls
Option Cluster Intervention
1 j= 0 j= 1, . . . ,c
2 j= 1, . . . ,l j=l + 1, . . . ,c
3 j= 1, . . . ,k j=k + 1, . . . ,c
Recent work by Flight et al. [45] investigated the effect of the different methods of imposing
clustering in the control arm presented in Table 4.2 in four pnRCT case-studies. The four case-
studies covered trials evaluating the effect of: specialist leg ulcer clinics (clustered by clinic),
acupuncture for low back pain (clustered by acupuncturist), postnatal support in the community
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(clustered by community support worker), and telephone befriending for maintaining quality of
life in older people (clustered by volunteer facilitator) Little difference was found between the
different methods for the fully clustered mixed effects models and there was no difference found
between the different methods for the partially nested mixed effects models.
4.4.6 Degrees of freedom for fixed effect estimates
In addition to the correct choice of model, the test statistics and degrees of freedom in mixed
effects models also need to be considered. In the mixed effects models described in sections 4.4.2
and 4.4.3 we typically wish to carry out significance tests for the intervention effect, θ. The
intervention effect, θ, is estimated using MLE or REML and the significance is estimated using
the likelhood-ratio or Wald test statistic. The significance of the intervention effect is typically
determined using a Wald test statistic in statistical packages. The Wald test statistic is used to
test the hypothesis that the estimated regression coeficient θ̂ is 0, it is obtained by comparing




For large sample sizes in mixed effects models, the Wald test statistic for fixed effects can be
assumed Normally distributed. However, for small samples the large sample approximations
may not be appropriate and the t and F distributions can be used as an approximation of
the distribution of the Wald test statistic. The denominator degrees of freedom for the t and F
statistics can be approximated using the Satterthwaite [139] or the Kenward-Roger [140] method
to account for small samples and unbalanced data or balanced data with complicated covariance
structures.
Comparison of degrees of freedom correction methods has been undertaken for cRCTs and
pnRCTs with small numbers of clusters [122, 141]. The Satterthwaite small-sample degrees
of freedom correction takes into account the variance structure of the data, for pnRCTs, it
has been shown to be superior to the between-within method for maintaining Type I error rates
(and comparable to the Kenward-Roger method) [122]. When an unadjusted analysis is suitable,
Baldwin et al. [122] argue the Satterthwaite unequal variance t-test is appropriate. Following
these results, the Satterthwaite approximation was used to calculate degrees of freedom (using
dfmethod() option for mixed, available in Stata 14 onwards [142, 143]).
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There are two commonly used packages for fitting mixed effects models in R: lme4 and nlme.
The Satterthwaite approximation can be implemented for lme4 using the lmerTest package.
However, lme4 does not currently implement nlme’s features for modelling heteroscedasticity
and correlation of residuals so it is not possible to fit the heteroscedastic model in equation 4.4
using lme4, nlme is required. At the time of running this simulation study, I was not aware of a
method to implement the Satterthwaite approximation in nlme. Hence, the statistical software
Stata was used for the simulation study. Stata allows the fitting of the heteroscedastic partially
nested model (equation 4.4) with the Satterthwaite degrees of freedom correction.
4.4.7 Summary of analysis methods
Table 4.3 presents a summary of the models for the analysis of pnRCTs from the previous section
and which were used in the simulation study.
In the simulation study, the fully clustered model 2 was parametrised using the imposed clus-
tering from Table 4.3. The models were defined as:
1. Model 2.1 fully clustered mixed effects model with singleton clusters in the control arm;
2. Model 2.2 fully clustered mixed effects model with one large cluster in the control arm;
3. Model 2.3 fully clustered mixed effects model with pseudo clusters in the control arm.
It was anticipated that the method of imposing the clustering in the control arm would not affect
the results of the methods which model clustering in only one arm, however, this was evaluated
in the simulation study.
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Table 4.3: Models for the analysis of pnRCTs
Model description Statistical model Heteroscedastic
residuals
Model 1 Linear regression
(ignore clustering)
yi=β0+θti+εi
εi ∼ N(0, σ2ε ) the individual level
variation
No
Model 2 Fully clustered
(impose clustering)
yij=β0+θtij+ uj+εij
uj ∼ N(0, σ2u), a random effects term
representing between cluster variation
εij ∼ N(0, σ2ε ) the individual level
variation
No
Model 3 Partially nested
homoscedastic
yij=β0+θtij+ ujtij+εij
uj ∼ N(0, σ2u), a random effects term
representing between-cluster variation in
clustered arm
εij ∼ N(0, σ2ε ) the individual level
variation
No
Model 4 Partially nested
heteroscedastic
yij=β0+θtij+ ujtij+rij(1−tij) +εijtij
uj ∼ N(0, σ2u), a random effects term
representing between cluster-variation in
clustered arm
rij ∼ N(0, σ2r) the individual level
variation in the non-clustered control
arm.
εij ∼ N(0, σ2ε ) the individual level
variation in the clustered arm
Yes
4.5 Simulation study methods
4.5.1 Overview
A simulation study was conducted to evaluate the aims presented in 4.2, evaluating the statistical
analysis models for pnRCTs presented in Table 4.3 and the imposed clustering of the control
arm presented in Table 4.2. The simulation study utilised guidance on design, conduct and
reporting of simulation studies [144, 145]. All models were fitted using a REML. REML has
been shown to be more robust than MLE [40].
The number of iterations used in simulations was 1000, therefore, an estimated type I error of
5% would have a Monte Carlo standard error of approximately 0.7%. The Satterthwaite degrees
of freedom correction computed using dfmethod(sat) is computationally intensive, hence, the
number of simulations were partly limited due to computational time required. See Appendix
A.2 for simulation code.
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4.5.2 Software
All simulations were done in Stata [142] and graphs produced using ggplot2 [146] in R [147].
Stata is a statistical software package, which allows programming of simulations and analysis
and presentation of results. Stata does have a simulation command, however, it was not used
for this study as it did not provide enough flexibility. Simulations were instead written directly
using a combination of loops and the Stata postfile commands.
Random number generation within Stata is technically pseudo-random, numbers are not truly
random but generated from a specific algorithm. To allow the simulations to be replicable, a
random number seed should be provided at the start of a simulation study and recorded. The
seed for the Stata pseudo-random number generator was set at the start of each set of simulations
and recorded so that simulations could be reproduced if required.
4.5.3 Data-generating mechanism
Data were simulated to replicate a two-arm parallel pnRCT trial with a non-clustered con-
trol arm and a clustered intervention arm (randomised 1:1) and a continuous outcome. Data
were simulated under various design scenarios and under both the null (θ = 0) and alternative
hypothesis (θ = A, where A 6= 0).
Data were simulated from the following model with the intercept set to zero and group allocation
denoted by t (t = 0 for control arm, t = 1 for intervention arm):
1. For the control arm (t = 0) yij = zij
√
γ(1− ρ)





Where uj ∼ N(0, 1) and zij ∼ N(0, 1). This simulates an ICC of ρ and a ratio of individual level
variance between the non-clustered control arm and the clustered intervention arm of γ. If γ = 1,
there is homoscedasticity between the individual level variance in the control and intervention
arms. Full simulation study steps, including the data generation process and modelling, are
presented in Figure 4.1.
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Figure 4.1: Flowchart representing the simulation study steps
4.5.4 Scenarios to be investigated
Simulation scenarios are presented in Table 4.4. The intervention effect, ICC, cluster size,
number of clusters, and ratio of individual variance between the trial arms were varied across
scenarios. Values were chosen based on literature on pnRCTs [42, 45, 48, 49, 122, 124, 132, 134],
as well as extending these to more extreme cases of γ and ρ that may occur in rare instances.
Reporting of ICCs in iRCTs with clustering is limited at present and it is plausible that ICCs in
pnRCTs differ from those of cRCTs. Current evidence suggests ICCs in iRCTs with clustering
in either one or both arms are generally small and often less than 0.05 [45, 46, 48, 50], hence the
choice to include a small ICC ρ = 0.01 in the simulations. If γ = 0.25 then individual variance
in the control arm is one quarter that in the intervention arm and if γ = 4 then individual
variance in the control arm is four times that in the intervention arm. The number of clusters
in the intervention group was 3, 6, 12 or 24. These figures reflect the small numbers of clusters
recruited in many pnRCTs and, coupled with the cluster sizes of 5, 10, 20 or 30, they allowed
alternative combinations of cluster size and number of clusters to be investigated for a given
total trial size. For each of the total of 1,440 scenarios 1,000 datasets were generated.
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Table 4.4: Simulation input scenario values (total 1,440 scenarios)
Variable Notation Values
Number of clusters c 3, 6, 12, 24
Cluster size m 5, 10, 20, 30
Intervention effect θ 0, 0.2, 0.5
ICC ρ 0, 0.01, 0.05, 0.1, 0.2, 0.3
Ratio of individual variance
between control and cluster
trial arms
γ 0.25, 0.5, 1, 2, 4
4.5.5 Methods
Each simulated dataset was analysed using the models described in Table 4.3: a linear regression
model, a fully clustered mixed effects model, partially nested mixed effects homoscedastic model,
and a partially nested heteroscedastic mixed effects model.
4.5.6 Estimand
The estimands of interest were the intervention effect θ and the ICC ρ.
4.5.7 Performance measures
The following performance measures were used:
 Bias of the intervention effect estimate: calculated as the difference between the average
estimate of the effect and the true effect using Bias = E(θ̂)− θ.
 Mean square error (MSE): provides a measure of accuracy which incorporates both bias
and variability and calculated using E[(θ̂ − θ)2].
 Coverage of the intervention effect estimate 95% confidence intervals: proportion of sim-
ulations that the obtained 95% confidence interval contains the true specific intervention
effect θ.
 Type I error rate: proportion of simulations in which the p-value < 0.05 when the null
hypothesis is true, true intervention effect θ = 0.
 Power: proportion of simulations in which the p-value < 0.05 when the alternative hy-
pothesis is true, true intervention effect θ 6= 0.
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 Where applicable, model estimated ICC was calculated. ICC calculated using ρ̂ = σ̂2u/(σ̂2ε + σ̂2u),
where σ̂2ε and σ̂
2
u are within- and between-cluster variance estimates for the clustered in-
tervention arm.
4.6 Results
Models converged between 95% and 100% of the time across the different scenarios. Results in
this chapter are presented mainly in figures and tables of results are included in the Appendix
A.
4.6.1 Imposed clustering in the control arm
Methods for imposing clustering in the control arm, presented in 4.2, had a negligible impact
on the performance measures of the partially nested mixed effects models (models 3 and 4).
Under the simulation scenarios, the differences in the p-value, 95% confidence intervals and
estimated ICC between the methods were only present at four decimal places. Model fitting was
considerably faster (around four to five times faster) using either one large cluster or the pseudo
clusters compared to the singleton clusters, however, this will likely be immaterial when fitting
only a small number of models.
Methods for imposing clustering in the control arm had a large impact on the performance
measures of the fully clustered mixed effects models (models 2.1, 2.2, and 2.3). Specific results
for each performance measure are presented in the subsequent sections.
Results are reported only for the partially nested mixed effects models (models 3 and 4) with
the non-clustered controls classified as one large cluster, as other methods were comparable. All
three methods for classifying the non-clustered control arms for the fully clustered mixed effects
model (models 2.1, 2.2, and 2.3) are reported.
4.6.2 Bias
The bias of the intervention effect estimate was not affected by the analysis model used, indi-
vidual variances (γ) or the ICC (ρ). All models produced bias of the intervention effect less
than |0.057| under all scenarios considered. Figure 4.2 presents a box-plot of bias of intervention
effect estimate θ̂ by θ and model.
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4.6.3 Mean square error
The models produced unbiased estimators with no difference in the observed MSE between the
different models. The MSE of the intervention effect estimate had a mean of 0.051 (SD 0.056)
and maximum of 0.346. Figure 4.3 shows the MSE of the intervention effect estimate by ρ and
γ for model 4 as there was no difference across models.



























































4.6.4 Type I error
Plots of the mean Type I error rates split by model, the ratio of individual variances (γ) and the
ICC (ρ) are presented in Figure 4.4. As would be expected the linear regression model which
ignores clustering had inflated Type I error rates, with Type I error rate affected by ICC (ρ),
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the ratio of individual variances (γ), number of clusters (c), and cluster size (m). Although the
inflation was minimal when ICC ρ = 0.01, the mean Type I error was 0.061 (SD 0.010). When
cluster size m ≤ 10 and ICC ρ = 0.01 the mean Type I error rate was 0.056 (SD 0.007).
Model 2, the fully clustered models with imposed clustering in the control arm resulted in biased
Type I error rates. Imposing clustering as singleton clusters (model 2.1) led to Type I error rates
which were largely affected by the ratio of individual variances (γ) and ICC (ρ). Imposing one
large cluster in the control arm (model 2.2) resulted in Type I error rates of zero (due to the
Satterthwaite degrees of freedom correction resulting in large degrees of freedom when imposing
one large cluster in the control arm). Imposing pseudo clusters in the control arm of the same
size as the intervention arm (model 2.3) provided relatively good control of Type I error rates,
mean Type I error of 0.039 (SD 0.018), but was affected slightly by both the ratio of individual
variances (γ) and the ICC (ρ).
Both the homoscedastic and heteroscedastic partially nested models (models 3 and 4) provided
good control of Type I error rates (model 3: mean Type I error 0.045 (SD 0.016) and model 4:
mean Type I error 0.044 (SD 0.014)) with little difference present between the two models.
For more detailed comparison Figure 4.5 presents the Type I error rates for the linear regression
model (model 1), the homoscedastic (model 3) and the heteroscedastic (model 4) partially nested
models by ICC (ρ), the ratio of individual variances (γ), number of clusters (c), and cluster size
(m). Higher ICC values resulted in higher Type I error rates in each model. The impact
of ignoring clustering (model 1) depends on both ICC (ρ), cluster size (m), and number of
clusters (c). Larger number of clusters (c) resulted in better control of Type I error rates for
the partially nested models. When ICC ρ = 0, the Type I error rates of the partially nested
models (models 3 and 4) were reduced from the nominal 5% level. This is due to the cluster
variance components being estimated when they are not actually present in the data. When the
ICC was small (ρ ≤ 0.05) and the individual variance in the control arm was smaller than that
in the intervention arm (γ < 1), the Type I error rates of partially nested models were reduced
from the nominal 5% level. When ICC was large (ρ = 0.3) the partially nested models generally
resulted in inflated Type I error rates. As ICC increased Type I error rates increased, with the
partially nested models 3 and 4 only reaching above the nominal Type I error rate of 5% on
average when ICC ρ ≥ 0.2.
The Satterthwaite correction used in Stata mixed (dfmethod(sat)) did not fully correct the
Type I error rates to the nominal level of 5%, even with the use of the heteroscedastic model 4.
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2.1:Fully clustered RE (singleton cluster)
2.2:RE one cluster
2.3:RE pseudo cluster
3:Partially nested homoscedastic RE
4:Partially nested heteroscedastic RE
The heteroscedastic model 4 did have slightly improved control of Type I error rates compared
to the homoscedastic model 3.
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4.6.5 Coverage
Plots of the mean coverage of the 95% confidence intervals of the intervention effect estimate,
split by model, ICC (ρ) and the ratio of individual variances (γ) are presented in Figure 4.6 under
the alternative hypothesis. The linear regression model (model 1) resulted in under coverage
when ICC was small (ρ ≤ 0.05) and the coverage rates decrease as ICC (ρ) increases. The fully
clustered models with imposed clustering in the control arm resulted in both over and under
coverage dependent on the direction of the variance ratio and the method of imposed clustering.
Imposing clustering as singleton clusters (model 2.1) resulted in coverage rates largely affected
by the ratio of individual variances (γ). Imposing one large cluster in the control arm (model
2.2) resulted in over coverage, due to the Satterthwaite degrees of freedom correction. Imposing
pseudo clusters in the control arm (model 2.3) provided mean coverage rates of 0.961 (SD 0.018).
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Both the homoscedastic and heteroscedastic partially nested models (models 3 and 4) provided
good control of coverage rates of 95% confidence intervals (model 3: mean coverage rate 0.956
(SD 0.014) and model 4: mean coverage rate 0.956 (SD 0.014)) with little difference between
the two models. In the simulations over coverage of the 95% confidence intervals for the het-
eroscedastic model 4 occurred when ICC ρ ≤ 0.05, except when the ratio of individual variances
γ = 4. Hence, the results were generally conservative when ICC was small. Under coverage of
the 95% confidence intervals for the heteroscedastic model 4 only occurred for large ICC (ρ) and
ratio of individual variances (γ).
Figure 4.6: Mean coverage of 95% CI, by ρ and γ over all scenarios
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2.1:Fully clustered RE singleton cluster
2.2:Fully clustered RE one cluster
2.3:Fully clustered RE pseudo cluster
3:Partially nested homoscedastic RE
4:Partially nested heteroscedastic RE
4.6.6 Power
Increasing the number of clusters as opposed to increasing the cluster size had a bigger impact on
power with a fixed sample size. Figure 4.7 shows the power of the linear regression model (model
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1), the homoscedastic (model 3) and the heteroscedastic (model 4) partially nested models when
intervention effect θ = 0.5 by ICC (ρ), the ratio of individual variances (γ), number of clusters
(c), and cluster size (m) (see Appendix A for when θ = 0.2). Under the simulation scenarios
conducted, 12 or more clusters and cluster sizes of ten or more were generally required for a
power greater than 80%. Using three or six clusters rarely gave power over 80%. Only for ICC
ρ ≤ 0.05 and relatively large cluster sizes m ≥ 20 did the power go over 80%.
For ICC ρ ≤ 0.05, which is commonly assumed when planning complex intervention trials in
healthcare, power of 80% was generally achieved with: 24 clusters of any size, 12 clusters of size
ten or more, and six clusters of size 20 or more (120 in each arm).
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Under a ratio of individual variances γ = 1 the total residual variance in both trial arms is equal
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to one, hence, the intervention effect (θ) simulated is the standardised intervention effect. Figure
4.8 shows the power of models 1, 3 and 4 under homoscedastic individual variances (γ = 1).
The heteroscedastic model 4 is over-parametrised in the case of the ratio of individual variances
γ = 1, however, it did not result in a substantially lower power than the homoscedastic model.






































































































Table 4.5 presents the power of model 4 and model 1 under ICC ρ = 0, model 4 is over-
parametrised here. There is a loss in mean statistical power which ranged between 2-6%.
Table 4.5: Mean and SD of power of model 4 versus model 1 under ρ = 0 over all scenarios
Intervention Model Power
effect (θ) Mean SD
0 1 0.050 0.007
4 0.033 0.014
0.2 1 0.388 0.276
4 0.327 0.286




Figure 4.9 presents the mean estimated ICC across the fully clustered and partially nested mixed
effect models, by the ratio of individual variances (γ) and ICC (ρ). ICC estimation was consistent
under the heteroscedastic partially nested model (model 4). The homoscedastic partially nested
model (model 3) resulted in biased ICC, with the direction of bias dependent upon the ratio of
individual variances (γ).
Figure 4.10 presents the ICC for the homoscedastic (model 3) and heteroscedastic (model 4)
partially nested models by the ratio of individual variances (γ), ICC (ρ), number of clusters (c),
and cluster size (m). The ICC estimation from the homoscedastic model was highly affected by
γ. The ICC from the heteroscedastic model was not affected by γ. Using the heteroscedastic
model, there was a slight positive bias in the ICC estimation when ICC ≤ 0.05, and when ICC
≥ 0.2 there was slight negative bias in the ICC estimation. For example, when ICC = 0.0 the
mean ICC estimate was 0.028 (SD 0.018), and when ICC = 0.05 the mean estimate was 0.060
(SD 0.014). As expected ICC estimation improved as sample size increased. The ICC estimation
was only consistent across all values of ICC (ρ) regardless of cluster size when there were 24
clusters. For an accurate estimate of ICC when ICC = 0.05, under the simulation scenarios
cluster sizes (m) of 20 or 30 were required or at least six clusters of size ten or 24 clusters of size
five.
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2.1:Fully clustered RE (singleton cluster)
2.2:Fully clustered RE (one cluster)
2.3:Fully clustered RE (pseudo cluster)
3:Partially nested homoscedastic
4:Partially nested heteroscedastic RE
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4.6.8 Summary of results
Simulation results are summarised in Table 4.6 presenting the performance of the simple linear
regression model (model 1), homoscedastic partially nested mixed effects model (model 3) and
heteroscedastic partially nested mixed effects model (model 4) under different design scenarios.
Results from the fully clustered mixed effects models (model 2) are excluded from Table 4.6 as
these are not recommended in any scenario regardless of the method used to impose clustering
in the control arm. None of the fully clustered mixed effects models provided full control of the
Type I error rates and the partially nested mixed effects models always outperformed them.
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Table 4.6: Summary of simulation results in terms of Type I error (α̂) and ICC estimation (ρ̂)










Model 1 Model 3 Model 4
α̂ α̂ ρ̂ α̂ ρ̂
0 5 - 10 3 - 6 0.049 (0.007) 0.025 (0.009) 0.047 (0.043) 0.026 (0.013) 0.047 (0.020)
12 - 24 0.052 (0.007) 0.040 (0.010) 0.035 (0.040) 0.042 (0.009) 0.023 (0.010)
20 - 30 3 - 6 0.050 (0.007) 0.023 (0.011) 0.014 (0.012) 0.024 (0.014) 0.013 (0.004)
12 - 24 0.050 (0.007) 0.038 (0.010) 0.010 (0.011) 0.040 (0.009) 0.006 (0.002)
0.01 5 - 10 3 - 6 0.058 (0.007) 0.028 (0.010) 0.052 (0.043) 0.030 (0.016) 0.052 (0.017)
12 - 24 0.055 (0.006) 0.041 (0.011) 0.041 (0.044) 0.043 (0.007) 0.029 (0.010)
20 - 30 3 - 6 0.064 (0.015) 0.029 (0.010) 0.021 (0.016) 0.029 (0.016) 0.019 (0.003)
12 - 24 0.066 (0.008) 0.044 (0.012) 0.017 (0.016) 0.046 (0.008) 0.013 (0.001)
0.05 5 - 10 3 - 6 0.072 (0.016) 0.031 (0.011) 0.077 (0.057) 0.031 (0.016) 0.079 (0.016)
12 - 24 0.071 (0.012) 0.047 (0.012) 0.067 (0.061) 0.048 (0.008) 0.058 (0.007)
20 - 30 3 - 6 0.120 (0.035) 0.041 (0.008) 0.051 (0.031) 0.039 (0.011) 0.052 (0.002)
12 - 24 0.123 (0.032) 0.052 (0.017) 0.050 (0.036) 0.050 (0.006) 0.050 (0.001)
0.1 5 - 10 3 - 6 0.093 (0.024) 0.037 (0.007) 0.108 (0.068) 0.037 (0.012) 0.114 (0.011)
12 - 24 0.092 (0.025) 0.050 (0.013) 0.103 (0.082) 0.050 (0.008) 0.100 (0.004)
20 - 30 3 - 6 0.192 (0.058) 0.053 (0.011) 0.090 (0.046) 0.050 (0.012) 0.093 (0.004)
12 - 24 0.185 (0.055) 0.055 (0.015) 0.097 (0.056) 0.050 (0.007) 0.099 (0.002)
0.2 5 - 10 3 - 6 0.136 (0.049) 0.047 (0.012) 0.174 (0.091) 0.044 (0.012) 0.187 (0.008)
12 - 24 0.135 (0.047) 0.054 (0.011) 0.183 (0.113) 0.051 (0.005) 0.193 (0.004)
20 - 30 3 - 6 0.301 (0.087) 0.060 (0.009) 0.169 (0.072) 0.057 (0.012) 0.177 (0.011)
12 - 24 0.286 (0.077) 0.051 (0.011) 0.188 (0.084) 0.049 (0.006) 0.196 (0.003)
0.3 5 - 10 3 - 6 0.181 (0.068) 0.056 (0.011) 0.242 (0.108) 0.053 (0.010) 0.262 (0.012)
12 - 24 0.177 (0.065) 0.054 (0.012) 0.268 (0.135) 0.050 (0.007) 0.288 (0.006)
20 - 30 3 - 6 0.383 (0.092) 0.065 (0.010) 0.245 (0.090) 0.061 (0.011) 0.258 (0.017)
12 - 24 0.368 (0.094) 0.051 (0.009) 0.278 (0.105) 0.050 (0.007) 0.292 (0.005)
*Model 1: simple linear regression; Model 3: homoscedastic partially nested mixed effects model; Model 4: heteroscedas-
tic partially nested mixed effects model. Green highlighted ≤ than expected, red highlighted > than expected.
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4.7 Discussion
This chapter has investigated six modelling strategies for the analysis of pnRCTs with a con-
tinuous outcome. The simulation study showed that when analysing pnRCTs the use of the
heteroscedastic partially nested mixed effects model for normally distributed outcome data (us-
ing Satterthwaite degrees of freedom) in general provides: unbiased effect estimates; maintains
relatively good control of Type I error rates; and did not noticeably cause a reduction in power
even with homoscedastic individual variances across arms. The heteroscedastic partially nested
model takes account of the between-cluster variance (if present) and therefore provides valid
inferences for the intervention effect. When using the partially nested mixed effects model, the
method of classifying the non-clustered controls had a negligible impact on statistical inference
under the simulation scenarios, agreeing with findings from analysis of four example pnRCTs
by Flight et al. [45].
The findings were broadly similar to those of Baldwin et al. [122]. However, they did not assess
the method of classifying the non-clustered controls or performance of models under small ICC
(ρ = 0.01) which commonly occur in pnRCTs [45, 46, 48, 50, 122]. Unlike findings from Baldwin
et al. [122], the Satterthwaite degrees of freedom correction did not fully control the Type I error
rate in the simulations. The most discrepancy from the nominal level occurred when the ICC
was small, ratio of individual variances γ < 1, and under small sample sizes.
It was illustrated that using a näıve linear regression model which ignores clustering in pnRCTs
gives inflated Type I error rates and results in under coverage of confidence intervals when
clustering of outcomes was present. When ICC 0.01 ≤ ρ ≤ 0.05, which is typical in pnRCTs
[45], ignoring clustering led to largely inflated Type I error rates using the linear regression
model. A low ICC may still have a large impact, particularly when there are large cluster sizes.
When ICC was small and/or with very few clusters and small cluster sizes using the partially
nested mixed effects models 3 and 4 resulted in deflated Type I error rates. These models
correctly reflect the design of the trials; however, they can result in conservatism regarding the
precision of estimates due to the bias in estimating the variance estimates when there are a small
number of clusters. Consequently, using the partially nested mixed effects models with small
ICC may make it difficult to detect differences between the trial arms when present.
Sanders [134] recommend evaluating whether ICC is significantly different from zero prior to
selecting an analysis method. The use of significance testing for ICC and similarly testing for
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heteroscedasticity are generally discouraged in agreement with Roberts and Roberts [48] and
Donner and Klar [148]. These tests will generally lack power in a pnRCT and it is not the
statistical significance of the ICC that matters but impact of the magnitude on inference. In
general, the use of the partially nested models when analysing pnRCT trials is recommended,
particularly if conservatism and an ICC estimate are desired. However, model choice decision
and the requirement or not for conservatism needs to be considered in the context of the specific
trial setting.
Similar to cRCTs [40], in a pnRCT increasing the number of clusters rather than increasing the
cluster size had a greater increase in power for a fixed total sample size. The simulation results
showed that this will also provide a more accurate estimation of the ICC. When the number of
clusters is small, for example, three clusters in the intervention arm, the ICC estimation will
likely be upwardly biased. With six clusters in the intervention arm, the ICC estimate was
relatively unbiased once the true ICC ≥ 0.1. ICC estimation became consistent regardless of
cluster size or true ICC only once there were 24 clusters in the simulation scenarios. This reflects
findings from previous research that a large number of clusters are required to reliably estimate
the size of clustering effects [149].
This chapter investigated the case of analysing pnRCTs under complete compliance. Non-
compliance in the clustered arm of a pnRCT may occur when some participants randomised
to a particular treatment group or therapist do not attend any sessions or receive treatment as
part of different treatment group or therapist intended at randomisation. Consequently, non-
complier outcomes may be assumed independent if they do not receive the clustered intervention.
Schweig and Pane [135] describe and compare models for pnRCTs with non-compliance using
a simulation study. They argue that an unbiased intention-to-treat (ITT) estimate under non-
compliance on a pnRCT may be obtained using a Complier Average Causal Effects (CACE)
model. This method involves estimating the treatment effect for compliers and scaling this
CACE effect estimate by the proportion of compliers to provide an ITT effect estimate. The
issues posed by non-compliance warrant further investigation, considering a broader range of
scenarios and investigating the degrees of freedom corrections for valid statistical inferences.
A wide variety of terminology is used in iRCTs with clustering, including partially nested, par-
tially clustered, multi-level, and individually randomized group intervention. A more consistent
use of terminology would reduce confusion, improve reporting and make finding relevant ICCs
from previous trials easier. The terminology partially nested randomised controlled trial is
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suggested to describe an iRCT with clustering in one arm.
4.7.1 Limitations
All the mixed effects models assume that the cluster effects follow a Normal distribution. This
may not be a valid assumption, for example, when there are a small number of clusters.
The simulations used fixed cluster sizes. In practice, cluster size may vary, causing a loss in
efficiency when estimating the intervention effect. A Monte Carlo simulation study by Candel
and Van Breukelen [128] found the efficiency loss in the intervention effect estimate was rarely
more than 10%, requiring recruitment of 11% more clusters for the intervention arm and 11%
more individuals for the control arm. The loss of efficiency in the intercept variance reached
up to 15%, requiring 19% more clusters in the clustered arm, and no additional recruitment in
the control arm. Additionally, it has been shown in cluster trials if the coefficient of variation
in cluster size is small, less than 0.23, then the correction on sample size is negligible [150]. It
should be noted that cluster sizes are likely more similar in the group administered treatment
compared to trials which impose clustering by being treated by the same care provider [48].
Throughout the simulations it was assumed that there was no effect of clustering in the control
arm, this may not strictly be true in practice. In healthcare intervention trials, a commonly used
control intervention is ‘care as usual’. This type of control may induce some form of low-level
clustering, for instance, treatment by a healthcare practitioner. If the same practitioner treats
numerous individuals, it can be assumed, in the same sense as was done for the intervention
arm, that these individuals are clustered and include this in the modelling procedure. However,
this information is often not available in trial data and is not unique to pnRCTs.
Partially nested trials pose a number of challenges, in particular, the issue of internal validity
[49]. The grouping of individuals as part of the delivery of a treatment may affects the outcome.
However, taking a pragmatic viewpoint, the grouping is considered as part of the treatment
as a whole if this is reflective of treatment delivery in real-world practice. In addition, if the
ungrouped controls are the true comparison in real life a pnRCT design will provide external
validity.
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4.7.2 Model fit code for Stata, R, and SAS
It is still common for clustering in pnRCTs to be ignored in the design and analysis stages.
To encourage the use of analysis methods which take account of clustering, Table 4.7 presents
commands to implement the homoscedastic and the heteroscedastic partially nested models in
three commonly used statistical packages, Stata, R, and SAS, along with the degrees of freedom
correction options (where available). The homoscedastic model is included for clarity and where
there is a strong priori belief of homoscedasticity it may be more suitable to use. Both the
homoscedastic and heteroscedastic models can be fitted in Stata and SAS with the option of
the Satterthwaite degrees of freedom correction. Both models can be fitted in R, however, at
the time of submission of this thesis I was not aware of a method that allows the fitting of
the heteroscedastic partially nested model (model 4) using the Satterthwaite degrees of freedom
correction. Instead, it is possible to use bootstrapping to obtain confidence intervals and the
likelihood ratio test to obtain p-values for the effect estimate.
Table 4.7: Stata, R and SAS model fitting commands for the partially nested models




Stata mixed command with dfmethod(sat)
option
mixed command with dfmethod(sat)
option and residuals(independent,
by(intervention))
Example code mixed y treat || cluster:treat, nocons
reml dfmethod(sat)
mixed y treat || cluster: t, nocons reml
residuals(independent, by(treat))
dfmethod(sat)
R* lmer function from lme4 package, and
package lmerTest for Satterthwaite df
lme function from nlme package with
weights=varIdent(form=∼1|treat)
option. No option for Sattertwaite df.




SAS proc mixed command with the option
ddfm=sat
proc mixed command with the option
ddfm=sat and repeated / group =
treat;
Example code proc mixed covtest;
class cluster treat;
model y = treat / solution ddfm=sat;





model y = treat / solution ddfm=sat;
random intercept treat / subject =
cluster;
repeated / group = treat;
run;
y = outcome, treat = intervention arm indicator, cluster = intervention cluster indicator. *At present cannot fit
the heteroscedastic partially nested model with degrees of freedom correction in R. The function lmer in R does not
allow for different variances for each level of a grouping factor.
115
4.8 Summary
This chapter has described the scenarios in which pnRCTs may arise, the reason clustering
needs to be considered, and available analysis methods. Partially nested RCTs are increasingly
used in complex intervention research. Ignoring clustering can lead to large inflations of the
Type I error rates, even for small ICCs. When analysing a pnRCT it is recommended to use
a heteroscedastic partially nested mixed effects model with corrected degrees of freedoms such
as the Satterthwaite method, for continuous outcomes similar to those generated under the
scenarios of the simulations study. The model is easy to implement in standard statistical
software and does not cause a notable reduction in power under homoscedastic variances. The
method used for classifying the non-clustered controls made a negligible impact on the results
using the partially nested mixed effects model. With few clusters, small cluster sizes and small
ICC, the partially nested model underestimated Type I error rates and gave largely inflated
ICC estimates, hence, for such designs there is no optimal model and we need to be cautious in
model interpretation. Finally, in order to aid the design and prior selection of an appropriate
analysis plan for pnRCTs, it is strongly recommended to report both estimated ICC and 95%
confidence interval for primary and secondary endpoints when publishing trials results.
The next chapter expands upon findings from this chapter and the systematic review in chapter
3, the analysis of within-arm pnRCTs is investigated, pnRCTs with clustering of only some of
the intervention arm based on intermediate response.
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Chapter 5
Within-arm partially nested trials
5.1 Introduction
In chapter 4 it was demonstrated that it is possible to analyse pnRCTs appropriately parametris-
ing the model with fixed and random effects. When there are a sufficient number of clusters,
partially nested mixed effect models provide an unbiased effect estimate, maintaining nominal
Type I error rates and account for the clustering in one arm providing ICC estimation. When
clustering is only present for some in the intervention arm, termed within-arm pnRCTs herein,
analysis which reflects the design of the trial becomes more challenging. This chapter expands
upon chapter 3 and 4 and investigates the analysis of within-arm pnRCTs through a simulation
study.
Proportionate interventions can induce a complicated hierarchical data structure. The system-
atic review in chapter 3 found that, similar to the E-SEE trial, trials of proportionate interven-
tions often induce some form of clustered outcomes at different stages of the intervention. One
or more of the intervention stages can result in the presence of possibly non-ignorable clustering
[54]. This clustering may be due to therapist effects, for example therapists running the trauma
focussed CBT sessions in step two of the stepped care trial by Salloum et al. [112], or group
effects, for example the Incredible Years-Infant parenting groups in the E-SEE trial [3], or both
the group and the group facilitator effects (if group facilitators run more than one parenting
group).
When clustered outcomes are present for all individuals in the intervention arm, for instance
when stage one induces clustering, these can be defined in the same manner as pnRCTs and
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analysis models parametrised accordingly using partially nested mixed effects models. However,
the clustering may not affect all participants in the intervention arm, and if so it is typically
not at random (participants who receive the clustered intervention stage are those who did not
respond to the previous intervention stage), and defined as post-randomisation clustering.
Within-arm partial nesting can occur from both the design of the intervention, such as propor-
tionate interventions, or from non-compliance within the trial. This chapter considers the case
related to design, non-compliance has been considered elsewhere [135]. A series of simulation
studies are used to evaluate appropriate analysis methods for within-arm pnRCTs with contin-
uous outcomes. A range of scenarios are evaluated including the effect of ICC, cluster size and
the number of clusters.
5.2 Chapter aims
This chapter aims to evaluate the performance of commonly used analysis methods for within-
arm pnRCTs to establish which methods are most appropriate and why. The specific objectives
are to:
1. evaluate models for within-arm pnRCTs using linear regression and mixed effects models;
2. evaluate linear regression with robust/bootstrap standard errors to account for clustering;
3. quantify the impact that ignoring clustering can have on Type I error and precision;
4. provide recommendations for the most appropriate analysis methods for within-arm par-
tially nested randomised controlled trial considering the ICC and cluster size.
5.3 Analysis methods for within-arm partially nested trials
This section presents and discusses the modelling approaches available to analyse within-arm
pnRCTs, expanding on those presented in chapter 4 including: ignoring clustering altogether
using linear regression; linear regression with cluster robust standard errors; linear regression
with cluster bootstrap standard errors; and mixed effects model.
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5.3.1 Within-arm partially nested trial design
In order to be able to evaluate the different methods of analysis, all models are tested on the same
within-arm pnRCT trial scenarios. Attention is limited to a two arm, two stage intervention as
follows:
1. first stage is delivered at the individual or universal level, for example, bibliotherapy for the
treatment of depression. If individuals do not respond to stage one (based on pre-defined
decision rules) they are offered,
2. second stage intervention which is delivered in a manner that results in intervention induced
clustering of outcomes, for example, Cognitive Behavioural Therapy treatment by therapist
for depression.
Figure 5.1 represents the trial design described above in a flow diagram form; this is a version of
a stepped-care trial with two steps. The primary aim of a trial using this design (and primary
analysis used to power such a trial) is typically to evaluate the effectiveness of the overall
intervention being tested (comprised of stage one and two) compared to the control arm. The
control is commonly care as usual or a comparator treatment. Therefore, the aim of the trial
in Figure 5.1 would be to evaluate the overall effectiveness of the proportionate intervention
compared to control, regardless of whether participants were only offered stage one, or were
offered both stage one and two.
Figure 5.1: Diagram representing the simple proportionate intervention with clustering of out-









There are specific issues that arise in the analysis of Figure 5.1. The outcome follow-up after
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stage two is clustered due to intervention induced clustering of stage two. We ideally wish to
adjust for this clustering in the analysis. However, not all individuals in the intervention arm
get stage two and it is not randomly allocated, clustering is dependent on previous outcome
after stage one intervention.
For the following modelling approaches, define yfij as a continuous outcome at follow-up f for
the ith individual and jth cluster, i = 1, . . . , N and j = 1, . . . , k. The intervention indicators
are t11j is the trial arm indicator (0 = control, 1 = intervention, and all in the intervention arm
receive stage one intervention) and t2ij is the stage two indicator (0 = no stage two intervention
received, 1 = stage two intervention received). Let the outcome follow-ups occur after stage one
intervention, y1ij , and after stage two intervention, y2ij . Let θ denote the overall intervention
effect and θ1 and θ2 denote the effect of stage one and stage two interventions, respectively.
Error terms are again defined depending on the model, represented using ε, u and r, and β0 is
an intercept term.
5.3.2 Linear regression model and other naive analysis
One approach to analysis of within-arm pnRCTs (the one most commonly used to date and
seen in the systematic review results of chapter 3) is to ignore the treatment induced clustering
altogether. For instance, analysis could be done using a t-test, ANOVA, linear regression model,
or a mixed effects model analysing the longitudinal follow-up data of patients by including a
random effect for patient (accounts for within person correlation). The näıve linear regression
model presented in equation 4.1 can be used to analyse the within-arm pnRCT.
Due to the design induced clustering we may wish to choose a more robust method than fitting
OLS regression. Possible methods are described in the following sections.
5.3.3 Mixed effects regression
Chapter 4 recommended the use of a heteroscedastic partially nested mixed effects model. Fol-
lowing this, the initial modelling strategy was to try and extend and parametrise a mixed effects
model for the within-arm pnRCT data, which would model the clustering for only those who
receive the clustered intervention stage two. Schweig and Pane [135] formulated a similar mixed
effects model to account for non-compliance in pnRCTs and estimate the intervention effect,
this attributed random effects only to those individuals who received the cluster intervention
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and suppressed random effects for those that did not receive the clustered intervention.
A mixed effects model for the analysis of within-arm pnRCT shown in Figure 5.1 would require
a fixed intervention effect for intervention arm t1ij (0 = control arm, 1 = intervention arm),
individual random variation and an additional random effect for those who receive the clustered
intervention. Hence, the random intercept term uj represents the between cluster variation in
the stage two intervention (clustered), where t2ij is an indicator for stage two (0 = no stage two
intervention, 1 = stage two intervention) and εij are the individual level residuals in the control
arm and rij are the individual level residuals in the intervention arm. Additional predictive
covariates can also be added to the model in practice. The outcome at follow-up two (f = 2)
for individual i in cluster j, i = 1, . . . , N , j = 1, . . . , k, is given by the model
y2ij = β0 + θt1ij + ujt2ij + rij(1− t1ij) + εijt1ij , (5.1)
uj ∼N(0, σ2u),
rij ∼N(0, σ2r )
εij ∼N(0, σ2ε ).
The mixed effect model in equation 5.1 is expected to result in a biased estimate of the overall
intervention effect. The rationale is based on the parametrisation of the model and the structure
of the data. Firstly, the model includes a random intercept at the cluster level (uj) for the
individuals who receive stage two and no fixed effect for stage two intervention. Secondly, the
clusters or treatment groups in within-arm pnRCTs are not organised randomly. Only those with
interim measures below a threshold (non-responders) are assigned to groups. This effectively
down-weights the contribution of these participants when allowing for non-dependence (with a
random effect) because these participants are more similar even before they receive any stage
two intervention and hence the estimate of the mean effect estimate is biased.
To account for the intervention effect and clustering effect of stage two both a fixed and random
effect would need to be directly included in a mixed effects model. A partially nested mixed
effects model accounting for clustering of stage two treatment and adding a fixed effect for stage
one and one for patients who receive stage two using the following model
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y2ij = β0 + θ1t1ij + θ2t2ij + ujt2ij + rij(1− t1ij) + εijt1ij , (5.2)
uj ∼N(0, σ2u),
rij ∼N(0, σ2r ),
εij ∼N(0, σ2ε ).
Equation 5.2 will also provide an estimate of the ICC for stage two intervention, t2ij , using
ρ = σ2u/(σ2u + σ2ε ). However, as stage two is not given at random it is important to note this
will produce biased intervention effect estimates when randomisation occurs only at baseline.
This is confirmed using a small simulation study described in section 5.4. Although the anal-
ysis method in equation 5.2 will typically not be powered for during the design phase, it will
provide an estimate of the ICC. The ICC may be of descriptive interest to evaluate how the
outcomes are correlated within clusters. Equation 5.2 can be considered a heteroscedastic par-
tially nested mixed effects model accounting for clustering of stage two treatment and adding
subgroup covariates.
Preliminary work to evaluate bias of the mixed effect models given in equations 5.1 and 5.2 was
undertaken using simulations of a number of different scenarios, with a single large simulated
dataset for each scenario. This work showed the models to be largely biased when estimating
the intervention effect estimate. The preliminary work coupled with the statistical properties
of the mixed effect models in equations 5.1 and 5.2 suggest that these models are inappropriate
and largely bias the effect estimate. This is formally confirmed using a small simulation study
described in section 5.4. Only a small simulation study is required to demonstrate the large-
sample bias of the effect estimator identified in the preliminary work [151]. Guidance for the
simulation study is taken from Morris et al. [151] to demonstrate a large-sample bias of an
estimator. The sample size of the simulated dataset is large to show that the effect estimator is
largely bias from its true value and two scenarios are chosen (one under the null and the other
under the alternative hypothesis).
So far this chapter has explored how to construct a mixed effects model for within-arm pnRCTs.
The following section will discuss alternative analysis which may be able to account for clustering
and provide an estimate of the interventions effect (θ).
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5.3.4 Linear regression with robust standard errors
Robust standard errors are a method of estimating standard errors in linear regression analysis.
They are robust to minor concerns about the OLS regression assumptions, such as concerns
about normality, heteroscedasticity, or having some observations with large residuals, leverage
or influence. The robust variance estimator is also called the sandwich estimator, Huber-White
sandwich estimators are used in Stata [142].














where ei = yi−xiθ, xi is the ith row of X which is an n×p matrix of covariates, n is the number
of observations and p the number of parameters.
5.3.4.1 Cluster robust
When using the robust estimator of the variance it is possible to relax the assumption of in-
dependent observations by using cluster-robust standard errors. Cluster robust standard errors
require that observations are independent across clusters but not necessarily within-clusters.
They do not require specification of a model for within-cluster error correlation, but cluster-
robust standard errors do assume “that the number of clusters, rather than just the number of
observations, goes to infinity” [58, p.318].













where j is the cluster identifier, uj =
∑
eijxij and nc is the number of clusters. The clustered
robust variance formula is that of the robust (unclustered) estimator with the individual eijxij ’s
replaced by their sums over each cluster.
Cluster-robust standard errors were incorporated into Stata by Rogers et al. [152]. They can be
implemented in Stata using the vce(cluster clustervar) command, where clustvar spec-
ifies to which cluster each observation belongs, for example, vce(cluster cluster1) in data
with observations in the clusters defined by cluster1. This affects the standard errors and vari-
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ance–covariance matrix of the estimators but not the estimated regression coefficients. Using
the cluster estimator is expected to result in more conservative errors when positive correlation
exists [152].
5.3.5 Linear regression with bootstrap standard errors
Bootstrapping was first proposed by Efron and Tibshirani [153], it can used for estimating
standard errors and other statistical measures whilst making few assumptions. It is a non-
parametric approach using computational re-sampling techniques rather than formulae.
The basic concept of bootstrapping is presented in the following. Let θ̂ again denote the estimate
of our parameter from the original sample. A nonparametric bootstrap procedure can be used
to calculate standard errors using the following steps [154]:
1. Draw B independent random bootstrap samples, each consisting of n data values drawn
with replacement from the sample dataset x, generating B pseudo-samples (for estimating
standard error B is usually in the range of 25-200 [153]);
2. Estimate the desired statistic corresponding to each of these bootstrap samples, which
forms the sampling distribution of θ̂;












where θ̂b, b = 1 . . . , B denote the B estimates of β from the bootstrap samples, and θ∗ =
(1/B)
∑B
b=1 θ̂b is the mean of the estimates across the B bootstrap samples. Though the boot-
strap estimates of the statistic are used to estimate the standard error, the actual estimated
value used for the statistic is still the original observed value θ̂ computed using the original
observations.
Bootstrap confidence intervals can be calculated using the Normal approximation or using the
percentile method. The percentile method is constructed from the sampling distribution of the
B bootstrap estimates of the parameter of interest, reading off the 2.5% and 97.5% percentiles
of the distribution gives you the 95% confidence interval. Though an obvious choice for the
confidence interval the percentile method can be biased, hence, it is generally not recommended
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as the best method [153]. This bias can be estimated and corrected for using the bias corrected
and accelerated (BCa) method [153, 154]. Bootstrapped confidence intervals may, therefore, be
asymmetric and be better able to deal with skewed data.
5.3.5.1 Cluster bootstrap
Bootstrap resamples from the original data and assumes the data are independently and identi-
cally distributed. If clustering is present and we ignore the dependence of the data by resampling
at the level of the individual observation we cannot preserve the distribution of the estimate
of the desired statistic, this can result in under estimated standard errors and give incorrect
inferences [155].
It is possible to bootstrap at the cluster level. We can recognize that observations within a
cluster are not independently distributed by, instead of drawing individual observation units with
replacement, each sample drawn during each replication is a bootstrap sample of clusters drawn
with replacement. Each bootstrap resample will have exactly k clusters. Some of the original
clusters will not appear at all while other original clusters may be repeated in the bootstrap
sample two or more times [58]. Cluster bootstrap standard errors also assume independence
across clusters of observations.
Although the majority of the data in a within-arm pnRCT are independent, correlated outcomes
exist for participants that receive the clustered stage two treatment. Pals et al. [43, p.1421] notes
that “bootstrap standard errors are correct in the context of within-group correlation only when
bootstrapping is done at the group level”. Hence, it was assumed that the simple bootstrap
ignoring the cluster level would be invalid. If the ICC is positive then the cluster bootstrap
standard errors compared to the usual bootstrap standard errors will result in a larger standard
error and consequently larger confidence intervals.
Bootstrap standard errors are included in many statistical packages with the option of boot-
strapping at the cluster level. In Stata bootsrap standard errors of the parameter estimates can
be caluclated using the vce(bootstrap) command. Again, issues arise when there are a small
number of clusters. Bootstrap cluster confidence intervals may have poor coverage properties
when there are a small number of clusters [155]. It is also possible to re-sample separately from
each stratum (using the strata option in Stata).
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5.4 Simulation study methods
5.4.1 Overview
A simulation study was undertaken to address the aims of this chapter, to evaluate the analysis
models for within-arm pnRCTs presented in section 5.3 and summarised in Table 5.2. As in
chapter 4 the study utilised guidance on design, conduct and reporting of simulation studies
[144, 145].
5.4.2 Software
Software used for the simulations was the same as that used in chapter 4: simulations in Stata
[142] and graphs produced using ggplot2 [146] in R [147]. See Appendix B.2 for example simu-
lation code.
5.4.3 Data generating mechanisms
Data were simulated to replicate a parallel within-arm pnRCT with an unclustered control arm
and a two stage treatment in the intervention arm (randomised on a 1:1 basis), with clustering in
the second stage treatment and a continuous outcome. Data were simulated under various design
scenarios and under both the null and alternative hypotheses. Data generating mechanisms are
explained in more detail in this section.
Data were simulated from the following model with the intercept set to zero and trial arm
allocation denoted by t1 (t1 = 0 for control arm, t1 = 1 for intervention arm). All in the
intervention arm receive stage one, t1 = 1. Fifty percent of the intervention arm receive stage
two, based on outcome after t1 t2 = 1 if y1 < θ1, (t2 = 0 no stage two intervention, t2 = 1 stage
two intervention). The outcome y was simulated after t1 and after t2, y1 and y2 respectively.
The model is:
1. For the control arm (t = t1 = t2 = 0):
y1ij = y2ij = rij (5.4)
2. For the intervention arm:
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(a) Stage one treatment (t1 = 1)
y1ij = θ1 + eij (5.5)
(b) Stage two treatment (t2 = 1). If y1 < θ1 (the non-responders) then t2 = 1 and the
outcome
y2ij = θ1 + θ2 + uj + eij (5.6)
where rij ∼ N(0, σ2r ) uj ∼ N(0, σ2u), eij ∼ N(0, σe2). Values of σ2e and σ2u were chosen to
simulate the ICC, ρ, of clustered stage two intervention to be approximately 0.01, 0.05, 0.1, and
0.2. The variances σ2e + σ
2
u = 1 and the individual variance σ
2
r = 1 for all scenarios.
Full simulation study steps, including the data generating process and modelling, are presented
in Figure 5.2. An additional error term could be added for the time effect thus representing the
repeated measures design, the error terms in the above equations would need to be changed so
that the simulation still induces an ICC of ρ.
Figure 5.2: Flowchart representing the simulation study steps under null hypothesis.
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5.4.4 Scenarios to be investigated
Simulation scenarios are presented in Table 5.1. For each of the total 98 scenarios 1,000 datasets
were generated.
The bias of the mixed effect models were evaluated using simulated within-arm pnRCT data for
two scenarios, one under the null hypothesis and one scenario under the alternative hypothesis.
Only two scenarios were simulated as the parametrisation of the model and preliminary inves-
tigations showed the mixed effects model to be largely biased, the aim here was to demonstrate
(large-sample) bias. It was decided that a large simulated dataset would provide this (number
clusters was chosen to be 50 to ensure there were no issues with small number of clusters).
The other objectives of this chapter were to evaluate whether linear regression (with OLS stan-
dard errors, cluster robust standard errors or cluster bootstrap standard errors) in terms of bias
and confidence interval coverage rates as well as quantifying the impact of ignoring clustering.
Simulation values were chosen based on findings from the systematic review in chapter 3 and
some constraints of the data generating model. For all simulations equal allocation to two
treatment arms was assumed and the proportion of the intervention arm who receive the clus-
tered stage two treatment patients (π2) was simulated as approximately 50%. The proportion
of participants that receive the second clustered intervention stage will vary slightly based on
the response to the first stage and the uptake of the intervention being offered. Due to the
proportionate design of this type of trial the sample size of those who receive the second stage
treatment is smaller than the sample size at randomisation. As y1|t1 = 1 ∼ N(θ1, σ2e) choosing
t2 = 1 for those with y1 < θ1 we expect half the intervention arm to receive t2 = 1. The
overall intervention effect θ is made up of θ1 and θ2. Under HA {θ1, θ2} = {0.25, 0.5} and the
expectation of the overall intervention effect is θ = 0.5. The cluster size, number of clusters,
ICC of the clustered stage two intervention and intervention effect were controlled and varied
across scenarios. A description of the scenarios used are summarised in Table 5.1.
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Table 5.1: Simulation scenarios for within-arm pnRCT
Parameter Notation Value
Investigation the bias of mixed effects model (two scenarios) under H0 and HA (2
scenarios)
Proportion in stage two π2% 50%
No. clusters c 50
Cluster size m 10
ICC* ρ 0.05
Intervention effect θ made up of θ1, θ2 Under H0 {θ1, θ2} = {0, 0} or
Under HA {θ1, θ2} = {0.25, 0.5}
Investigating bias and coverage of linear regression models (OLS, cluster robust and
cluster bootstrap) under H0 and HA (96 scenarios)
Proportion in stage two π2% 50%
No. clusters c 5, 10, 20
Cluster size m 3, 6, 12, 24
ICC* ρ 0.01, 0.05, 0.1, 0.2
Intervention effect θ made up of θ1, θ2 Under H0 {θ1, θ2} = {0, 0} or
Under HA {θ1, θ2} = {0.25, 0.5}
5.4.5 Methods
Table 5.2 presents a summary of the analysis models fitted during the simulation study. Un-
clustered participants were treated as singleton clusters based on findings from the simulation
study in chapter 4.
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Table 5.2: Models used for the analysis of simulated within-arm partially nested trials




yij = β0 + θt1ij + ujt2ij
+rij(1− t1ij) + εijt1ij ,
uj ∼ N(0, σ2u),






yij = β0 + θ1t1ij + θ2t2ij + ujt2ij
+rij(1− t1ij) + εijt1ij ,
uj ∼ N(0, σ2u),
εij ∼ N(0, σ2ε )






yi = β0 + θt1i + εi,





yi = β0 + θt1i + εi,






yi = β0 + θt1i + εi,




*Resampling was stratified on t2, whether a participant received stage two intervention or not.
5.4.6 Estimand
The estimand of interest was the overall intervention effect θ, and the intervention effect of stage
one and stage two θ1 and θ2.
5.4.7 Performances measures
The following performance measures were used:
 For models M1, L1-L3, bias of the average intervention effect estimate for those in the
intervention arm compared to control, regardless of whether they received stage two treat-
ment or not using Bias = E(θ̂)− θ. For model M2 bias of intervention effect estimates of
stage one and stage two using Bias = E(θ̂1)− θ1 and = E(θ̂2)− θ2.
 For models M1, L1-L3, mean square error of the intervention effect estimate using E[(θ̂−
θ)2]. For models M2 mean square error of the intervention effect estimates using E[(θ̂1 −
θ1)
2] and E[(θ̂2 − θ2)2].
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 Type I error rate: proportion of simulations in which the p-value < 0.05 when the null
hypothesis is true, true intervention effect θ = 0.
 Coverage of the 95% confidence intervals of the intervention effect estimate: proportion of
simulations that the obtained 95% confidence interval contains the true intervention effect
θ when the alternative hypothesis is true (using Bias corrected confidence intervals for the
cluster bootstrap standard errors).
5.5 Results: Mixed effects model
5.5.1 Bias, mean square error and coverage
Results of the bias and MSE for the overall intervention effect θ̂ from mixed effects model M1
with a single fixed effect are provided in Table 5.3. The model included a fixed effect for the
intervention arm and random effect representing a random intercept for the clustering of stage
two. The mixed effect model M1 (equation 5.1) resulted in a bias of the intervention effect
estimate. The model largely overestimated the intervention effect, bias of the intervention effect
estimate was 0.739 when θ = 0 and 0.464 when θ = 0.5, (equating to 73% and 93% percentage
bias). The corresponding confidence intervals did not include the true intervention effect θ.
Table 5.3: Results of simulation investigating the bias of mixed effects model M1 with a single




θ = 0 0.739 0.548
θ = 0.5 0.464 0.217
Results of the bias and MSE for the intervention effect θ̂1 and θ̂2 from mixed effects model M2
with two fixed effects are provided in Table 5.4. The mixed effect model M2 resulted in bias of
both intervention effect estimates θ̂1 and θ̂2.
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Table 5.4: Results of simulation investigating the bias of mixed effects model M2 with two fixed




Bias MSE Bias MSE
H0 : θ = 0,
{θ1, θ2} = {0, 0}
0.789 0.624 -1.580 2.497
HA : θ = 0.5,
{θ1, θ2} = {0.25, 0.5}
1.039 0.624 -1.079 2.494
5.6 Results: Linear regression models (OLS, cluster robust and
cluster bootstrap standard errors)
5.6.0.1 Bias
All three linear regression models (OLS, cluster robust and cluster bootstrap) compared in this
simulation study led to unbiased estimates of the intervention effect. The maximum absolute
bias of the intervention effect was |0.015| for all models. Bias of the intervention effect was not
affected by the analysis model used, the ICC or the proportion in stage two.
5.6.1 Mean square error
MSE did not differ by model. The MSE of the intervention effect had a mean of 0.002 (SD
0.073).
5.6.2 Type I error
Plots of the mean Type I error rates split by model and the ICC (ρ) are presented in Figure
5.3. As expected the linear regression model which ignores clustering had inflated Type I error
rates, with Type I error rate affected by ICC (ρ), number of clusters (c), and cluster size (m).
Although the inflation was minimal when ICC was small, mean Type I error when ρ = 0.05 was
0.057 (SD 0.008) and mean Type I error when ρ = 0.01 was 0.051 (SD 0.005).
The linear regression model with both cluster robust and cluster bootstrap standard errors
(models 2 and 3) resulted in biased Type I error rates. The cluster robust standard errors over
corrected the Type I error and the cluster bootstrap standard errors resulted in inflated Type I
errors.
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Figure 5.3: Type I error rate of linear regression model for analysis of within-arm partially
nested trials: using OLS standard errors (model L1), cluster robust standard errors (model L2),


































Figure 5.4 shows the Type I error rates for the linear regression model with OLS standard errors
(model L1), cluster robust standard errors (model L2) and with cluster bootstrap standard
errors (model L3) by ICC (ρ), number of clusters (c), and cluster size (m). When using the
linear regression model with cluster robust standard errors Type I error rates were reduced from
the nominal 5% level under all ICC values. In contrast, when using the linear regression model
with cluster bootstrap standard errors Type I error rates were inflated from the nominal 5%
level under all ICC values. Higher ICC values resulted in higher Type I error rates in each
model. The impact of ignoring clustering (model L1) depends on both ICC (ρ) and cluster size
(m).
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Figure 5.4: Type I error rate of linear regression model for analysis of within-arm partially
nested trials: using OLS standard errors (model L1), cluster robust standard errors (model L2),















































































































































Number of clusters (c) ● ● ● ●3 6 12 24
5.6.3 Coverage
Plots of the mean coverage of the 95% confidence intervals of the intervention effect estimate
split by model and the ICC (ρ) under the alternative hypothesis are presented in Figure 5.5. The
linear regression (which ignores clustering) resulted in under coverage, with coverage affected
by ICC (ρ) and cluster size (m). The coverage rate of the 95% confidence intervals decreased as
ICC (ρ) increased.
Linear regression with either cluster robust or cluster bootstrap standard errors (models 2 and 3)
resulted in biased coverage rates. Cluster robust standard errors resulted in coverage rates above
the nominal 95% level. In contrast, the cluster bootstrap standard errors resulted in coverage
rates below the nominal 95% level. Figure 5.6 presents the coverage rates in more detail for
the linear regression model with OLS standard errors (model L1), cluster robust standard errors
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(model L2) and with cluster bootstrap standard errors (model L3) by ICC (ρ), number of clusters
(c), and cluster size (m).
Figure 5.5: Coverage rate of 95% confidence intervals of linear regression model for analysis
of within-arm pnRCTs: using OLS standard errors (model L1), cluster robust standard errors
















































Figure 5.6: Coverage rate of 95% confidence intervals of linear regression model for analysis
of within-arm pnRCTs: using OLS standard errors (model L1), cluster robust standard errors









































































































































































Number of clusters (c) ● ● ● ●3 6 12 24
5.7 Discussion
This chapter expands upon the simulation study in chapter 4 to the more complex within-arm
pnRCTs. Different modelling strategies have been investigated for the analysis of a within-arm
pnRCT with a continuous outcome and a two staged intervention with clustering at the second
stage. Initial investigations into formulating an appropriate mixed effects model for within-
arm pnRCTs showed that it was not possible to parametrise a mixed effects model that both
accounts for the clustering of stage two and provides an unbiased intervention effect. The bias of
the intervention effect estimate from a mixed effect model was demonstrated with a simulation
study under ICC ρ = 0.05. The model was biased under both the null and alternative.
The linear regression models were found to provide unbiased effect estimates regardless of the
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method used for standard error estimation. The findings presented in this chapter demonstrate
that ignoring within-arm partial nesting using a linear regression model can result in under
coverage rate of 95% confidence intervals. When ICC ρ ≥ 0.05 the coverage rate of the linear
regression model was almost always under the nominal 95% level regardless of the cluster size
m or number of clusters c. This in turn may result in misleadingly over precise estimation of
intervention effect estimates. However, when the ICC was small ρ = 0.01 the Type I error was
only minimally inflated.
Neither of the methods used with the aim to account for clustering of stage two intervention,
cluster robust or cluster bootstrap standard errors, provided coverage at the nominal level. In
addition, the mixed effect model presented in equation 5.1 resulted in biased effect estimates.
Caution in the analysis of this trial design can result in more spurious effect estimates and/or
coverage rates.
One of the objectives of this chapter was to provide recommendations for the most appropriate
analysis methods for within-arm pnRCTs considering the ICC estimates. The scenarios explored
in this simulation study suggest that it is not possible to account for clustering in a within-arm
pnRCT at the a latter stage of intervention whilst also obtaining an unbiased effect estimate
using the methods evaluated in this chapter. In a proportionate intervention if either the ICC
and/or the proportion of participants expected to receive the conditional clustered intervention
stage(s) are expected to be large then the findings from this chapter suggest caution should be
taken in considering what a trial of such an intervention will be able to provide us. Such a
within-arm pnRCT will likely not be able to provide estimates of the intervention effect with
usual expected precision. It is recommended to ignore the clustering when it is realistic to
assume ICC is small. Where feasible, methods to reduce the affect of clustering such as small
clusters and standardising the intervention are also suggested. It may be possible to group or
cluster those who do not receive the clustered intervention into pseudo clusters. Pseudo clusters
impose a clustered structure for participants who do not have one. Although the affects of this
would need to explored, as those in the pseudo clusters do not have clustered outcomes.
An ideal solution for analysing within-arm pnRCTs was not identified in this chapter. However,
as will be shown in chapter 7, treatment induced clustering is often small (ρ ≤ 0.01) and thus its
impact on results may be expected to be relatively small particularly if cluster sizes are small.
If non-random clustering occurs it is not recommended to account for it using the methods
evaluated in this chapter (cluster robust or cluster bootstrap standard errors). If a study aim is
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to evaluate the effect of different intervention stages with a treatment pathway and also account
for the clustering of these stages randomisation after each stage of the intervention would be
required. For instance, a SMART trial design re randomises individuals sometimes multiple
times as seen in chapter 3. These designs are typically used to find an optimal intervention
as opposed to a confirmatory trial of effectiveness. Multiple randomisations could result in
requiring prohibitively large sample sizes for the overall trial design and a greater administrative
burden. Landau and Chalder [52] argue that if the allocation of clusters is driven by patient
characteristics (for example, the “best” therapist sees “worst” patients) then therapist effects
cannot be separated from patient effects. Within-arm pnRCTs do not necessarily link allocation
of care providers to patient characteristics. However, typically the non-responders or high risk
patients proceed to more intense latter stages of the interventions, thus it is not possible to
untangle the effect of clustering from the fact that these patients are higher risk (non-responders).
Being unable to untangle the confounding of cluster effects and patient characteristics is not
helpful if we wish to estimate clustering effects for the use in future sample size calculations.
However, ICC estimates can still be obtained from such trials and are recommended to be able
to better understand the validity of the precision of effect estimates. For individuals who receive
the clustered interventions given proportionately, it may be possible to report the pre-treatment
ICC (at the decision stage) and compare this with post-treatment ICC to see if ICC has increased
by treatment.
Ideally, to ensure internal validity, it is recommended that the allocation of participants to
clusters should be done at random. However, the nature of a using a RCT to evaluate the
overall intervention effect of a proportionate intervention with randomisation at baseline will
mean this is not possible.
5.7.1 Limitations
Fixed cluster sizes have been used in this simulation study and it has been assumed there is no
effect of clustering in the control arm (as in chapter 4). Both of these things may not strictly
be true in practice, the implications have been discussed in more detail in chapter 4.
This simulation study only considered a two stage intervention design. As seen in the systematic
review in chapter 3 there are often more than two stages in a proportionate intervention stage.
Although, as we move further along the treatment pathway it seems plausible that there will
be fewer patients that receive the latter stepped-up intervention stages. The proportion of
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participants clustered at latter stages will likely reduce to small percentages of those in the
intervention arm. The fewer patients that have clustered outcomes the smaller affect this has
on the precision of the standard errors.
5.8 Summary
This chapter has built on findings from the systematic review in chapter 3 and the simulation
study in chapter 4. Different analysis methods were evaluated for within-arm pnRCTs with a
continuous outcome and a two staged intervention with clustering at the second stage. Neither a
mixed effects model nor a linear regression model using either cluster robust or cluster bootstrap
standard errors provided both an unbiased effect estimate and coverage rates around the nominal
95% rate. Consequently, no ideal solution for analysing within-arm pnRCTs was identified in this
chapter. In a proportionate intervention if either the ICC and/or the proportion of participants
expected to receive conditional clustered intervention stage(s) are expected to be large then it is
important to bear in mind what a trial of such an intervention will be able to provide us. Such
a within-arm pnRCT will not be able to provide estimates of the intervention effect with usual
expected precision.
In the next chapter that follows sample size formulae for pnRCTs are summarised. No optimal
analysis strategy which accounts for clustering was found for within-arm pnRCTs, hence, sample




Sample size methods for partially
nested trials
6.1 Introduction
Previous chapters highlighted the importance of the analysis method for iRCTs with clustering.
Chapter 2 also introduced the concept of the use of the design effect to inflate sample sizes
for trials with clustering. This chapter identifies and collates sample size formulae currently
available for pnRCTs with continuous outcomes, presents a worked example of these methods,
and identifies some possible areas for further work. There is a growing body of literature
on sample size methods relevant for pnRCTs. There are accessible methods and corresponding
software to allow for the design complexities of clustering in trials with continuous outcomes and
these can be extended for further complexities such as variable cluster sizes and incorporation
of baseline measures in the analysis.
A priori sample size calculations are used when designing trials. The calculation is used to
estimate the minimum number of participants required to be able to detect an intervention
effect to a specified probability. The size of an intervention effect, with the precision conveyed
by a confidence interval, also need to be estimated. Sample size calculations are an important
and often challenging part of a trial. Lack of independence in pnRCTs introduces complexities
to the design phase of a trial, similar to that which occur in cRCTs. Ignoring the clustering in
the sample size calculation could result in underpowered studies.
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6.2 Chapter aims
This chapter aims to identify and collate a comprehensive summary and resource for sample size
methods available for pnRCTs. The specific objectives are to:
1. provide a summary of existing methods;
2. provide practical guidance around the use of different methods;
3. link these methods to relevant available software.
This chapter also highlights the sensitivity of sample size calculations to both the ICC and
cluster size. The focus is on parallel group trials with continuous outcomes.
6.3 Methods
6.3.1 Literature search
A comprehensive literature search was used to identify published methods for sample size calcu-
lations for pnRCTs. The database Ovid MEDLINE was searched on 30th June 2017 for relevant
articles. The search criteria presented in Figure 6.1 was implemented. Search terms were chosen
based on literature already reviewed for this thesis, carefully looking for search terms in the
documents, particularly at the title, abstract and the key words used.
To keep up to date, an Auto Alert was created within Ovid MEDLINE to provide a monthly
notification of new citations that match the search specifications after the 30th June 2017 and
reviewed until 30th June 2018.
Figure 6.1: Ovid MEDLINE search criteria for relevant articles on pnRCTs sample size calcu-
lations
Controlled Clinical Trials as Topic/mt, sn OR




"Individual$ Randomized Group Treatment
Trial$".mp OR.
"Multilevel data".mp.
The results were hand searched based on titles, abstracts and where necessary the full article,
to identify relevant results. In addition to the database search, papers known by myself or
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supervisors to be relevant were included. The results were reviewed and summarised, identifying
the most relevant articles describing methodology for sample size calculations in pnRCTs.
6.3.2 Literature search results
The Ovid MEDLINE search identified 296 unique articles. After the searching 16 full text
articles were selected (15 from MEDLINE and one already known to author). These texts
include methodology, application, and software specific articles with methods for pnRCTs.
6.4 Results: sample size formulae
The sample size formulae for pnRCTs are presented. For clarity, this chapter builds up from
the standard parallel two arm trial, to the fully clustered trial design which introduces the need
to account for clustering, and finally moving onto the fully and partially nested design with
results from the literature search. Sample size formulae have been re-expressed in consistent
terminology and all assume a continuous outcome.
All sample size in this chapter assume a two-sided significance level α and power of 1− β. The
following considers a superiority RCT used to test the hypotheses,
H0 : δ = 0 versus HA : δ = δ
∗,
where δ∗ is the clinically meaningful difference.
Sample size formulae commonly assume large samples (n ≥ 30); it has been suggested that
the asymptotic Normality assumption of the test statistic is acceptable if there are 30 or more
individuals in each trial arm [156]. When sample sizes are small the additional uncertainty can
be accounted for by using a t-distribution. Although the total number of individuals in an RCT
with clustering may be large the number of clusters is often small.
6.4.1 Trial design features that impact on sample size
In conducting a priori sample size calculation certain trial design features need to be estimated,
key design features are presented in Table 6.1. These are typically decided upon using a com-
bination of previous trial data, observational data and health records, financial and practical
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constraints, and expert opinion. Some features can be manipulated by the researcher, however,
others will be constrained by the limits of the data, the ICC, or financial resources. Chapter 7
adds to the evidence of ICC for the choice of ICC ρ in iRCTs with clustering.




Endpoint Endpoint used for the primary outcome y
Error rates Type I error α
Type II error β
Effect size Minimum clinically important difference measured on
primary endpoint
δ
Variance Population variability for primary outcome.
Total variance σ2
Individual variance control arm σ2r
Individual variance intervention arm σ2ε
Cluster variance σ2u
Cluster size Number of participants in each cluster, may be fixed or








How much of the outcome variability is due to
clustering: ICC ρ = σ2u/σ2u + σ2ε
ρ
Other Expected drop-outs/attrition rates
6.4.2 Sample size formulae for individually randomised trial
Consider an iRCT using a parallel group design with Normally distributed outcomes y, with
mean ȳ and standard deviation σ and assume equal variance between arms. The intervention
effect size is the expected mean of the outcome value in the intervention arm minus the expected
mean value in the control arm
δ = ȳ1 − ȳ0 (6.1)
The standard parametric test for the hypotheses for a superiority RCT (expressed above) is an
independent two-sample t-test. The test is based on the test statistic, T , which under the null
hypothesis has a central t-distribution on v = nI(r + 1)− 2 degrees of freedom where nI is the
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sample size in one trial arm and r is the allocation ratio between the two arms. The T test











where δ is the expected effect size, σ is the estimated population standard deviation and δs is
the standardised effect size, δs = δ/σ.
6.4.2.1 Intervention effect estimator variance
We wish to minimise the variance of the intervention effect estimator, hence, it is used as the
optimality criterion; minimal variance results in maximal power to detect an intervention effect.



















where nB = rnI and Z1−β and Z1−α/2 are the 100(1−β)% and 100(1−α/2)% points of a standard
Normal distribution.
6.4.2.2 Approximate sample size formulae using asymptotic methods
For moderately large sample sizes (≥ 30) the t-distribution approximates to a standard Normal
distribution. The approximate sample size per arm using the Normal approximation, from
equations in 6.3, is
nI =





where r is the allocation ratio, δ is the expected effect size, σ2 is the estimated population






6.4.2.3 Exact sample size formulae
When a clinical trial is undertaken the population variance σ2 is usually considered to be un-
known and a sample variance is used in its place, s2, estimated with v = nI(r+ 1)−2 degrees of
freedom. Uncertainty in the variance estimate can be reflected by replacing the Z-statistic with
a t-statistic. The following sample size formulae can be used to achieve a power of at least 1−β
nI ≥




This equation does not have a direct solution as nI appears on both sides of the equation. The
equation can be written in terms of power and solved using an iterative technique




− t1 − α/2,nI(r+1)−2
)
(6.6)
where Φ(.) is the cumulative density function of N(0, 1). When a sample variance is being used,
s2, the power should be estimated from the cumulative t-distribution instead of the Normal
distribution. In addition, power is estimated under the alternative hypothesis and Senn [157]
showed more accurate sample size calculations can be done using the non-central t-distribution.
The power is actually being estimated under δ 6= 0, hence, the corresponding t-distribution
should be non-central which represents the distribution of the test statistic under the alternative






The power equation can be rewritten to give
1− β = 1− T−1
(






where T−1 is the cumulative density function of the non-central t-distribution. Again this
equation cannot be solved for nI explicitly. Practically, the Normal approximation can be used
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as an initial sample size and then use an iterative solution until the required power is reached.
Alternatively, to allow for the Normal approximation to the t-distribution a correction factor of
Z1−α/2
4 can be added to equation 6.4 to approximate and give
nI =







When sample sizes are small the Normal approximation to the t-distribution is poor, this can
result in overestimation of power. The differences between the Normal distribution and the
non-central t-distribution are generally minimal [33]. In general, the central t-distribution is
used, Machin et al. [158] propose that the use of t rather than Z adds 1 and 2 per group for the
5% and 1% significance level, respectively.
6.4.3 Sample size formulae for cluster randomised trial
A simple approach to take account of the clustering effect when designing a cluster trial was
proposed by Donner et al. [159]: calculate a sample size for an iRCTs (as in section 6.4.2)
and inflate this by the design effect (DE) to reach the required statistical power under cluster
randomisation
DE = 1 + (m− 1)ρ (6.9)
where m is the number of individuals per cluster and ρ is the ICC. For example, when the
ICC is 0.05 and the cluster size is eight, the design effect equals 1.35 meaning that 35% more
participants would need to be recruited to achieve a sufficient sample size. This design effect (in
equation 6.9) is actually for cluster level analyses which compares relevant summary statistics
from the cluster level. Different design effects are summarised by Eldridge et al. [150] for the
different analyses methods; when individual level analyses are planned using equation 6.9 is
conservative.
6.4.3.1 Approximate sample size formulae using asymptotic methods





(1 + (m− 1)ρ)
nC =nI ×DE (6.10)
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u is the between cluster variance and σ
2
ε is the
within cluster variance. The number of clusters required per arm, k, is then given by
k =
(




6.4.3.2 Exact sample size formulae and small number of clusters
Sample size formulae in equations 6.11 assume a relatively large number of clusters, thus the
Normal approximation will be appropriate. When the number of clusters is small, using the
Normal approximation is likely to overestimate power and underestimate sample size [148]. As
in the standard parallel two-arm iRCT, it is possible to replace the Normal distribution with a
non-central t-distribution. Donner and Klar [148] presented a power calculation for cluster-level









The above gives us a formulae for power of
1− β = 1− T−1










The degrees of freedom for the t-distribution are determined by the number of clusters, which
is what we are trying to estimate using sample size calculations. Hence, the above requires an
iterative process of estimation. Harrison, Brady, et al. [160] also show that more accurate power
calculations can be done using the non-central t-distribution, presenting formulae for sample
size and power under the non-central t-distribution alongside a Stata command to perform
these calculations sampncti.
6.4.3.3 Unequal cluster sizes
The standard design effect given in equation 6.9 assumes that the cluster sizes are equal. How-
ever, it is common to have variable cluster sizes, for example variable GP practice sizes or
variable school sizes. Exact cluster sizes may not be known at the design stage due to lack of
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information and variability over time. However, a priori estimates of the distribution of cluster
sizes may be available (mean and standard deviation). Where the cluster sizes are unequal it is
helpful to consider the impact this can have when designing a trial.
The design effect in equation 6.9 can be approximated by including a simple correction for the
variable cluster size as shown by Eldridge et al. [150]
DE = 1 + ((cv2 + 1)m̄− 1)ρ (6.14)
where cv is the coefficient of variation in cluster size. Coefficient of variation is the ratio of the
standard deviation of cluster sizes, σm, to the mean cluster size, m̄ (σm =
∑(
mi − m̄)2/(k − 1)
)





Eldridge et al. [150] demonstrate that using the coefficient of variation formula in cluster size
provides either good or conservative estimate of sample size requirements.
6.4.4 Sample size formulae for partially nested randomised trials
Sample size formulae for iRCTs with treatment induced clustering have similarities to those for
cRCTs. Where there is differential clustering between arms, as in a pnRCT, the variance may
differ and thus the analysis needs to account for this variation. The analysis of a pnRCT may in
its simplest form correspond to that of an unequal variances t-test [136], however, it is typically
the case that analysis adjusted for baseline covariates is required and can provide more precise
effect estimates (analysis methods were evaluated in chapter 4 of this thesis).
Assuming the individual variance in the unclustered control arm is given by σ2r , the individual
variance in the cluster arm by σ2ε and the between cluster variation in the clustered arm by σ
2
u.
The ICC in a pnRCTs, ρ, is only present in the clustered intervention arm, and is again given
by ρ = σ2u/σ2u + σ2ε.
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6.4.4.1 Partially nested randomised trials sample size literature
A simple solution to incorporate clustering effects in pnRCTs sample size calculations is to:
calculate sample size for the corresponding iRCT; calculate the design effect as in a cluster trial;
and inflate only the clustered arm by this design effect. Similarly, for nRCTs both trial arms may
be inflated, either using the same design effect for both arms or if different ICCs and/or cluster
sizes are anticipated for different trial arms then two separate design effects can be calculated
one for each trial arm as suggested by Pals et al. [43]. Although this method does recognise
the clustering effect and has been used, it does not fully account for the potential differential
variance between arms in pnRCTs and may not provide an optimal allocation ratio. A review of
recent methodological developments in group randomised trials design by Turner et al. [161] gave
a brief summary of relevant literature dedicated to what they term Individually Randomised
Group-Treatment trials, with references to various sample size articles. This chapter aims to
extend this, with further information, a focus on pnRCTs, and a summary of software for sample
size calculations in pnRCTs.
There are various articles reporting specific sample size formulae for trials with clustering of
outcomes in only one trial arm. Roberts and Roberts [48] present an optimal allocation ratio
for pnRCTs. Moerbeek and Wong [131] derive sample size formula for pnRCTs, which account
for both the clustering in one arm and the possible heteroscedastic variance between arms.
Similar formulae assuming homoscedastic variances have also been derived [57, 122, 132, 137].
Lohr et al. [133] derive a design effect for pnRCTs, however, this makes the assumption that
the individual variance parameters are equal across arms σ2r = σ
2
ε , which may not always be
the case. During the design phase of a trial specific information on the individual variances
may not be available, however, with improved reporting of such trials this will have hopefully
lead to more information on variance estimates and a better understanding of potential levels
of heteroscedasticity of variances across arms. Hoover [136] suggested a sample size and power
formula for small studies for the Satterthwaite unequal variance t-test. Roberts and Roberts [48]
state that where variance is larger in the larger group (feasibly that this is true when comparing
group therapy to individual therapy) the formula underestimates power.
Multi-centre trials introduce an additional level of data hierarchy in pnRCTs. Heo et al. [137]
consider centre level clustering, they derive sample size formulae for pnRCTs under homoscedas-
tic variances. They derive sample size formulae for testing main effects of a group-based inter-
vention compared to individual-based control based on two- and three-level mixed-effects linear
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models. The two-level mixed effects model represents when there is only clustering due to the
group base intervention. The sample size formulae in Heo et al. [137] differs from Moerbeek
and Wong [131] due to the assumption of homoscedastic variances and the assumption of equal
allocation across arms. Appendix C provides a table comparing the two methods under different
designs. The three-level mixed effects model represents when there is clustering due to the group
based intervention and clustering due to the centre. In practice, the centres in multi-centre trials
are commonly included as a stratification variable in the randomisation procedure and included
as a fixed effect in the mixed effect model as opposed to a random effect. However, the use of
random effects can have advantages compared to fixed effects in many scenarios [54].
Other complex designs, including clustered designs with clustering by therapist in both trial
arms, or the crossed design where each therapist provides therapy in both trial arms, have been
discussed with a focus on psychotherapy but are more widely applicable [38, 39].
6.4.4.2 Intervention effect estimator variance
The variance of the intervention effect estimator, δ̂ = ȳ1 − ȳ0, in a pnRCTs was derived by




















where γ = σ2u + σ2ε/σ2r is the ratio of variance in the clustered arm to the unclustered arm. The
cluster size and number of clusters are denoted by m and k and npn is the number of individuals
in the control arm.
Equation 6.16 can be simplified under the assumption of equal individual variances across the






















The variance of the intervention effect estimator, δ, expressed in equations 6.16 and 6.17 is
dependent upon the cluster size m, number of clusters k, and the number of individuals in the
control arm npn. The combination of these parameters is referred to as a design, ξ = {m, k, npn}.
Different designs can result in the same power level, with an optimal design providing the best
combination of ξ = {m, k, npn} under the structure, budget and practicalities of a particular
trial.
6.4.4.3 Approximate sample size formula using asymptotic methods
Equal allocation is commonly used for RCTs, this typically maximises power for a given total
sample size. However, if costs and variances differ between trial arms, often the case in pnRCTs,
the power may be maximised by changing the allocation ratio between the trial arms. The
following presents both optimal allocation ratios and sample size formulae to achieve desired
power and Type I error rate.
Sample size for fixed cluster size and optimal allocation ratio
If the cluster size is known and we wish to choose the optimal sample size calculations for a
pnRCT a number of steps are required. An optimal allocation ratio for large partially clustered
trials is given by Roberts and Roberts [48] as the ratio of the individuals in the unclustered





1 + (m− 1)ρ. (6.18)






γ(1 + (m− 1)ρ). (6.19)
An increase in the design effect and the variance ratio both result in an increase in the sample
size in the clustered arm. The number of individuals required in the control arm is given by
Moerbeek and Teerenstra [130] as
npn =
(√





where the standardised effect size expresses the intervention effect in relation to the standard
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deviation in the control arm, δs = δ/σr. In practice, the number of control participants required
is calculated using equation 6.20 in conjunction with the allocation ratio formula in 6.19 to
calculate the number of intervention groups, k (and the number of individuals in the clustered
intervention arm, mk). The steps to undertake a pnRCT sample size for a known cluster size
calculation are illustrated below.
Calculate sample size for a partiality nested trial assuming two-sided test with α = 0.05
and power 1− β = 0.80:
1. Information assumed provided by investigator: Intervention effect size of interest
δs=0.5 and expected number of patients per cluster m=10
2. Obtain an estimate of ρ (from previous studies, observational data, and/or discus-
sions with investigator): ICC ρ=0.05
3. Preliminary sample size: Estimated sample size of control arm npn = 69.20 and
clustered intervention arm mk = 83.33, total sample size of 152.53, using equations
6.19 and 6.20 and assuming variance ratio γ = 1.
4. Calculate sample size required: Round clustered intervention arm to multiple of
cluster size m.
 Rounding down gives mk = 80 and recalculate control arm sample size npn =
73 to achieve desired power, total sample size of 153.
 Rounding up gives mk = 90, nine clusters of size ten, and recalculate control
arm sample size npn = 64 to achieve desired power, total sample size of 154.
5. Allowing for 10% drop-out in participants from baseline to follow-up, this gives
mk = 108 nine clusters of size 12 and control arm sample size npn = 72 to achieve
desired power, total sample size of 180.
Table 6.2 illustrates the sample sizes required in a pnRCT to achieve 1-β=0.80 in a two-sided
test with α=0.05 to detect a standardised intervention effect δs = 0.5, γ = 1 (assuming ho-
moscedasticity between individual variance across trial arms) for various values of cluster size
m and ICC ρ. For instance, for ρ = 0.05, m = 10 eight clusters are required in the intervention
arm mk = 80 and npn = 73 in the control arm. For a parallel group iRCT, with no clustering,
the required sample size would be 64 per arm. Calculations in Table 6.2 use equations 6.19 and
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6.20. When calculating sample sizes which include clusters, it is generally necessary to round
the clustered intervention arms to a multiple of the cluster size. The required sample size in the
clustered intervention arm can be either rounded down or up to the nearest multiple and the
control arm sample size calculated accordingly using equation 6.20. Similar total sample sizes
are required in the examples given in Table 6.2, however, this is not always the case if cluster
size or ICC are large rounding can have a larger influence on the required total sample size to
achieve desired power.
It is evident from sample sizes presented in Table 6.2 that for larger cluster sizes m larger overall
sample sizes are required to achieve the same power. This agrees with findings from chapter 4.
For instance, with an ICC of ρ = 0.05 we require a total sample size of 138 with a cluster size
of m = 5 and a total sample size of 181 with a cluster size of m = 20.
Table 6.2: Sample size for pnRCT to achieve 1-β=0.80 in a two-sided test with α=0.05 to detect
a standardised intervention effect δs=0.5, γ=1 (assuming homoscedasticity between individual






k mk npn Total k mk npn Total k mk npn Total
0.01
Up 13 65 64 129 7 70 62 132 4 80 59 139
Down 12 60 69 129 6 60 74 134 3 60 84 144
0.05
Up 15 75 64 139 9 90 64 154 6 120 65 185
Down 14 70 68 138 8 80 73 153 5 100 81 181
0.1
Up 17 85 66 151 11 110 69 179 8 160 73 233
Down 16 80 70 150 10 100 78 178 7 140 90 230
*Rounding method of sample size calculation refers to the method of rounding from the original calcula-
tion: either rounding number of clusters up or rounding number of clusters down.
Sample size for fixed cluster size and fixed number of clusters
The number of individuals in the control arm for fixed cluster size m and number of clusters in
















Sample size including costs
The optimal allocation ratio and sample size formulae can also be extended to account for
differential costs. It may be the case that costs do not depend only on the total sample size but
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are based on other parameters. If a trials budget includes the intervention running costs then
there are likely to be differing costs between trial arms. The cost ratio c1/c0 where c1 and c0






γ(1 + (m− 1)ρ)c1
c0
. (6.22)
The number of individuals required in the control arm accounting for costs is
npn =
(√








The notion of including intervention costs to calculate the optimal allocation ratio to reduce
overall costs for a pnRCT design was put forward by Moerbeek and Teerenstra [130] and Mo-
erbeek and Wong [131]. No trials of where differential intervention costs had been used in the
sample size could be found to provide an example in this chapter. It is likely that this is more
suitable for certain healthcare settings dependent upon the funding models.
6.4.4.4 Exact sample size formulae: small sample sizes and unequal variances
The sample sizes calculations in equations 6.19-6.21 are based on the standard Normal approx-
imation of the test statistic, and thus assume asymptotic Normality which is only suitable for
large number of clusters. For small studies using these formulae will underestimate sample size
and overestimate power. In addition, Roberts and Roberts [48] noted that in small studies the
optimal allocation ratio they derived (equation 6.19) will give a smaller allocation ratio than is
optimal.
Again for small studies the t-distribution can be used as an approximation to the Normal
distribution and the test statistic under the alternative hypothesis can be approximated with a
non-central t-distribution.




















Using the non-central t-distribution the power is derived as









with degrees of freedom v. The degrees of freedom for the t-distribution are determined by
the number of clusters, which is what we are trying to estimate using sample size calculations.
Equation 6.25 requires an iterative process of estimation, the approximate sample size using
asymptotic methods can be used as an intial sample size (from section 6.4.4.3) and then use an
iterative solution until the required power is reached. As shown in chapter 4, the Satterthwaite
degrees of freedom correction can be used to estimate v, which avoids the assumption of equal
variances and makes a small sample correction for small number of clusters [139, 162]. The
Satterthwaite approximation for effective degrees of freedom is made up of a weighted linear























For small samples Candel and Van Breukelen [162] used a numerical evaluation to formulate
corrections when using the Normal approximation in iRCTs with clustering in both arms; they
recommend that in a two-tailed test using REML, a correction for 80% and 90% power, is to
add three clusters to each trial arm for a 5% type I error rate and four clusters to each trial arm
for a 1% type I error rate.
6.4.4.5 Unequal cluster size
A pnRCT may have unequal cluster sizes. For example, the CASPER plus (CollAborative
care for Screen-Positive EldeRs) trial evaluated collaborative care for older adults with major
depressive disorder compared to usual care, a total of 20 collaborative care case managers treated
a mean of 11.9 patients ranging between 1 to 46 patients [163].
This section extends the optimal allocation ratio and sample size formulae for the number of
individuals in the control arm from Moerbeek and Wong [131], to now account for the variable
cluster size by including the coefficient of variation, cv, and the mean cluster size (combining




















If homoscedastic variances and/or equal costs are assumed, γ and/or c1/c0 can be removed from
the above equations. The effect of varying cluster sizes in trials with differential clustering was
investigated by Candel and Van Breukelen [128] using a Monte Carlo simulation study. Under
the simulations scenarios it was found the efficiency loss in the intervention effect estimate was
rarely more than 10%, requiring recruitment of 11% per cent more clusters for the intervention
arm and 11% more individuals for the control arm. Additionally, Eldridge et al. [150] showed in
cRCTs if the coefficient of variation in cluster size is small, less than 0.23, then the correction
on sample size is negligible. However, the coefficient of variation may be high in iRCTs with
treatment induced clustering. In the SHEAR trial there were 402 patients in the intervention
arm treated by 79 clinicians. Clinicians treated between 1 to 35 patients and a coefficient of
variation of cluster size of cv = 1.14 (this was calculated using the data provided by the trial
statistician for work in the following chapter 7 cv = σm/m̄ = 5.72/5.03) [164]. Another approach
for incorporating cluster size viability in sample size calculations would be to take a simulation
approach to sample size. Table 6.3 presents the effect of cv on sample size using equation 6.27
for a number of different scenarios of ρ and cv.
Table 6.3: Effect of coefficient of variation of pnRCT sample size, with 1−β = 0.80, a two-sided
test with α = 0.05, δs = 0.5, γ = 1, and m = 10.
ρ cv
Sample size ignoring cv Sample size including cv
k mk npn Total k mk npn Total
0.05
0.2 9 90 70 160 9 90 70 160
0.4 9 90 70 160 9 90 71 161
0.6 9 90 70 160 9 90 72 162
0.8 9 90 70 160 10 100 74 174
1 9 90 70 160 10 100 76 176
1.2 9 90 70 160 11 110 78 188
0.1
0.2 11 110 75 185 11 110 76 186
0.4 11 110 75 185 11 110 77 187
0.6 11 110 75 185 12 120 79 199
0.8 11 110 75 185 12 120 82 202
1 11 110 75 185 13 130 85 215
1.2 11 110 75 185 14 140 89 229
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6.4.4.6 Statistical software
To facilitate the work of statisticians planning trials it is important that statistical software is
readily available to calculate sample sizes for pnRCTs. Available software for parallel arm pn-
RCTs sample size calculations are summarised in Table 6.4 referring to commonly used statistical
software packages, sample size software and standalone software.
Table 6.4: Software for sample size calculations in pnRCTs
Software Functionality
PASS Not aware of any built-in functionality at this time
nQuery Two group Satterthwaite’s t-test (unequal variance) computes
power and sample size [165], computed using formulas from Moser
et al. [166]
R Not aware of any built-in functionality at this time
SAS Not aware of any built-in functionality at this time
Stata User-written command clsampsi: can compute sample size and
optimal allocation ratio for pnRCTs for continuous and binary
outcomes. Uses the non-central F distribution and Satterthwaite
degrees of freedom [127].
SPA-ML Matlab stand-alone program. Sample size calculations for pn-
RCTs, and fully nested iRCTs with clustering in both arms. Uses
the t-distribution where possible and Hoover [136] degrees of free-
dom [167].
The two statistical software sepcifically designed with pnRCTs in mind are clsampsi Stata
program [127, 168] and SPA-ML [167]. The clsampsi Stata program [127, 168] was developed
to calculate the power or the number of clusters and cluster sizes required to evaluate the
difference of means or proportions in the presence of differential clustering effects in each trial
arm, including pnRCTs. The paper published in The Stata Journal [127] explains that by
default, the program clsampsi calculates power by integrating the non-central F-distribution as
described by Moser et al. [166]. It uses a numerical search to find sample sizes, initially starting
with estimated number of clusters based on the normal approximation as a starting value and
then the number of clusters are increased until sufficient power is reached. This program also
‘roughly’ approximates the optimum allocation ratio between trial arms for a given power.
SPA-ML (Statistic Power Analysis for Multilevel Design) is written in Matlab and available as
stand-alone program for Windows [130, 167]. SPA-ML uses the theoretical sample size formula
for pnRCTs from Moerbeek and Teerenstra [130] and Moerbeek and Wong [131] included in this
chapter. It is based on mathematical relations between sample size and power: no Monte Carlo
simulations are used. The output is provided as text and in graph format. Whenever it was
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possible, instead of the presented Normal approximation, the software uses the t-distribution
to calculate the required sample size/power (this was found out from email correspondence
with the SPA-ML developer hence there is no reference). The degrees of freedom for the t-
distribution were taken from the Hoover [136] paper. As a result there will be some small
discrepancies between the estimations based on the formulas and obtained with the software
SPA-ML, particularly for smaller samples.
Comparison of software
Below shows a comparison of the two sample size software designed specifically with pnRCTs
in mind, SPA-ML and clsampsi for Stata, for the scenario of 80% power, ρ = 0.05, δs = 0.5,
and m = 10. The sample size using approximate asymptotic equations 6.20 and 6.19 gives a
total sample size of 154 (9 clusters of size 10 and 64 individuals in control arm); using clsampsi
this has an estimated power of 78.4% slightly lower than the approximated 80% using Normal
approximation.
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Stata clsampsi gives total sample size = 166, output from Stata below.
Estimated power/sample size using the Satterthwaite approximate F test for two-sample
comparison of means with clustering
Test Ho: mu1 = mu2, where mu1 is the mean in population 1
and mu2 is the mean in population 2
Assumptions: alpha = 0.0500 (two-sided)
Sample 1 Sample 2
Mean (mu) 0 .5
Total St. Dev.(sd) 1 1
Number of Clusters (k) 10 66
Cluster Size (m) 10 1
Cluster Size Var.(varm) 0 0
Sample Size (N) 100 66
Intra-Cluster Corr. (rho) .05 0
SD (summary level) .380789 1
Total Sample Size: 166
Allocation ratio (N2/N1): .66
Ratio of Number of clusters (k2/k1): 6.6
Ratio of Cluster sizes (m2/m1): .1
Satterthwaite’s degrees of freedom: 32.69
Sample size (ni) for integration: 1000
Estimated power: 0.8027
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SPA-ML gives total sample size = 168, output from SPA-ML below.
Individual randomized trial, clustering in experimental condition. Scenario: use cost
function and fixed size of experimental clusters to calculate number of control subjects
and number of experimental clusters. Outcome variable type: continuous. Tail(s) = two;
Type I error rate = 0.05; Desired power = 0.8; Cost ratio = 1; Size of experimental
clusters = 10; Intracluster correlation coefficient = 0.05; Standardized effect size = 0.5;
Variance ratio = 1;
Number of control subjects = 68; Number of experimental clusters = 10; Total sample
size = 168; Total costs = 168; Actual power = 0.8013.
—————————————————————————————
There are no alternative designs.
Summary of sample size formulae for pnRCTs
Figure 6.2 presents a flowchart summarising the sample size formulae for pnRCTs.
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Figure 6.2: Summary of sample size formulae for pnRCTs
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where v is the Satterthwaite degrees of freedom.
Recommend use of software clsampsi or SPA-ML due
to the need for iterative calculations.
6.4.5 Sample size formulae for within-arm pnRCT
It is typically true that the analysis of a trial should reflect the design, and so a clustered design
should be followed by analysis which accounts for clustering. Within-arm pnRCTs involve some
of a trial arm having clustered outcomes. An appropriate analysis method which both accounted
for the clustering and obtaining an unbiased intervention effect was not identified in chapter 5.
When this clustering is dependent upon a post-randomisation outcome/intermediate outcome
then it has been shown, in the previous chapter 5, that it is not possible to analyse these types of
trials accounting for the clustering and obtaining an unbiased intervention effect. Consequently,
the use of such designs is cautioned if a large ICC or large clusters are expected (this will result
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in an inflation of the Type I error in the analysis). When within-arm pnRCT designs are used
and clustering is non-random the results of chapter 5 suggest ignoring clustering in the analysis
such as using a linear regression model.
Sample size calculations are often done from a conservative standpoint. Although no appropriate
method was identified in chapter 5 for analysing within-arm pnRCTs (which both accounted for
clustering and provided an unbiased effect estimate), in the near future an appropriate method
of analysis which accounts for clustering may be found. Inflating sample size to account for
within-arm clustering (for example using methods developed for pnRCT sample sizes) would in
future allow newly developed appropriate analysis methods to be used.
6.4.6 Inclusion of baseline measures
Trials often include baseline measurements of the outcome of interest. Making use of this
measure in the analysis by including both the baseline measure and the intervention group as
covariates in the analysis model can improve the precision of the effect estimate of treatment by
decreasing the variability (intra-subject variance is reduced). This consequently may allow us
to study fewer patients for a given power. When the primary outcome is continuous European
Medicines Agency (EMA) guidelines specify that the baseline variable should be included as a
covariate in the primary analysis regardless of which outcome is chosen in this scenario (either
be the raw outcome variable or the change from baseline) [169].
We would need to know how much the adjustment will reduce the standard deviation of the
endpoint. If the correlation between outcome variable and the adjustment variable are known,
the reduction in standard deviation can be estimated. With one outcome follow-up measure and
one baseline measure the adjusted variance using the baseline measure is given by
Variance = σ2(1− ρ2f ) (6.29)
where ρ2f is the correlation between the baseline and follow-up measure of the outcome. The
above variance estimator can be substituted into the relevant sample size formula. To halve the
sample size required the standard deviation needs to be halved, this requires a correlation of
0.87
(√





This chapter has identified and summarised methods for sample size calculations in pnRCTs
with continuous outcomes. Methods have been shown to calculate the number of clusters in
the intervention arm when there is a fixed cluster size and to calculate the optimum number of
controls, incorporating costs, unequal cluster sizes, inclusion of baseline measures. Asymptotic
sample size formulae exists for pnRCTs assuming Normal approximation. Exact sample size
methods are also available in specific software SPA-ML and clsampsi. The asymptotic methods
have been extended to include the simple correction for coefficient of variation to account for
variation in cluster size. This is similar to the commonly used method for cRCTs and simple
to implement thus should enable widespread use of this approach as opposed to a potentially
more complicated method. However, this will likely have small effect on sample size unless the
coefficient of variation is large. Further work investigating the coefficient of variations seen in
pnRCTs would be of interest to inform appropriate sample size adjustments.
There is a balance to be met between generalisability, internal validity, and pragmatism when
designing trials in which we believe the care provider or group effects have an influence on the
outcome. As in cRCTs, precision levels in pnRCTs can typically be improved if more clusters
and fewer individuals per cluster are sampled for the study.
However, the extra costs of training and recruiting staff to deliver interventions or running extra
groups needs to be considered in parallel with the reduction in sample size that increasing the
number of clusters and reducing the cluster size will lead to. Although too few clusters will result
in unreliable estimates of the ICC and results with limited generalisability to care providers or
groups outside the trial.
Chapter 5 evaluated the effect of clustering in within-arm pnRCTs. No method of analysis eval-
uated was able to account for this within-arm clustering dependent upon intermediate response.
However, taking a conservative standpoint it may be appropriate to still inflate sample size to
allow for clustering and in the near future an appropriate method of analysis which accounts for
clustering may be found.
Sample size calculations require estimates of various measures. This chapter demonstrates that
the ICC is key in any trial with clustering. There is a need for more empirical ICC estimates
from iRCTs with clustering, the next chapter 7 provides empirical estimates of ICCs from 15
HTA iRCTs with treatment induced clustering.
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6.6 Summary
This chapter describes the sample size formulae for pnRCTs with continuous outcomes. Asymp-
totic sample size formulae exists for pnRCTs assuming Normal approximation. Exact sample
size methods have also been identified and explicitly expressed in familiar sample size termi-
nology in this chapter. The asymptotic methods have been extended to include the simple
correction for coefficient of variation to account for variation in cluster size.
These methods can be used in conjunction with recommendations from both the simulation
chapters which evaluate analysis methods, chapters 4 and 5, and the following chapter 7 which





Review of individually randomised
trials with clustering
7.1 Introduction
Previous chapters highlighted that clustering commonly occurs in individually randomised trials
in health research. Chapter 6 presented methods to account for clustering of outcomes in the
design of iRCTs, these methods require an estimate of the ICC. The correlation of outcomes is
increasingly being recognised in both the design and analysis of such trials. However, there is
poor transparency of the methods used, how clustering is reported in trial reports, and a limited
evidence base of ICCs used and observed for future studies. This chapter explores the extent
and reporting of intervention induced clustering in HTA funded iRCTs, adds to the evidence of
ICCs used in sample size calculations and empirical ICC estimates, and provides exemplars for
design and reporting.
Clustering in iRCTs has been recognised in methodology literature [38, 39, 48], this study in-
vestigates how this has translated into application in publicly funded trials and provides further
evidence of ICCs in such trials. It was anticipated that the increase in publications related to
clustering in iRCTS has raised awareness of this area. CONSORT guidelines are often used by
trialists not only when reporting trials but also as a guideline when designing and analysing
trials to ensure the relevant criteria will be met when reporting results. Additionaly, the CON-
SORT extension for nonpharmacologic treatments (CONSORT-NPT) [17, 44] states that where
applicable clustering by care provider or centre should be accounted for.
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This chapter presents a review of the extent and reporting of clustering in iRCTs with interven-
tion induced clustering and provides evidence of ICCs. HTA reports of individually randomised
single or multi-centre RCTs are reviewed and trials with potential intervention induced cluster-
ing identified. The NIHR is a major funder of research into the clinical and cost effectiveness
of healthcare interventions and tests in the UK, with the NIHR HTA funding the largest pro-
gramme within this. The HTA programme funds both researcher-led and commissioned health
related research including RCTs [170]. Information from the HTA trials are extracted, relating
to: trial characteristics, sample size, clustering characteristics, information on ICC, and whether
clustering was accounted for in each of the design, statistical analysis, and reporting of the trial.
Data completeness in relation to relevant CONSORT items is recorded.
The chapter acknowledges the information provided by various corresponding authors and trial
statisticians of the included HTA studies. In particular, Beth Stuart of the University of
Southampton for providing a preprint of a manuscript of their work investigating clustering
at the general practice level in iRCTs in primary care [171].
7.2 Chapter aims
The main aim of this chapter is to determine the extent and quality of reporting of clustering
in iRCTs with intervention induced clustering and provide empirical estimates of ICCs. The
specific objectives are:
1. review the extent and reporting of clustering in single and multi-centre individually ran-
domised control trials funded and published by the UK’s NIHR HTA Programme;
2. add to the evidence on clustering in iRCTs by reporting ICCs for a number of outcomes;
3. provide exemplars of well-reported iRCTs with clustering, which can be used to enhance
adequate trial reporting.
7.3 Background
Investigators are frequently hampered when planning the sample size of trials with clustering
due to a lack of prior information on the probable size of the ICC [55]. The ICC is an important
component of sample size calculation. To better inform the design of trials with clustering
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empirical evidence of ICCs are required, from both trials and observational studies. The ICC
will vary depending on the outcome (and follow-up time), population, intervention, and setting
and the method of analysis [172]. Therefore, a rich resource of estimates are needed from which
to choose from to enable consideration of the planned study population and design
Several studies have detailed ICC estimates in various trial settings for cRCTs, examples include:
ICCs from primary care [63]; primary and secondary care implementation studies [172]; maternal
and paternal health [173]; low and middle income countries [174]; and school based studies [175].
However, fewer studies exist reporting ICC estimates from iRCTs with clustering, examples
include: surgical trials [46], psychotherapy trials [57], and general practice level clustering [171].
A small number of studies have identified and reviewed the extent of clustering in iRCTs in
different study areas, including: public health and behavioral health journals [43]; orthopaedic
surgery [176]; British Medical Journal (BMJ) [41], and surgical trials [46]. Overall these reviews
concluded that clustering in iRCTs is highly prevalent and commonly not accounted for in
either the design and/or analysis of the trial, resulting in possibly misleadingly precise effect
estimates. Of the 42 iRCTs identified in the review by Lee and Thompson [41], 38 had some
form of clustering, 17 (40%) with clustering by health professional imposed by the design of the
trial and only six of the 38 (16%) mentioned clustering as an issue. Pals et al. [43] reviewed
published articles across four public health and behavioural health journals which identified 34
articles reporting results of iRCTs in which treatment was delivered in groups. Thirty two (94%)
used analysis at the individual level, ignoring the group level clustering entirely and six (18%)
articles reported size of groups/clusters (between 6-12), and three reported number of groups
per trial arm.
As indicated previously, ICC estimates do exist from a small number of studies which collate
estimates from iRCTs with clustering specifically. Cook et al. [46] calculated ICCs from ten
multi-centre surgical trials: 198 ICC estimates for both centre and surgery level. The median
(range) number of centres and surgeons was 19 (8-27) and 49 (16-191), respectively. The largest
ICCs came from outcomes such as operation time and length of stay (related to cost), hence,
they concluded that clustering was likely to have the most impact on economic evaluation.
Baldwin et al. [57] calculated ICCs from psychotherapy trials, mainly behavioural or cognitive
behavioural. They included 20 studies and report 495 ICC estimates relating to therapists. The
number of therapist sessions ranged between 1 to 23, number of therapists ranged between 2
to 581, and average number of patients per therapist ranged from 2.2 to 51.1. General practice
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level clustering in iRCTs was investigated in a recent paper by Stuart et al. [171]. The paper
evaluated 17 primary care studies to provide ICC estimates by GP practice, concluding that
iRCTs in primary care should also take account of clustering in sample size (particularly when
cluster sizes are expected to be large). See Appendix D.1 for links to ICC estimates from other
studies.
7.3.1 What ICCs are of interest?
In iRCTs there may be different levels of clustering either related to intervention or centre in a
multi-centre trial. Details of different types of clustering were presented in more detail in chapter
2 section 2.7.2. The main focus of this study is to investigate intervention induced clustering,
however, where potential centre clustering is also present this is included.
7.3.1.1 Intervention induced ICC
Intervention induced clustering refers to the clustering which occurs due to the nature of the
intervention itself. For example, a healthcare provider delivered intervention or a group inter-
vention. For intervention induced clustering it can be realistically assumed that ICCs at baseline
will often be zero. An instance where this may not be the case could be when more experienced
care providers treat patients with worse baseline outcome measures. Consequently, the baseline
ICC will be non-zero as an artefact of the design, patients are effectively sorted and more similar
ones put in the same group. It is the intervention induced ICCs at follow-up that are generally
are of interest as they will effect the precision of the effect estimate thus used when designing
iRCTs with intervention induced clustering.
7.3.1.2 Centre ICC
There may be more than two-levels of hierarchy in iRCT data. Large iRCTs in health research
are commonly run across multiple centres, for example multiple geographical regions, NHS hos-
pitals or mental health clinics. Multi-centre studies recruit participants across multiple centres
to both achieve the required sample size and to improve generalisability of findings. Participants
from the same centre may be expected to have similar outcomes implying a positive correlation
and possibly the need to account for the centre based clustering.
A multi-centre iRCT design can result in two or more levels of hierarchy in the data. For
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example, the Stretching and Strengthening for Rheumatoid Arthritis of the Hand (SARAH)
study was a randomised multi-centre trial to evaluate the clinical and cost-effectiveness of an
exercise programme in addition to usual care for Rheumatoid Arthritis. The trial included four
levels of data hierarchy from: seventeen NHS trusts in England, comprising 21 rheumatology
and therapy departments, 48 hand therapists, and finally individual level variance [53]. However,
at times it can be difficult to include multiple levels of variability in the analysis model, adding
extra levels of variability can result in non-convergence (particularly in small samples).
Randomisation procedures in multi-centre trials often involve permuted blocks stratified by
centre. These are used to ensure similar proportions of intervention assignments across the
multiple centres, helpful for practical reasons and/or as centre is expected to be confounded
with other prognostic factors. EMA guidelines recommend that stratification variables used in
the randomisation procedure are adjusted for in the primary analysis:
“If centre was used for stratification in a multi-centre trial problems might arise in
case of many centres recruiting small numbers of patients (‘small centres’). Adjusting
for many small centres might be possible but raises analytical problems for which
there is no best solution. Analyses either ignoring centres used in the randomisation
or adjusting for a large number of small centres might lead to unreliable estimates
of the intervention effect and P-values that may be either too large or too small.”
[169, p.7]
When outcomes are continuous there are two key methods of adjusting for centre in the analysis,
using models which use fixed centre effect or random centre effect. Including fixed centre effects
can be helpful when the centre effects themselves are of interest. However, where there are a
large number of centres relative to number of patients it can be difficult as this can involve
estimating a large number of parameters compared to the total sample size.
In the literature there are different interpretations of analysis using fixed or random centre effects.
Using fixed centre effects, the results are only applicable to the centres included in the trial.
When using random centre effect it has been suggested that results are generalisable to centres
not included in the trial. However, Kahan and Morris [177] reason that this interpretation of
results using random centre effect assumes the centres in a trial are randomly sampled from
the population of centres. It is rarely the case that centres are a true random sample, centres
are typically chosen based on their willingness, readiness and ability to participate and recruit
participants according to trial protocols. Consequently, it can be argued that both fixed and
random centre effects adjustments for centres have the same interpretation. As Kahan and
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Morris [177, p.1139] notes “any generalisation to patients or centres outside the trial should be
carried out on the basis of external validity, rather than on the basis of a particular statistical
model”.
Random centre effects have been shown to perform comparably or better than fixed centre effects
and were robust to non-Normal centre effects and centre outliers [177]. An additional advantage
of random centre effects is that clustering is explicitly modelled and thus the different levels of
variability in the data can be investigated [40]. When using random centre effects with a small
sample size a degrees or freedom correction is recommended to ensure coverage is maintained
at nominal levels. Consequently, random centre effects can offer advantages over fixed centre
effects.
7.3.2 Reporting guidance for trials with intervention induced clustering
Clear and consistent reporting of trials is vital for readers to understand the design and analysis
and to fully interpret the results. This study aimed to review the reporting of clustering in
single and multi-centre iRCTs, this was done in relation to relevant CONSORT items. The
following is a description of the identification of relevant CONSORT items with features specific
to clustering in single and multi-centre iRCTs.
The CONSORT 2010 statement consists of guidelines for reporting parallel group randomised
trials [16]. It provides guidance on reporting RCTs, focussing on parallel group trials and
includes a 25-item checklist and a participant flow diagram template. The CONSORT statement
has been extended for various specific types of designs and interventions. Two CONSORT
extensions specifically relevant for iRCTs with clustering are the CONSORT extension to cluster
randomised trials (CONSORT-cluster) [34] and the CONSORT-NPT [17, 44].
Other guidelines have crossovers with the CONSORT statements including the Template for In-
tervention Description and Replication (TIDieR) checklist and Criteria for Reporting the Devel-
opment and Evaluation of Complex Interventions (CReDECI 2) in healthcare [178]. CONSORT-
NPT items 5, 5a, 5b, 5c, 5d are consistent with the TIDieR checklist.
Table 7.1 presents the relevant reporting items from the CONSORT-cluster and CONSORT-
NPT. The CONSORT-NPT statement was originally published in 2008 and recently updated in
2017. In extension to the CONSORT 2010 statement for parallel group randomised trials both
the CONSORT-cluster and the CONSORT-NPT explicitly instruct authors to, where applicable,
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report details of whether and how clustering by care providers or centres was addressed in
the sample size and statistical methods, and results (incorporating into the participant flow
diagram). A further results section checklist item exists in the CONSORT-cluster, item 17a.
Item 17a instructs authors to report a coefficient of intra-cluster correlation (ICC or k) for each
primary outcome. An equivalent checklist item for the results section does not exist in the
CONSORT-NPT.







Participants 4a None When applicable, eligibility
criteria for centres and for care
providers
Sample size 7a Method of calculation, number
of clusters(s) (and whether
equal or unequal cluster sizes
are assumed), cluster size, a
coefficient of intracluster
correlation (ICC or k), and an
indication of its uncertainty.
When applicable, details of
whether and how the clustering




12a How clustering was taken into
account
When applicable, details of
whether and how the clustering







13a For each group, the numbers of
clusters that were randomly
assigned, received intended
intervention, and were analysed
for the primary outcome
The number of care providers or
centres performing the
intervention in each group and
the number of patients treated
by each care provider or in each
centre
Baseline data 15 Baseline characteristics for the
individual and cluster levels as
applicable for each group
When applicable, a description
of care providers (case volume,
qualification, expertise, etc.)




17a Results at the individual or
cluster level as applicable and a
coefficient of intracluster
correlation (ICC or k) for each
primary outcome
None
Figure 7.1 presents the explanation for the extension to CONSORT-cluster extension item 17a.
A similar explanation could also be reasoned for reporting the ICC for each primary outcome
analysed in trials of non-pharmacological treatments (when applicable). It was unclear from the
published literature why such a statement was not included. Donner and Klar [55] state that
for trials with more than one level of clustering, ICCs at each level should be reported and also
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Figure 7.1: Explanation of Item 17a taken from CONSORT statement cluster extension [34]
“When reporting the results of a cluster randomised trial, point estimates with con-
fidence intervals should be reported for primary outcomes. Given the impact of the
extent of the intracluster correlation on the power of the study, the intracluster cor-
relation coefficient or k statistic, for each outcome being analysed should also be
provided. This information will allow readers to assess the appropriateness of the
original sample size calculations as well as the magnitude of the clustering for each
outcome. Showing both adjusted and unadjusted estimates would provide another
indication of the extent of the clustering. Several authors have advocated publishing
intracluster correlation coefficients to allow them to inform the development of future
cluster trials in similar settings.”[34, p.10-11]
argue that a complete report should include estimates of between- and within-cluster variance
for each ICC estimate. The CONSORT-NPT first author Isabelle Boutron was contacted by
myself to discuss their reasoning for not including this item in the original CONSORT-NPT
in 2008 or the update in 2017. Boutron fed-back that it was not added as people felt it was
already good to have the clustering/ICC addressed in the methods and it does not apply to all
NPT trials. Although similar can be said for the CONSORT-NPT methods items 7a and 12a
as these do not apply to all NPT trials. Boutron also stated that it would be a very important
point to discuss for further updates. Consequently, this study investigates how many trials are
already reporting the ICC for each primary outcome analysed and identifies some examples of
good practice.
7.4 Methods
This section describes the methods used to conduct the review, providing rationale for the
process undertaken.
7.4.1 Trial identification
Reports of iRCTs published in the NIHR HTA Journal from January 2013 to December 2017
were reviewed. A previous review investigating recruitment and retention in trials funded and
published by the UK HTA Programme had been conducted by statisticians at the University of
Sheffield up to the end of April 2016 [179]. Access was gained to the data from this review in an
Excel file. This was updated to cover up to 31st December 2017 and data extraction undertaken
relating to clustering and ICCs for all relevant trials between 2013 and 2017.
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Trials published between 2013 and 2017 inclusive were chosen as the interest was in recent re-
porting to understand current practice. It was envisaged reporting and accounting for clustering
in recently published trials will be improved compared to past trials due to the higher prevalence
of published papers and specific CONSORT guidelines.
HTA publishes research on the effectiveness, costs and broader impact of health technologies for
those who use, manage and provide care in the NHS. The NIHR HTA funding is a national peer-
reviewed funding programme. Reports are published in the HTA Journal if they have resulted
from work for the NIHR HTA Programme and they are of a sufficiently high scientific qual-
ity as assessed by the external reviewers and journal editors (https://www.journalslibrary.
nihr.ac.uk/hta/about-the-hta-journal.htm). HTA Journal trial reports were selected for
a number of reasons. They are of high quality and provide detailed trial, design and analysis in-
formation. HTA Journal reports are comprehensive, hence, it was anticipated that the reporting
of design and analysis including the reporting of ICCs in results sections of these trial reports
would be generally more detailed than other journal publications and likely to contain ICC if
reported at all. Limiting the review to publicly funded trials published in the HTA Journal
identified trials from medicine, surgery and therapy from a range of disease areas.
HTA Journal reports were obtained from the NIHR Journals Library website (http://www. jour-
nalslibrary.nihr.ac.uk/hta). Efforts were made to check publicly available sources for additional
information about identified studies. If published, the International Standardised Randomised
Controlled Trial Number (ISRCTN) was used to check the ISRCTN register of clinical tri-
als for any additional information, a trial website or any previously unobtainable trial reports
(http://www.isrctn.com/). Author name, study name and ISRCTN number were used to iden-
tify published trial papers and trial protocols where available. The HTA Journal report was
used as main source of information if any discrepancies in reporting existed.
7.4.2 Inclusion/exclusion criteria
Trials included in the review were single and multi-centre RCTs that were either fully or partially
randomised and where recruitment to the trial was finished. Trials were not restricted to iRCTs
with clustering in only one arm. Though this design is common, the aim of this review was to
capture iRCTs with potential intervention induced clustering regardless of the the number of
trial arms this occurred in. Results would thus be more generalisable and useful to a broader
range of trials designs. Nested parallel trials as part of another RCT and trial reports of two
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or more parallel RCT were included. Trials with a continuous primary endpoint were included
(the focus of this thesis).
During review, trials with the following designs were excluded: cluster randomised trials, trials
with non-continuous primary endpoints, adaptive designs, and pilot or feasibility trials. Feasi-
bility studies are not designed to provide robust effect estimates, hence, estimates of the ICC
from such trials may not be reliable. Additionally, the reporting of feasibility and pilot studies
would follow the CONSORT extension for pilot and feasibility trials [180]. Ethics approval was
not required for this study as analysis was based on either published results or existing datasets
from previously conducted studies (which had appropriate approvals in place).
7.4.3 Data extraction
7.4.3.1 Trial information
The standardised data extraction form from the original University of Sheffield statistics review
was obtained from the authors with approriate permissions. It included detailed trial information
from the HTA reports. Data from the original form used in this review were: the trial design,
the clinical area, intervention type, type of control, number of arms, single or multi-centre and
number of centres, recruitment setting, the number and timing of follow-up visits, and the sample
size. Data extraction was updated to include trials published up to 31st December 2017 [179].
Trials with potential intervention induced clustering were identified. For these trials additional
data were extracted for the purpose of this review relating to clustering and ICCs, including:
potential clustering both by healthcare provider/group intervention and by centre, number of
clustered arms, whether clustering was recognised, ICCs used in sample size, evidence source
for ICCs, results ICC, and information on number and size of clusters.
ICC estimates (and 95% confidence intervals), where available, were taken from trial reports.
When observed ICCs were not reported contact was made with the corresponding author to
ask them to either provide this information or the corresponding data for relevant calculations,
with follow-ups when no initial response was received. If no response was received by 31st June
2017 no further follow-up was taken, this provided time for analysis and writing-up of results.
The ICC can be estimated either from an ANOVA or a mixed effects model. An advantage
of using a mixed effects model is that covariates can be included in the model. Including any
potential confounders as covariates whilst estimating the ICC represents the kind of analysis
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that is undertaken in practice. Where possible the ICC was requested to be from an adjusted
mixed effects model to reflect the statistical analysis of a trial.
For both intervention induced clustering and centre based clustering the median ICC, interquar-
tile range (IQR) and range for all trials and all outcomes were calculated and specifically for the
primary endpoint (primary outcome at primary follow-up). Where the ICC was reported as <
or ≤ it was rounded up to that number for calculations (for example ≤ 0.001 rounded to 0.001).
7.4.3.2 Reporting quality
Data were also extracted based on the reporting of relevent CONSORT extension items related
to clustering. A seven item checklist was developed based on extension checklist items identi-
fied from the CONSORT-cluster [34] and CONSORT-NPT [17, 44] statements in section 7.3.2.
Items were identified that deserved special consideration when reporting in iRCT with potential
intervention induced clustering. Adherence to the following items was recorded:
1. Methods - When applicable, eligibility criteria for centers and for care providers (CONSORT-
NPT 4a);
2. Methods - When applicable, details of whether and how the clustering by care providers
or centers was addressed (CONSORT-NPT 7a);
3. Methods - When applicable, details of whether and how the clustering by care providers
or centers was addressed (CONSORT-NPT 12a);
4. The number of care providers or centers performing the intervention in each group and
the number of patients treated by each care provider or in each center (CONSORT-NPT
13a);
5. As 4 above in diagram form (CONSORT-NPT 13a);
6. Results - When applicable, a description of care providers (case volume, qualification,
expertise, etc.) and centers (volume) in each group (CONSORT-NPT 15);
7. Results - Where applicable, to report a coefficient of ICC for each primary outcome (based
on CONSORT-cluster 17a)
The CONSORT-cluster item 17a was translated for applicability to CONSORT-NPT: “where
applicable, to report a coefficient of ICC for each primary outcome”. Reporting adherence of
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these items was recorded according to the following system of completeness: “absent”, “totally
complete”, “partially complete”, “cannot access” and “not applicable”. The number and pro-
portion of studies meeting at least partial, compliance in reporting criteria for each checklist
item was calculated. Furthermore, a total measure of the number and proportion of checklist
items meeting total and at least partial compliance criteria was calculated.
See Appendix D.2 for further details on what the data extraction included.
7.5 Results
7.5.1 Overview
Figure 7.2 details the selection of studies in this review. In total 399 reports were published
between January 2013 and December 2017 in the HTA Journal and 103 of these were reports of
iRCTs (excluding pilot/feasibility studies). Of the 103 trials, 48 (47%) had a continuous primary
endpoint. Twenty nine (60%) of which were categorised as having potential intervention induced
clustering. Intervention induced clustering relates to either healthcare provider or group based
clustering.
Figure 7.2: Flowchart representing process for a review of trial reports published in the Health
Technology Assessment Journal between 2013 and 2017 inclusively.
HTA Journal reports published between 2013 - 2017 (n = 399)
Individually randomised trials identified from HTA
Journal published between 2013 - 2017 (n = 103)
Trials excluded (n = 55,
primary endpoint not continuous)
Individually randomised trials analysed (n = 48)
- With treatment induced clustering (n = 29)




The characteristics of the 29 trials included in the review are summarised in Table 7.2 and Table
7.3. The majority, 72% (21/29), of trials were parallel group two arm trials. Included trials cov-
ered a range of intervetnions: therapy, surgery, complex intervention, and those categorised as
other (for example a group weight management programme in the SWAP trial [181]), with ther-
apy the most common intervention type 41% (12/29). No drug intervention trials were identified
as having potential intervention induced clustering due to the nature of such trials. Trials were
most commonly in the clinical areas of mental health 31% (9/29) and orthopaedics/rheuma-
tology/musculoskeletal 28% (8/29). The trial settings were evenly spread across hospital 28%
(8/29) general practice 28% (8/29) and community settings 24% (7/29).
The median number of centres was 17 (IQR 4.5 to 35, range 1 to 94). The median number of
intervention induced clusters was 20 (IQR 11 to 70, range 1 to 244), where number of clusters
was available in reports for 21 trials explicitly and derived for one trial from the report.
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nurse. Step 2 -
therapist.
529 2 2 51 -
2 AIM - close contact casting vs
open surgical reduction and
internal fixation for unstable
ankle fractures in patients > 60
years [182]
Surgeon 620 2 2 24 100





356 2 2 5 17
4 Booster - ”booster”
interventions to sustain
increases in physical activity in




282 2 3 1 6
5 BREATHE - self-guided
intervention vs. ‘face-to-face’
physiotherapy for asthma [185]
Physiotherapist 655 1 3 34 1











705 1 2 32 18








485 1 2 74 20





444 1 2 5 11
9 CLASS - foam sclerotherapy vs.
endovenous laser ablation vs.
surgery for varicose veins [188]
Surgeon 798 3 3 11 -
10 COBRA -behavioural activation







440 2 2 36 10 & 12




Surgeon 777 2 2 29 -





115 1 2 3 -
13 Getting out the house - outdoor
mobility rehabilitation





568 1 2 15 29
14 IMPACT - CBT vs. short-term
psychoanalytic psychotherapy
(STPP) vs. brief psychosocial
intervention (BPI) for







372 3 3 15 38, 44 & 63
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Surgeon 2352 2 8 34 116
16 OCTET - supported
computerised CBT vs. guided
self-help vs waiting list for





475 2 3 14 93
17 PD REHAB - physiotherapy





762 1 2 38 -








306 1 2 3 18
19 PhysioDirect - physiotherapist
initial assessment and telephone
advice, with face-to-face care
when necessary for
musculoskeletal problems [196]
Physiotherapist 2256 2 2 94 32
20 POWeR+ - brief advice vs.
internet-based behavioural
intervention with: nurse
support face-to-face vs. remote
for obesity [197]
Nurse 818 2 3 56 -
21 ProFHER - surgery vs.
non-surgical treatment for
fracture of the proximal
humerus [198]
Surgeon 250 1 2 33 66
22 SARAH - exercise programme
for hands and upper limbs for
rheumatoid arthritis [53]
Hand therapist 490 1 2 17 48
23 SHEAR - brief advice for
excessive alcohol consumption
[164]
Clinician 802 1 2 3 79
24 START - manual-based




260 1 2 4 10
25 STRIDE - CBT for fear of
falling in older people [200]
Health-care
assistant
415 1 2 3 3
26 SWAP - group weight
management programme vs.
practice nurse intervention in




330 2 2 2 4 & 15




445 3 3 7 -
28 UK DRAFFT - Kirschner-wire
fixation vs. locking-plate
fixation for fracture of the
distal radius [202]
Surgeon 461 2 2 18 244
29 UKUFF - open vs. arthroscopic
rotator cuff repair [203]
Surgeon 662 2 2 47 20
* Where more than one number reported this refers to no. clusters in different arms if more than one arm
clustered. Some trials with more than one clustered arm reported no. of clusters overall. - : number of
clusters not reported.
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Mental health 9 (31)






Complex intervention 3 (10)
Other 9 (31)
intervention induced clustering
Care provider 25 (86)
Group & care provider 4 (14)
7.5.3 Reporting of checklist items specific to clustering
Figure 7.3 represents data completeness in relation to CONSORT guidelines and clustering
information. As shown in Figure 7.3, suboptimal reporting compliance was observed in items
relating to sample size (7a), participant flow diagram (13a) and outcomes (17a). The following
proportions exclude items 17a - Outcomes and 13a - Participants flow diagram as these are
not explicitly required according to CONSORT-NPT. The proportion of trials meeting at least
partially complete reporting (of items 4a, 7a, 12a, 13a, and 15) was 48% (14/29) and meeting
complete reporting was 21% (6/29). Regarding the suggested CONSORT-NPT addition item 17a
(“were applicable, a coefficient of ICC for each primary outcome”), 24% (7/29) and 28% (8/29)
partly and fully reported, respectively. Item 17a is not a checklist item included in CONSORT-
NPT at present, it was identified as a key component of reporting for iRCTs with intervention
induced clustering. Reporting of item 13a was separately recorded relating to participant flow
and the participant flow diagram (which is strongly recommended to report a participants flow
diagram in the CONSORT guidelines).
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13a Participant flow diagram
15 Baseline data
17a Outcomes
0% 25% 50% 75% 100%
Absent Partly complete Complete Not applicable
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7.5.3.1 Sample size calculations
The trial characteristics related to sample size calculations are summarised in Table 7.4. Among
the 29 studies sample size calculations were reported as follows: 52% (15/29) at the individual
level, 38% (11/29) took account of ICC at intervention level, 3% (1/29) took account of ICC at
centre level, and 3% (1/29) took account of ICC at intervention and centre level. The ProFHER
trial [198] was classified as ‘other’ regarding whether the sample size calculations took account of
ICC, the sample size calculation explained that it did not take account of any potential cluster
effect as they did not expect there to be many patients treated by individual surgeons. The
most common intervention level ICC used in sample size calculations was 0.02 (range between
0.01 to 0.1).
Table 7.4: Trial characteristics relating to sample size calculations
Characteristic n (%)
Sample size calculations
Reported at individual level 15 (52)
Reported to account for ICC (intervention level) 11 (38)
Reported to account for ICC (centre level) 1 (3)
Reported to account for ICC (centre & intervention level) 1 (3)
Other 1 (3)
Sample size ICC intervention level
0.01 - 0.025 4 (14)
0.026 - 0.05 5 (17)
≥ 0.06 3 (10)
None 17 (59)





None reported 10 (34)
Previous trial/s 3 (10)
Previous observational research 1 (3)
Not applicable* 15 (52)
*Sample size calculation did not account for clustering
7.5.3.2 Reasons stated when clustering is not accounted for
This section explains and provides accounts of trials included in this review that did not ac-
count for clustering but provided reasoning for this decision. Explanations were identified either
through published journal reports or through correspondence with authors and trial statisticians
when contacted for more information regarding the ICC.
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Three key reasons emerged for not accounting for clustering, including:
1. lots of small clusters;
2. difficult to define clusters;
3. non-convergence mixed effects models with cluster as a random effect.
Some trials provided more than one of these reasons. More detail on each of these reasons is
provided in the following paragraphs.
Firstly, a number of the trials either had clusters of size one or very small clusters, hence, the
effect of clustering by healthcare provider was expected to be negligible or zero. For instance, the
UK DRAFT trial [202] did not include a random effect for surgeon or centre: surgeon because
surgeons mainly treat only one person (number of patients treated per surgeon ranged from one
to 27) and they used a likelihood ratio test to test for centre effect. However, it is generally
recommended not to test for significance of clustering in trials as the test is not powered.
Results stated that “any individual surgeon operated only on a small number of patients (n =2
or 3) enrolled in the study; 88% of surgeons (215 out of 244) treated fewer than three study
participants. This greatly reduces the likelihood of a surgeon-specific effect on the outcome at
any one centre, that is one particularly good or bad surgeon dominating the other surgeons in
the study” [202, p.25]. On the opposite end of the spectrum was the BREATHE trial [185] in
which all participants involved in the face-to-face physiotherapy arm were treated by a single
physiotherapist.
Secondly, was the issue of undefined or hard to define intervention induced clusters (common
in primary care and pragmatic trials). This was evident in the PD REHAB trial [194], from
further correspondence with the trial statistician they explained that they did not look at the
ICC due to the large number of permutations of staff that worked with the patients making
it unmanageable. For example, the patient may have seen the same occupational therapist
each time, but seen different physiotherapists, or seen by multiple physiotherapists and multiple
occupational therapists. The recording of cluster definition can also be an obstacle to accounting
for it. The UKUFF trial [203] was undertaken in 19 centres and in many of the centres more than
one surgeon participated. The physiotherapy post-surgery was part of routine care, it was not
recorded who did it or whether it was all done in the hospital where the surgery was performed.
Similarly, the PhysioDirect trial [196] did not collect data related to clustering at the level of the
care provider. The corresponding author explained that individual physiotherapists providing
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consultations were recorded in the PhysioDirect software held within the NHS, but not within
the research data. In addition, participants had contact with more than one provider and given
the brief nature of the intervention (assessment and advice) there was not considered to be
any likelihood of major intervention-induced clustering affecting the estimates of effect. In the
TIME-A trial [201] the NIHR funded part of a larger international trial and data on therapists
was not held in this dataset, the methods section specified that clustering was accounted for in
the analysis, however, ICC was not reported in the final results.
Thirdly, mixed effects models did not converge when intervention induced clustering was added
as a random effect in analysis of some of the trials. For example, the Families for Health trial
[13] planned to fit a three-level hierarchical mixed-effects model including a random effect for
delivery group and a random effect for family. However, it was stated in the results models
comprising the delivery group random effect failed to converge and thus a two-level hierarchical
model was used. The AESOPS trial [95] primary analysis compared minimal intervention with
stepped care on the primary outcome measure, ADD, at 12 months post randomisation using a
mixed model, to account for any variation due to GP practice and the allocated therapist/nurse
delivering the intervention. However, the three-level model including the nurse/therapist failed
to converge, consequently a two-level mixed model was used with participants nested within GP
practice.
Finally, additional explanations included finding the clustering effect had little effect on the
results and consequently not including the random effects in the analysis model. The COBRA
trial stated in the methods that “although we initially planned to include therapist as a random-
effects variable in our models, given the low levels of observed clustering we took a parsimonious
approach and fitted our models without inclusion of therapist. We also checked that there was no
difference in inference with and without the inclusion of a random-effects therapist term” [189,
p.41]. Correspondingly, the results stated “there was evidence of a small, negligible clustering
of primary and secondary outcome scores at follow-up across therapists overall and within BA
and CBT groups (intracluster correlation coefficient of ≤ 0.04)” [189, p.67]. The SHEAR trial
also stated that including the clinician random effect had little effect on the results, and thus it
was ignored for the comparison of secondary outcomes [164].
These findings highlight that clustering in iRCTs is not always possible to account for. It may
initially be considered during the design stage, however, in the resulting analysis is not possible
to include.
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7.5.3.3 Empirical ICC estimates
In total there were 221 ICC estimates (39 clustering by centre, 179 clustering related to inter-
vention - 35 group, 1 family and 146 healthcare provider) from 17 studies for which an ICC was
either extracted from the original HTA report, further publication or from correspondence with
the author. This constituted both primary and secondary outcomes and outcomes reported at
multiple follow-ups.
Table 7.5 presents a collated summary of ICC estimates, for all ICC estimates and only those for
the primary endpoint, referred to as primary ICC from here on. There were 17 studies providing
estimates for 15 intervention induced and eight centre primary ICC estimates. The number of
estimates per intervention ranged from 1 to 27 (median 4, IQR 1.5 to 9.5). The median centre
based ICC was 0.015 (IQR 0.006 to 0.043). The median healthcare provider ICC was 0.009 (IQR
0.001 to 0.51). The median group based ICC was 0.019 (IQR 0.001 to 0.054). This suggests a
small amount of clustering at centre and intervention induced. These are summary estimates,
the summaries including all ICCs do not take account of the correlation within studies due to
multiple ICC estimates arising from the same study.
A table of all estimates of ICCs from the studies is included in Appendix D.1. An extended
table including further information such as sample size, cluster information and status of outcome
and follow-up (primary/secondary) has been collected into an Excel sheet, however it was not
possible to include all this in the Appendix. This is stored using ORDA - The University
of Sheffield Research Data Catalogue and Repository which is hosted on Figshare via https:
//figshare.com/s/d2645eb91b3ea9b65e0d.




Median IQR Min Max
Centre All 39 0.015 (0.006, 0.043) 0.0000 0.4490
Centre Primary 8 0.014 (0.005, 0.045) 0.0000 0.0730
Healthcare
provider
All 146 0.009 (0.001, 0.050) 0.0000 0.678
Healthcare
provider
Primary 15 0.007 (0.001, 0.030) 0.000 0.099
Group All 35 0.019 (0.001, 0.054) 0.000 0.156
Group Primary 3 0.001 (0.001, 0.036) 0.000 0.070
Family All/Primary 1 0.471 - 0.471 0.471
Figure 7.4 presents a visual comparison of the ICCs used in sample size matched to the primary
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ICC estimate. The majority of ICC estimates were lower than assumed in sample size. Two
studies found a higher ICC than assumed in the sample size calculation: the COBRA trial [189]
reported an ICC as ≤ 0.04 compared to sample size ICC of 0.01 and the family level ICC in the
Families for Health trial was 0.471 compared to sample size ICC of 0.270.
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7.5.4 Exemplars
One of the aims of this chapter was to explore exemplars of well-reported aspects of iRCTs with
clustering, which could be used to enhance adequate trial reporting. None of the publications met
full compliance with CONSORT checklist items identified in section 7.3.2. There were, however,
some good examples of reporting of iRCTs with potential clustering across the different checklist
items. This section seeks to provide exemplars from the HTA studies, for each of the checklist
items in turn. This adds to and expands on the examples of adequate reporting provided in
the CONSORT-NPT statement [17], now including examples of adequate reporting of checklist
item 17a “where applicable, a coefficient of ICC for each primary outcome”. A number of tables
and figures below have been reproduced from the original HTA reports (with no changes made
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and suitable acknowledgement to original reports) adhering to the copyright rules of the 2018
Queen’s Printer and Controller of HMSO.
7.5.4.1 Methods - Participants
In the case of reporting eligibility criteria for centres and for care providers (CONSORT-NPT
4a), the CHAMP trial [187] provided a clear description of therapists and the training they
received.
Example: “At each clinic we therefore trained a psychologist, research nurse or equiv-
alent health professional (G-grade or equivalent) to administer the treatment. ...Each
therapist attended two workshops at the beginning of the study and received up to 3
months’ training from the senior practitioners in the study, sometimes in vivo with
two therapists being present in treatment sessions, before taking on the care of pa-
tients alone.” [187, p.6]
The COBRA trial [189] reported experience and workload of therapists in each trial arm.
Example: “Ten MHWs provided BA [median 22 participants each (interquartile range
19–25 participants each)] and 12 therapists provided CBT [median 21 participants
each (interquartile range 13–23 participants each)]. MHWs had a mean of 18 months’
mental health experience (SD 11 months’ mental health experience) and CBT ther-
apists had a mean of 22 months’ experience (SD 24 months’ experience) post CBT
qualification. We removed one CBT therapist from the trial in the early stages who
did not meet acceptable competency”. [189, p.19]
7.5.4.2 Methods - Sample size
A number of studies reported sample size calculations providing details of whether and how
clustering by care providers or centres had been addressed. The SWAP trial [181] reported
sample size calculations which adhered to CONSORT-NPT, including assumed mean cluster
size and ICC.
Example: “To account for potential clustering effects due to group treatment in
the WAP arm, assuming a mean cluster size of 18 and an intracluster correlation
coefficient of 0.05, a total of 208 individuals will be required in the WAP arm. The
same power can be achieved with 108 in the nurse arm and 216 in the WAP arm, which
we increased to 110 in the nurse arm and 220 in the WAP arm to give an allocation
ratio between the two arms (2 : 1) that can be expressed in whole numbers. Thus,
we required a total of 330 individuals for the entire study.” [181, p.20]
The OCTET trial [11] reported sample size calculations with transparency for a crossed-therapist
design, therapists deliver interventions in more than one intervention arm.
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Example: “The comparison of either supported cCBT or guided self-help is a partially
nested design for which the sample size calculation needs to consider the intracluster
correlation coefficient (ICC) for therapist. The comparison of supported cCBT with
guided self-help is a crossed therapist design, as support for both treatments was
delivered by the same therapists. Sample size for crossed therapist design depends
on the ICC for therapist for treatment within therapist, which is smaller than the ICC
for therapists. Formulae for this calculation are given in Walwyn and Roberts. In
the absence of estimates of the two ICCs required for the two calculations, sensitivity
of study power to larger values was considered in the calculation below.
Assuming a standard deviation (SD) for the primary outcome (Y-BOCS-OR) at
6 months of 7.3 units, a correlation between baseline Y-BOCS-OR and 6-month Y-
BOCS-OR of 0.43, a study with 366 service users followed up to the primary end point
has a power > 80% to detect a difference of 3 Y-BOCS points for each comparison.
We were unable to find evidence for a ‘clinically important difference’. A reduction of
3 points was agreed based on clinical consensus with the study team. This calculation
assumed that supported cCBT and guided self-help were delivered by 24 therapists.
It also assumes that the ICC for therapists was 0.06 and an ICC for treatment within
therapist was 0.015, which implies that the correlation between the random effect for
supported cCBT and guided self-help is 0.75. The design effects, sometimes called
the sample size inflation factor, were 1.1225 and 1.06125 for the partially nested and
crossed designs, respectively. We considered these values of the ICC to be plausible,
but in the event that the ICC for therapist was as large as 0.1 and the ICC for
treatment within therapist was 0.05, the power of the trial is still > 75% for all three
comparisons.” [11, p.16]
7.5.4.3 Methods - Statistical methods
Details of whether and how the clustering by care providers or centres was addressed in the
staistical analysis methods was described in the START trial [199], adjusting for centre and the
partially nested design using a mixed-effects model.
Example: “Separate regression analyses were used to estimate group differences in
HADS-T score over the short term (using 4- and 8-month follow-ups) and the longer
term (using 12- and 24-month follow-ups). In both cases, random-effects models
accounted for repeated measurements and therapist clustering in the intervention
arm. Adjustments were made for baseline HADS-T scores and centre (on which
randomisation was stratified), and also on factors believed from the literature to affect
affective symptoms (carer age, sex, carer burden and care recipient neuropsychiatric
symptoms).” [199, p.18]
The SWAP trial methods explained clearly that analysis would account for clustering in both
arms, with mention of a small sample degrees of freedom correction.
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Example: “All analyses accounted for clustering by group in the WAP arm and
clustering by nurse in the nurse arm. Each participant has been defined as belonging
to a cluster, by which group they belonged to if they were in the intervention arm and
by which nurse they were treated by if they were in the control arm. This variable has
been included as a random intercept in a mixed-effects regression model. This analysis
assumes that the intraclass correlation coefficient is the same between groups in the
intervention arm as it is between nurses in the control arm. The Kenward–Roger
degree of freedom correction was used for all linear mixed-effects models.” [181, p.21]
7.5.4.4 Results - Participant flow
For clarity the results section should report the participant flow, for NPT trials this relates to
also reporting the number of care providers or centres performing the intervention in each group
and the number of patients treated by each care provider or in each centre. For example, the
IMPACT trial [192] provided a description of the care provider workload in both text and a
figure of the frequency distribution of number of trial participants for each therapy type seen
by a trial therapist.
Example: “All therapists delivering a trial therapy were given a trial therapist identi-
fier. The therapist identifier was missing for 18 (12%) BPI trial treatments, 13 (9%)
CBT trial treatments and 2 (1%) STPP trial treatments. A total of 63 therapists
delivered BPI, 44 delivered CBT and 38 STPP. For all three modalities, the young
person received their trial therapy from a single trial therapist. Figure 6 gives the dis-
tribution of the number of young people treated by each therapist for each treatment
arm. The number of trial participants seen by a particular therapist ranged from
1 to 15. Forty BPI therapists treated only one young person in the trial, whereas
the corresponding figures for CBT and STPP were 19 and 18, respectively. This
difference in number of therapists per treatment group is due, in part, to the rather
larger number of available BPI compared with CBT or STPP therapists within the
15 NHS CAMHS clinics.” [192]
7.5.4.5 Results - Participant flow diagram
Figure 7.5 presents the participant flow diagram used in the CASPER trial report depicting the
number of case managers (care providers) performing the intervention in the collaborative care
arm. An exemplar related to a surgical trial can be found in the ProFHER HTA trial report
(Figure 7) [198].
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Figure 7.5: Example of a participant flow diagram depicting iRCT with intervention induced
clustering (taken from [186])
7.5.4.6 Results - Baseline data
A clear description of care providers (case volume, qualification, expertise, etc.) and centres
(volume) in each group was presented in the report for the UK DRAFFT trial [202]. The
surgeon grade, experience by intervention arm was presented in a table and further information
regarding operating times etc. presented in figures.
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Figure 7.6: Example of a study including results at the individual or cluster level as applicable
and an ICC for each primary outcome (taken from Table 9 [186])
7.5.4.7 Results - Outcomes and estimation
Figure 7.7 presents an example of reporting ICCs from the PEPS study [195], which reported
an ICC and 95% confidence interval for each primary and secondary outcome at 72 weeks in
PEPS arm according to the therapy group, alongside a summary of the size and number of
clusters. This provides a clear summary of the level of clustering, it could be further improved
by clarifying which models were used to account for this clustering. Another exemplar can be
found in Table 8 of the Getting out the House study [191], which reported an ICC for each
primary and secondary outcome, however, without precision estimates or number of clusters.
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Figure 7.7: Example of study results reporting an ICC for each primary outcome (taken from
[195])
The CASPER trial [186] reported secondary analyses results which adjusted for clustering by
case manager, providing ICC and 95% confidence intervals for the primary outcome at each
follow-up.
Example: “The average ICC for clustering within case managers was found to be
lower than expected (ICC 0.0069, 95% CI 0.0000 to 0.0644, for PHQ-9 scores at 4





This study reviews and presents the extent, reporting and evidence of intervention induced
clustering (ICC estimates) in single and multi-centre iRCTs funded and published by the UK’s
NIHR HTA Programme with continuous outcomes. It was found that clustering in iRCTs was
often acknowledged and considered in either the design and/or analysis stages. Although, results
related to clustering (including number of clusters, range, ICC estimate and 95% confidence
interval) were typically not fully reported within the results section.
The reporting of an ICC represents an important contribution to the research literature, both
allowing future studies to plan for adequate power and providing evidence of, for example, the
role of care provider and centre cluster in the variation in outcome. This chapter has collated and
added to the evidence on clustering in iRCTs by reporting ICCs for a number of outcomes that
were missed from the original reports. The results of this study have highlighted the importance
of recording all elements of the complex intervention to enable clustering to be accounted for,
however, it is acknowledged that there are difficulties in this such as access to routine data.
It is useful to note that of those who fully reported, the majority had over-estimated the ICC
in the sample size. Many trials reported ICC and/or a p-value for the significance of the ICC
without a confidence interval. As in other statistical inferences it is good practice to report
confidence intervals alongside estimates and p-values. There is generally not enough power to
test for statistical significance of ICCs in trials. Consequently, it is of more interest to use a
sensitivity analysis for this type of analysis and compare both with/without therapist/cluster
effects.
There were various challenges identified related specifically to iRCTs with clustering. Clustering
was sometimes acknowledged in the text as a possibility but not directly included in the sample
size or analysis methods. This may be for valid reasons, such as expecting very small cluster
sizes [198] or trial participants being treat by multiple healthcare providers over the course of
an intervention and thus the cluster was difficult to define [194]. Additionally, as shown in
chapter 6, sample size methods and corresponding statistical software for iRCTs with clustering
are relatively newly developed so awareness may still be limited. Being treated by multiple care
providers will also reduce the likelihood of any one care provider having a effect on individual
patients outcome. Some trials included a very small number of clusters, and though this may
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still result in clustered outcomes it is difficult to account for the clustering in the analysis as
estimating an ICC from a small number of clusters can result in bias ICC estimates (as shown
in simulation results of chapter 4). Defining therapist/cluster in real life can be challenging as
therapists can leave or move roles and be replaced. For example, in the Getting out the House
[191] HTA trial two different definitions of therapist were used to evaluate therapist effects: the
main therapist was defined as the individual who was the therapist for the initial (assessment)
session and an alternative definition of the therapist, for instance for the exercise programme
arm, using the therapist who took the second session (first exercise session).
The main overarching factor for not accounting for clustering was the pragmatic nature of the
trials included. Many of the interventions had components that were routine practice and not
fully documented, which meant that researchers found it hard to define levels of clustering.
7.6.2 Comparison with literature
The extent of potential intervention induced clustering was 59% from trials included in this
review. Slightly higher than that found by Lee and Thompson [42] in a review of trials published
in the BMJ, 40% had clustering by health professional imposed by the design of the trial.
Reporting has been shown to need improvement across different study designs and therapeutic
areas. Samaan et al. [204] found of 50 systematic reviews reporting adherence to reporting
guidelines 80.6% reported suboptimal levels (across different clinical areas and study designs).
Specifically, Nagendran et al. [205] assessed adherence of RCTs in surgery to the standard
CONSORT and CONSORT-NPT guidelines. They identified 54 surgical trials and found of
the eight items with less than 30% overall compliance seven were from the CONSORT-NPT
extension. These items included: eligibility criteria for centres performing the interventions
(24%), how clustering by care providers or centres was addressed as it relates to sample size (6%),
how clustering by care providers or centres was addressed as it relates to statistical methods
(4%), a description of care providers (case volume, qualification, expertise, etc) and centres
(volume) in each group (0%). Adherence to CONSORT-NPT was much poorer than to standard
CONSORT, raising awareness of the CONSORT-NPT items and the need to consider and report
the role of centres and care providers in trials appears to be a key issue.
The HTA Journal endorses the CONSORT statement. According to the webpage, all RCTs
reporting in the HTA Journal are required to submit a CONSORT checklist alongside the report
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(reports cannot be reviewed without these forms). Guidelines have been shown to correspond
with improved reporting. The CONSORT Statement is endorsed by many medical journals, and
CONSORT is part of a wider effort to improve the reporting and quality of health research. Ivers
et al. [206] reviewed impact of the 2004 CONSORT-cluster trial extension on the reporting and
methodological quality of cluster randomised trials. They identified significant improvements in
five of 14 reporting criteria. However, only 18% of the 300 manuscripts [206] reviewed reported
an ICC, this was an improvement on previous estimates of 4% and 8%. Of the 29 studies
included in this review 24% and 28% partially and fully reported CONSORT-cluster item 17a
(related to reporting an ICC where applicable), respectively. This suggests that adding this
item to the CONSORT-NPT would not be an undue burden as there are already some studies
reporting ICCs at present.
Turning now to the reporting of ICC estimates, estimates of ICCs from iRCTs have been pro-
duced for a number of studies and will vary based on the intervention, population and outcome
of interest. There are numerous studies reporting ICC estimates relevent for cluster trials [63,
172–175]. However, ICC estimates from cluster trials are related to the unit of randomisation,
for example the centre or hospital, and not directly relevant for the ICC estimates for interven-
tion induced clustering. ICC estimates from epidemiological studies and observational research
may be more relevant to intervention induced clustering, such as therapist ICCs estimated from
observational data [207]. Estimates from observational data may be more precise due to the
often large sample sizes, however, estimates may also not be directly relevant to trials in health
research. The therapists, conditions, and more manualised interventions used within trials can
result in different ICCs to those seen in observational data. ICC estimates from iRCTs of care
provider effects include: surgeon ICCs median 0.014 (IQR 0.00 to 0.053 and range 0.000 to
0.514) [46] and therapist ICCs median -0.0255 (IQR -0.114 to 0.078 and range -0.343 to 0.450)
[57]. ICCs of centre based effects in multi-centre RCTs include: median ICC of 0.015 (IQR
0.000 to 0.059 and range 0.000 to 0.450) for centres in surgical trials [46] and median ICC of
0.01 (IQR 0.00 to 0.03) for general practice [171]. The ICC estimates collated in this study
provide a further resource for trialists planning new studies.
7.6.3 Strengths and limitations
This study adds to the evidence base of observed ICCs in iRCTs. The review includes a range
of intervention studies reported within the HTA journal, which includes detailed reports. In
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practice, ICC estimates will vary based on the outcome, study design, population, intervention,
setting and the method of analysis. Clustering in trials is complex and the exact ICC prior to
study completion will never be known. This study does, however, provide further evidence to
the potential ICCs that are present in iRCTs and, alongside other studies, can form the basis
of future sample size calculations
This study has several limitations. The study was restricted to publicly funded RCTs published
as reports in the HTA Journal. Journals adopting CONSORT have been shown to have better
reporting standards than others [208] and the limited space available in traditional journal papers
(unlike HTA reports) may mean that overall reporting standards in wider published literature
are worse than those we found. Data extraction was carried out by a single reviewer for the
purpose of this thesis. Some other studies reporting ICCs had access to original data sources for
all trials, hence, where able to use consistent methods of ICC estimation across all studies. This
study was focussed on investigating the ICCs seen and reported in practice and took a pragmatic
viewpoint, extracting empirical ICCs from HTA reports where reported. This resulted in ICC
estimates estimated using different methods across different studies (for instance an ANOVA
versus mixed effects model). Reporting of the methods or adjustment variables used in the
model used to estimate ICCs were not always clear, consequently, it is recommended to clearly
report this. ICC estimates calculated with adjustment for important factors such as baseline
measures are likely to be lower than unadjusted measures [46].
7.6.4 Implications and future work
The implications of this study are that the amount of clustering in iRCTs may often be small
and an unadjusted analysis may result in valid results. However, the true ICC value will not
be known during the design stage of the trial. The distribution of the ICCs and full list of
ICCs can be used to assist in future sample size calculations and analysis plans. To gain more
information on the potential for clustering effect in iRCTs, the clustering level should be at least
acknowledged and reported regardless of significance.
There are a number of ways the potential clustering effect can be reduced during the design stage
of a trial. When designing studies, using a large number of care providers will likely reduce their
clustering effect. For example in the Body Psychotherapy for Schizophrenia patients trial group
leaders (psychotherapist or Pilates instructor) were permitted to run a maximum of two groups in
an aim to limit the impact of any one group leader on the outcomes [183]. However, practically
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this may be a challenge in terms of recruiting, training and coordination of the trial. It is,
however, recommended not to use only one healthcare provider or one group where clustering
may occur as it will reduce the generalisability of the trial results. Results from such trials
cannot be certain that the results will generalise to treatment by a wider range of healthcare
providers. Using manualised therapies and interventions will likely reduce the clustering effect
by reducing the variation in intervention delivery.
It is recommended, where possible, to use ICC estimates from past studies for sample size
calculations. A sensitivity sample size calculation can be undertaken showing power at extremes
of ICC values, for instance what would the power of the planned study be at ICC of 0.05 when
an ICC of 0.02 was used in the original sample size calculation. When multiple ICC estimates
are available a formal meta-analysis would enable good use of available data and achieve greater
precision [46, 57].
This study has highlighted that reporting of clustering in iRCTs could be improved. In par-
ticular, in relation to the reporting of how clustering was accounted for in the sample size
calculations (CONSORT-NPT item 7a), clustering in the results including the participant flow
diagram (CONSORT-NPT item 13a) and the reporting of an ICC for each primary outcome
(CONSORT-cluster item 17a). Although at present reporting of ICC estimates in results is
not included as an item in the CONSORT-NPT. To encourage improvement in the design and
reporting of iRCTs with clustering adding a checklist item to CONSORT-NPT is recommended,
along the lines of: “when applicable, a coefficient of intracluster correlation for each primary
outcome”. The framework developed for reporting ICCs in cRCTs [209] is also broadly applica-
ble in iRCTs with clustering (either in the main paper or online supplementary material which
are now commonly available in open access journals), identifying three dimensions to consider
when reporting an ICC:
 a description of the dataset (including characteristics of the outcome and the intervention);
 how the ICC was calculated;
 and the precision of the ICC.
This has the potential to improve the assumptions about ICCs in iRCTs and raise awareness of
the need to account for clustering in both the sample size and analysis in iRCTs with clustering.
Finally, in the later stages of this study the CONSORT extension for social and psychological
interventions (CONSORT-SPI) [210] was published. This extension only mentions clustering
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and ICC in the extension for cRCTs for social and psychological interventions. Clustering in
psychological interventions is common [57] and it seems unfortunate that potential clustering is
not mentioned in CONSORT-SPI to further raise awareness in this research area.
Reporting guidelines are important to improve the standard of reporting, however, there needs to
be concurrent action to increase adherence to relevant guidelines. There is space for improvement
in the reporting of ICCs in iRCTs and in future investigations collating ICC estimates (from
general and specific study areas). This will, aid the understanding of cluster variability in
such trials and enable their use in future study designs with the possibility of meta-analytically
combining multiple ICC estimates for sample size calculations.
7.7 Summary
This chapter highlighted the extent of intervention induced clustering in iRCTS with continuous
outcomes. For primary endpoints the healthcare provider induced ICC identified was 0.007 (IQR
0.001 to 0.048) and for centre ICC the median was 0.014 (IQR 0.005 to 0.030). The intervention
induced ICC used in sample size calculation was typically higher than the empirical ICC estimate
from the results, where both were available. Empirical ICC estimates are provided (see Appendix
D.3) which can be used in conjunction with sample size formulae in chapter 6.
The exemplars demonstrate some good examples of practice with regards to reporting clustering
in iRCTs. Transparency of methods used to design and analyse iRCTs with clustering is im-
portant for trialists and to understand generalisability of such trials. To improve transparency
an additional CONSORT-NPT item related to reporting ICC where applicable is suggested to





The focus of this thesis was to answer the research question: what elements need to be considered
in the design, analysis and reporting of complex intervention trials with continuous outcomes,
with a particular focus on proportionate interventions and intervention induced clustering in
one trial arm?
The specific aims to address the research question were:
1. To review current practice of how randomised trials of proportionate interventions are
designed and analysed and the extent of clustering in such trials.
2. To evaluate commonly used analysis methods for partially nested randomised trials and
within-arm partially nested randomised trials to establish which methods are most appro-
priate and why.
3. To identify and collate a comprehensive summary and resource for sample size methods
available for partially nested randomised trials.
4. To determine the extent and quality of reporting of clustering in iRCTs with intervention
induced clustering and provide empirical estimates of ICCs.
This chapter summarises the thesis findings and how they address each of the research aims. The
results of the research are translated into guidance and recommendations for trialists involved
in RCTs of proportionate interventions and RCTs with intervention induced clustering. The
chapter concludes with a description of potential future work to build upon this research.
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8.2 Main findings and comparison to other work
Figure 8.1 shows an overview of the studies conducted for this thesis.
Figure 8.1: Thesis Overview
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The first aim was to review current practice of how randomised trials of proportionate inter-
ventions are designed and analysed and the extent of clustering in such trials. This aim was
addressed through a systematic review in chapter 3. The proportionate universalism frame-
work enables individuals to receive the care they require and reduces the burden of treatment
on an individual whilst reserving resources for those most in need [5]. Proportionate interven-
tions follow this line of thought in aiming to use resources efficiently by providing interventions
proportionate to individual need.
The systematic review represented in chapter 3 identified and elaborated on 44 trials of propor-
tionate interventions conducted in various therapeutic areas, the majority in mental health. The
trial designs often induced in complex hierarchical data structures, with clustering introduced
by both intervention and/or centre, in addition to longitudinal data.
Review findings were summarised into two key sub categories, stepped-care and optimal inter-
vention trials. There appears to be a move towards conducting trials of intervention pathways,
with some patients expected to respond to lower intensity interventions thus reducing both the
costs to healthcare and the burden of treatment to patients. By evaluating a staged or propor-
tionate intervention as a whole intervention effect using a trial (with randomisation at baseline
only) there is an underlying assumption that each of the stages of the intervention is effective.
If we were interested in the effect of the individual stages multiple subsequent randomisations
would be required possibly leading to the requirement of prohibitively large sample sizes (an
issue as many trials struggle to recruit to target [179]). The SMART trial design was used in
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a number of the review findings, this has been developed as a method of developing optimal
proportionate interventions which are then ideally evaluated in a full confirmatory trial.
Potential intervention induced clustering was identified in the majority, 84%, of the trials of
proportionate interventions identified in the review. The intervention induced clustering was
typically present at one or more stages of the intervention, often with clustered stages depen-
dent upon outcomes based on previous stages of the intervention. If outcomes are correlated,
standard errors will typically be underestimated if this correlation is ignored in the analysis.
This clustering was accounted for in the analysis of two of the trials included in review (both
published in the HTA Journal), hence appropriate analysis for within-arm partially nested trials
was identified as an aim to address in this research.
8.3 Partially nested trials and within-arm partially nested trials
Having highlighted the potential complex hierarchical data structures present in proportionate
interventions it prompted the investigation of how to appropriately analyse trials whilst account-
ing for clustering in the intervention arm. The research presented in chapter 4 and 5 addressed
the research aim to evaluate commonly used analysis methods for pnRCTs and within-arm pn-
RCTs to establish which methods are most appropriate and why. The initial aim was to evaluate
methods to analyse pnRCTs (trials with clustering in one arm) and then secondary use these
findings to inform evaluation of the more complex partially nested data similar to that seen in
the systematic review results in chapter 3, termed within-arm pnRCTs.
Analysis of pnRCTs using a partially nested mixed effects model with the Satterthwaite degrees
of freedom correction was shown to be unbiased and maintain confidence interval coverage near
to the nominal 95% level. The current findings are broadly consistent with previous simulation
studies [48, 122] that demonstrated the partially nested mixed effects model was suitable for
analysis under most design scenarios. However, previous research did not assess these methods
in a fully systematic manner, the method of classifying the non-clustered controls or performance
of models under small ICC (ρ = 0.01) which was found in the review of HTA trials in this thesis
(chapter 7) and other research [45, 46, 48, 50, 122] commonly occurs in pnRCTs. Unlike findings
from Baldwin et al. [122], the Satterthwaite degrees of freedom correction did not fully control
the Type I error rate in the simulations.
When ICC was small and/or with very few clusters and small cluster sizes using the partially
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nested mixed-effects models 3 and 4 resulted in Type I error rates below the nominal level.
These models correctly reflect the design of the trials; however, they can result in conservatism
regarding the precision of estimates due to the bias in estimating the variance estimates when
there are a small number of clusters. Consequently, using the partially nested mixed effects
models with small ICC may indirectly reduce power making it difficult to detect differences
between the trial arms when present.
Under homoscedastic individual variances across trial arms the heteroscedastic model is over
parametrised, however, it did not result in a substantially lower power than the homoscedastic
model. Even under an ICC of zero, no correlation, the heteroscedastic model resulted in a loss
in mean statistical power of 2-6% when compared to a linear regression model.
In terms of ICC estimation, when the sample size was small and the true ICC ≤ 0.05, then
the ICC was overestimated. ICC estimation improved as sample size increased. Increasing the
number of clusters, rather than increasing the cluster size, had a greater increase in power for a
fixed total sample size and this will also provide a more accurate estimation of the ICC, similar
to cRCTs [40]. Finally the method used to classify the unclustered controls had a negligible
impact on results, though using one large cluster for the control arm sped up the model fitting
computation time considerably.
Expanding on the work in chapter 4, an example of the more complicated data structures seen
in the systematic review and the E-SEE trial were evaluated in chapter 5. Though clustering
of partially nested trials has been discussed and evaluated in the literature, to my knowledge
no research has directly considered or investigated the more complex multilevel structures of
data that are being introduced by trials of proportionate interventions. Schweig and Pane [135]
and Roberts [211] evaluated analysis methods for within-arm pnRCTs when the clustering was
related to non-compliance. If this non-compliance is random then their methods appeared to
hold. However, in the case of proportionate interventions the within-arm clustering is due to
the delivery of the intervention and thus clustering is typically non-random.
Simulations of two stage within-arm pnRCTs were undertaken. The intervention comprised a
two-stage proportionate intervention with an individual universal stage one intervention and a
clustered stage two intervention delivered only to non-responders of stage one. Analysis of this
two stage within-arm pnRCT was shown to result in a biased intervention effect if a mixed-effect
model, accounting for the clustering of stage two, was used. Neither a linear regression model
with cluster robust standard errors or cluster bootstrap standard errors provided coverage of
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the effect estimate near the nominal 95% level, although the point estimate was unbiased. This
research could not identify a unified approach model for the analysis of within-arm pnRCTs
which provided both an overall intervention effect estimate and accounted for clustering. How-
ever, if the ICC was ≤ 0.05, then the mean coverage rate of the linear regression model with
OLS standard errors was 0.948 (SD 0.006) under the simulation scenarios.
Limited literature or guidance on analysing trials with non-random clustering was found during
research for this thesis [52]. However, there needs to be clarity on what effect adjusting for non-
random clustering can have on the bias of intervention effect estimates. Statisticians need to
exercise caution when adjusting for clustering. For instance, if the aim is to provide an unbiased
overall intervention effect and correct precision then statisticians may adjust for clustering,
however, this adjusted analysis can result in bias effect estimates.
8.3.1 Sample size methods for partially nested trials
One of the aims of this thesis was to provide a comprehensive summary and resource for sample
size methods available for pnRCTs. Several papers [43, 48, 57, 122, 128, 130–133, 136, 137,
162] and a book [130] containing sample size methodology for pnRCTs had been published but
none had provided a comprehensive overview and practical resource of the methods available.
Chapter 6 summarises and combines relevant sample size methods for pnRCTs with continuous
outcomes with links to corresponding software to allow for the design complexities of clustering
in trials with continuous outcomes.
The sample size formulae are built up from iRCTs to cRCTs and then to pnRCTs to make
the methods clear. The methods have been extended to include the coefficient of variation to
account for variable cluster size. This is familiar to the commonly used method for cRCTs thus
should enable ease of use of this approach as opposed to a potentially more complicated method.
Software for iRCTs with clustering, with options for pnRCTs, were identified and collated.
The practical use of sample formulae require estimates of the relevant input parameters, with
the ICC being a key parameter for the design of any trial with potential clustering. With this
in mind empirical estimates of ICCs were extracted and presented in chapter 7 and are included
in Appendix D.3.
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8.3.2 Extent, reporting and evidence of clustering in individually randomised
trials
The final aim was to determine the extent and quality of reporting of clustering in iRCTs with
intervention induced clustering and provide empirical evidence of the magnitude of ICCs. This
was addressed through a review of HTA trials in chapter 7. Of 103 trials published in the HTA
journal between 2013 and 2017, 48% had a continuous primary endpoint, of which 59% were
categorised as having potential intervention induced clustering. The extent in this review was
slightly higher than the 40% of trials which had clustering by health professional found in a
review of trials published in the BMJ [42]. This is likely due to the types of interventions funded
by the NIHR HTA funding programme in comparison to those published in BMJ, and a possible
increase in trials used to evaluate complex interventions.
The review included 29 trials, of these trials clustering was often acknowledged and consid-
ered in the design and/or the analysis but to a varying degree. Reporting has been shown
to need improvement across different study designs and therapeutic areas [204]. Reporting of
CONSORT-NPT checklist items related to clustering were found to be sub-optimal in the re-
view of HTA trials, though improved on the review of surgical trials by Nagendran et al. [205].
This may partly reflect an increased uptake of the CONSORT-NPT, or reflect the increased
space available in the HTA journal for reporting compared to traditional journal publications,
or reflect improved peer review standards in HTA. It is likely a combination of all three.
Empirical ICC estimates are provided (either from published reports or further correspondence
with authors, see Appendix D.3) which can be used as evidence to support assumptions in
conjunction with sample size formulae from chapter 6. For primary endpoints the median
treatment induced ICC identified was 0.007 (IQR 0.001 to 0.048) and for centre ICC the median
was 0.014 (IQR 0.005 to 0.045). These add to the evidence base of empirical ICCs from iRCTs for
both care provider effects [46, 57] and centre based effects in multi-centre RCTs [46, 171]. The
treatment induced ICC used in sample size calculation was typically higher than the empirical
ICC estimate from the results, where both were available. This suggests when clustering was
acknowledged in the design, trialsists were actually being relatively conservative in their use of
ICC for sample size, this may reflect the uncertainty about the ICC at the design phase and
thus conservatism has been used as a precaution.
The examplars in chapter 7 provide examples of good practice when intervention induced clus-
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tering is present in RCTs. The importance of transparency is highlighted, both in the design
(sample size and analysis methods) and reporting of results. It would be beneficial for the valid-
ity of an RCT and for future RCTs to see fully how clustering has been acocunted for and the
estimate of clustering effect in the rsults. This could follow the guidelines for reporting ICCs
in cRCTs as similar principles apply [209]. To improve transparency an additional CONSORT-
NPT item related to reporting ICC where applicable is suggested to bring the results in line
with the design and analysis of such trials.
8.4 Strengths and contributions of this research
This research contributes knowledge for the use of those planning and analysing trials in the
area of proportionate interventions and with intervention induced clustering.
Robust methodology have been used throughout the thesis. The systematic review, conducted
in chapter 3 was implemented using robust methods, including: developing a protocol, scoping
search, validation of search terms, data collection form, and following PRISMA guidelines.
The methods used to undertake the systematic review also aided the searching undertaken
for the review of sample size methodology in chapter 6 and the data collection for chapter
7. The simulation studies in chapters 4 and 5 followed the advice of Burton et al. [144] and
Morris et al. [151]. They had a pragmatic focus and covered a range of settings with scenarios
covering different cluster sizes, number of clusters, ICCs and under both the null and alternative
hypothesis.
This work is likely to have an impact in practice; a strength being its generalisability to com-
monly employed trial designs. The simulation studies focused on realistic scenarios, and made
practical recommendations for trial analysis. The model fitting code for R, SAS and Stata for
the analysis methods used in chapters 4 are provided to make the analysis clear. This, along
with the findings of previous research, gives strength to the conclusions that the partially nested
heteroscedastic mixed effects model is typically the most suitable analysis model for pnRCTs.
In addition, it was highlighted that proportionate interventions are initially appealing and come
under the remit of proportionate universalism. However, they induce structure that can be
difficult to fully accommodate in the analysis.
A final strength is the aim to influence better study design for a new wave of future studies.
The collation of sample size methods and ICCs from publicly funded trials provides important
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information for future trial designs and providing a broad range of empirical ICC estimates will
assist in researchers planning adequately powered trials. The lack of empirical estimates of ICCs
directly relevant to iRCTs with intervention induced clustering led to this research. As shown
in chapter 6 there are sample size formulae available for pnRCTs thus providing a broad range
of empirical ICC estimates will assist in researchers planning adequately powered trials.
Dissemination of results has been considered throughout this PhD. Two manuscripts based on
chapters 3 and 4 have been submitted to Trials and BMC Medical research Methodology open
access peer reviewed journals [68, 212], the first is currently under review and the latter has
been published. In addition, the results of chapters 3, 4 and 5 have been disseminated at a
number of statistics and clinical trials conferences, the Meeting of the Society for Clinical Trials
in 2018 [213], the joint International Clinical Trials Methodology Conference and Meeting of the
Society for Clinical Trials in 2017 [214], and at International Society for Clinical Biostatistics
conferences in 2017 and 2016 [215, 216].
8.5 Limitations
There are limits to the generalisability of the thesis findings and some limitations related to
resource limitations.
During the initial stages of this project it was considered that the issue of evaluating the effects of
different stages of proportionate interventions would be investigated. However, it became clear
that randomisation at each stage or some form of fractional factorial design would be required
to evaluate each intervention stage of proportionate interventions. There is a large team of
researchers investigating these sort of designs in USA thus it did not become the focus of this
research. The focus moved towards partial nesting/intervention induced clustering in iRCTs as
there was evidence of a lack of awareness of this issue and limited evidence of what to do in such
scenarios.
Due to resource limitations it was not possible to supplement the systematic review database
searching in chapter 3 with reference list checking or trial registries. The searching and data
extraction for both the systematic review and the review of publicly funded trials were typically
undertaken by one reviewer (JCa). This is a limitation as it could not be quality-assured during
the review process. However, steps were taken to improve the consistency and quality of both
reviews and have been explained in more detail in the methods of relevant chapters.
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Whilst a broad range of scenarios were considered in the simulation studies, only fixed cluster
sizes were used in both studies and only a 50% proportion of within-arm clustering was considered
for the within-arm pnRCT study. In practice, cluster size may vary, causing a loss in efficiency
when estimating the intervention effect. The proportion that receive subsequent stepped-up
intervention stages will vary dependent on the trial, however, the within-arm pnRCT simulation
study was able to represent the effect this sort of staged clustering can have in practice.
Trials with clustering in only one arm were considered in the simulation studies and the sample
size methodology. Although these designs are common in practice [49], the results are not
necessarily generalisable beyond these designs.
It was not possible to gain empirical ICC estimates from all of the HTA trials identified with
potential intervention induced clustering. However, a valid reason for the lack of available
empirical ICCs was generally provided from correspondence with authors or explanations in
HTA reports, either logistical, data limitations, time constraints, or from the nature of the
design itself. Where ICC estimates where provided or available they were often for only the
primary endpoint and did not extend to other follow-up times or secondary outcomes.
8.6 Implications and recommendations
This section translates the research findings into the implications and a series of recommen-
dations for the design, analysis and reporting of complex intervention trials with continuous
outcomes, specifically proportionate interventions and intervention induced clustering in one
trial arm. These recommendations are summarised in Figure 8.2 at the end.
8.6.1 Design
In terms of design of trials it is recommended to use specific sample size methods developed
for pnRCTs (when clustering is random). Sample size formulae are summarised and collated in
chapter 6, providing a useful resource for design of studies. Where available, it is suggested to
use prior empirical evidence of probable ICC value in sample size. The fact that this research has
shown a median ICC of 0.009 for care provider induced clustering and 0.019 for group induced
clustering provides a good starting point for statisticians when discussing the design of a trial.
However, the wider generalisability of such findings is cautioned and researchers should aim to
consider previous estimates of ICCs calculated from datasets relevant to their study. Sample size
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methods should be reported fully and undertaking a sensitivity sample size calculation showing
power under different ICC values can contribute to the transparency of the design. Chapter
7 provides some examplars of this linking back to CONSORT-NPT. It was also evident that
due to the pragmatic nature of many complex intervention trials there are often hard to define
or undefined clusters. Planning during the design phase for better recording of all elements
which may be considered part of a complex intervention, even when they are part of routine
care, would aid the analysis and improve understanding of the complex intervention delivery
and clustering effects. Finally, where proportionate interventions induce clustering based on
intermediate outcomes it is recommended to consider the impact this can have on precision of
intervention effect estimate (what proportion might be expected to receive this intervention and
how the effect of clustering may be reduced) and whether evaluating full intervention effect is
suitable.
8.6.2 Analysis
Overarching advice for the analysis of pnRCTs based on this research would be to use a het-
eroscedastic partially nested mixed effects model in general with a small sample correction,
particularly if conservatism and an ICC estimate are desired. However, model choice decision
and the requirement or not for conservatism needs to be considered in the context of the specific
trial setting. For within-arm pnRCTs with non-random clustering it is recommended to ignore
clustering in estimation of overall intervention effect. Taking a pragmatic viewpoint if the clus-
ter effect is small and only some of the intervention arm receive the clustered intervention then
the impact of ignoring clustering in the analysis on precision is likely to be minimal. Although,
estimation of an ICC from clustered intervention stages would help inform understanding of the
intervention. Researchers should be aware of the possible bias in ICC estimation when there are
a small number of clusters and true ICCs are small.
8.6.3 Reporting
Trial reports require information on the design and results to enable readers to fully interpret
the results. Intervention induced clustering is not always obvious and accounted for, better
reporting of trials could feasibly improve awareness of intervention induced clustering. Where
applicable, researchers should report their trial findings in accordance with CONSORT-NPT and
consider the extension suggested in chapter 7 related to reporting of ICCs for primary outcomes
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(as a minimum). It is suggested to add an item to CONSORT-NPT results stating: “when
applicable, a coefficient of intracluster correlation for each primary outcome”. In addition, full
reporting would include: number of clusters, mean (SD) cluster size, ICC and precision of the
ICC; adjusted analysis and what method was used to estimate ICC; and when an ICC cannot be
estimated during the analysis, a reason should be provided in the trial results reporting. If the
reporting of clustering is adopted into routine practice, as is expected from a cRCT, it should
improve the interpretation of iRCTs with clustering in the future and improve the evidence base
of empirical ICCs for future study design. These results, empirical ICC estimates and exemplars
of reporting, will prove useful in the design of trials in the future.
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Figure 8.2: Recommendations and considerations for the design, analysis and reporting of com-
plex intervention trials with continuous outcomes, specifically proportionate interventions and
intervention induced clustering in one trial arm
Design
 Use specific sample size methods developed for pnRCTs (when clustering is random);
 Where available, use prior empirical evidence of probable ICC value in sample size;
 Report sample size methods fully and undertake sensitivity sample size showing
power under different ICC values;
 Transparent and clear recording of all elements which may be considered part of a
complex intervention, even when they are part of routine care, including aspects of
clustering;
 Where proportionate interventions induce clustering based on intermediate out-
comes consider impact on precision of intervention effect estimate and whether
evaluating full intervention effect is suitable.
Analysis
 For pnRCTs typically recommended to use heteroscedastic partially nested mixed
effects model with small samples degrees of freedom correction;
 For pnRCTs with few clusters, small cluster sizes and small ICC the heteroscedastic
partially nested mixed effects model underestimates Type I error rates and there is
no optimal model;
 For within-arm pnRCTs with non-random clustering recommended to ignore clus-
tering in estimation of overall intervention effect;
 For within-arm pnRCTs estimation of an ICC from clustered intervention stages is
recommended to inform understanding of the intervention.
Reporting
 Report number of clusters, mean (SD) cluster size, ICC and precision of the ICC;
 Report adjusted analysis and what method was used to estimate ICC;
 When ICC cannot be estimated during analysis, provide reasoning in results;
 Add item to CONSORT-NPT - “when applicable, a coefficient of intracluster cor-
relation for each primary outcome”.
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8.7 Future research
There is potential for further research stemming from this thesis. The area of proportionate or
adaptive interventions is a current area of interest as researchers aim to evaluate the effectiveness
of intervention pathways which respond to individual need. In addition, the awareness of the
different and often multiple levels of clustering present in iRCTs is growing, and this thesis
documents only a small portion of the various trial designs and primary outcome measures.
The focus of this thesis was primarily on continuous outcomes, therefore, there is an avenue
to further research alternative outcome measures both binary and survival. There has been
recent work on the analysis and design of partially nested trials with binary outcomes [217].
This research could be extended to different trial designs, including but not limited to trials
with clustering in both arms, more complex crossed-nested trials and investigating the effect of
further levels of clustering in within-arm pnRCTs.
Chapter 7 highlighted the variation in cluster size sometimes present in iRCTs with intervention
induced clustering. The loss of efficiency and effect of varying cluster size is an area for future
research. Candel and Van Breukelen [128] provided sample size adjustments for varying cluster
sizes in pnRCTs, they evaluated a number of different scenarios with cv varying from 0.24 to
0.42, suggesting the addition of 11% more clusters to account for the varying cluster size. The
review of HTA trials in chapter 7 did suggest that the coefficient of variation in iRCTs with
clustering may actually be higher than the range investigated by Candel and Van Breukelen
[128], hence, investigating higher variation in cluster size is recommended as an extension to
this work.
Work could be extended to investigate the extent of heteroscedasticity in trials with clustering
in only one arm. If the ICC is typically quite small, say less than 0.01, we might expect the
individual residuals to also be quite similar across trial arms. Empirical work into the extent
of heteroscedasticity in partially nested trials would aid statisticians when calculating sample
sizes.
Missing data occurs in RCTs through various different mechanisms. Multiple imputation is
a commonly used method to handle missing data, it can improve estimation of the precision
of parameter estimates by incorporating information from individuals who have missing data
(unlike complete case analysis). In cluster trials it is recommended that a multiple imputation
model should be multilevel and thus reflect the cluster dependence [218], similar may be true for
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iRCTs with clustering, however, further research is required here to provide recommendations.
Various issues relating to reporting and acknowledging of intervention induced clustering have
been raised in this thesis. This research has highlighted the gap in reporting guidelines for
iRCTs with clustering, findings from chapter 7 advocate adding item 17a to CONSORT-NPT
at the next update. In addition, guidance and literature on trials of proportionate or adaptive
interventions need to raise awareness to the issue of clustering in such designs as they are being
increasingly used. Alongside this it is important to think about how to reduce the effect of
clustering as in any study, such as standardising the intervention (though not always suitable)
and keeping cluster sizes small.
8.8 Concluding remarks
This thesis has presented an investigation of the elements to be considered in the design, analysis
and reporting of complex intervention trials with continuous outcomes, with a particular focus
on proportionate interventions and intervention induced clustering in one trial arm. The findings
and recommendations will aid trialists designing such trials with intervention induced clustering.
A large amount of research and guidance has been focussed on the design and analysis of cRCTs
with continuous outcomes. Now there is raising awareness of the potential effects of clustering in
iRCTs, such trials require similar appropriate guidance. This work has provided evidence of the
extent of intervention induced clustering both in partially and within-arm partially nested trials.
The issue of clustering in trials of both proportionate interventions and the effect such staged
clustering can have on increasing Type I error rates has been highlighted. Recommendations
based on simulations results are given for the appropriate analysis of both pnRCTs and within-
arm pnRCTs. Sample size methods for pnRCTs have been collated and and compared. Relevant
reporting related to intervention induced clustering has also been investigated with examplars
identified for use to guide future studies.
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Figure A.2: Bias of between- and within-cluster variance estimates from the heteroscedastic
partially nested model (model 4) by ρ, γ, c and m
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Table A.1: Type I error rate (mean and SD) under null hypothesis by Model, γ and ρ
Model
γ ρ 1 2.1 2.2 2.3 3 4
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
0.25 0 0.05 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.02 0.01 0.02 0.01
0.01 0.07 0.01 0.04 0.01 0.00 0.01 0.03 0.01 0.03 0.01 0.03 0.02
0.05 0.12 0.05 0.07 0.03 0.00 0.01 0.04 0.01 0.03 0.01 0.03 0.02
0.1 0.18 0.08 0.10 0.03 0.00 0.01 0.05 0.01 0.04 0.01 0.04 0.01
0.2 0.28 0.11 0.15 0.05 0.00 0.01 0.06 0.01 0.05 0.01 0.05 0.01
0.3 0.35 0.13 0.19 0.06 0.00 0.01 0.06 0.01 0.05 0.01 0.05 0.01
0.5 0 0.05 0.01 0.03 0.01 0.00 0.01 0.03 0.01 0.03 0.01 0.03 0.01
0.01 0.06 0.01 0.04 0.01 0.00 0.01 0.03 0.01 0.03 0.01 0.03 0.01
0.05 0.11 0.03 0.06 0.02 0.00 0.01 0.04 0.01 0.04 0.01 0.04 0.01
0.1 0.17 0.07 0.08 0.03 0.00 0.01 0.05 0.01 0.04 0.01 0.04 0.01
0.2 0.26 0.11 0.12 0.04 0.00 0.01 0.05 0.01 0.05 0.01 0.05 0.01
0.3 0.33 0.13 0.16 0.05 0.00 0.02 0.06 0.02 0.05 0.01 0.05 0.01
1 0 0.05 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.03 0.01 0.03 0.01
0.01 0.06 0.01 0.03 0.01 0.00 0.01 0.03 0.01 0.03 0.01 0.03 0.01
0.05 0.09 0.03 0.04 0.01 0.00 0.01 0.03 0.01 0.04 0.01 0.04 0.01
0.1 0.14 0.05 0.05 0.01 0.00 0.01 0.04 0.01 0.05 0.01 0.05 0.01
0.2 0.22 0.09 0.07 0.02 0.00 0.01 0.05 0.01 0.05 0.01 0.05 0.01
0.3 0.29 0.12 0.09 0.02 0.00 0.01 0.05 0.01 0.06 0.01 0.05 0.01
2 0 0.05 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.04 0.01 0.04 0.01
0.01 0.06 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.04 0.01 0.04 0.01
0.05 0.08 0.02 0.01 0.01 0.00 0.02 0.03 0.02 0.05 0.02 0.04 0.01
0.1 0.12 0.04 0.01 0.01 0.00 0.02 0.04 0.02 0.06 0.01 0.05 0.01
0.2 0.18 0.07 0.01 0.01 0.00 0.01 0.04 0.01 0.05 0.01 0.05 0.01
0.3 0.23 0.10 0.02 0.01 0.00 0.01 0.05 0.01 0.06 0.01 0.06 0.01
4 0 0.05 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.04 0.01 0.04 0.01
0.01 0.06 0.01 0.00 0.00 0.00 0.02 0.03 0.02 0.05 0.01 0.05 0.01
0.05 0.07 0.01 0.00 0.00 0.00 0.02 0.03 0.02 0.05 0.02 0.05 0.01
0.1 0.09 0.03 0.00 0.00 0.00 0.02 0.03 0.02 0.06 0.02 0.05 0.01
0.2 0.14 0.06 0.00 0.00 0.00 0.01 0.04 0.01 0.06 0.01 0.05 0.01
0.3 0.18 0.08 0.00 0.00 0.00 0.01 0.04 0.01 0.06 0.01 0.06 0.01
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Table A.2: Power (mean and SD) under alternative hypothesis by Model, γ and ρ
Model
γ ρ 1 2.1 2.2 2.3 3 4
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
0.25 0 0.71 0.31 0.67 0.34 0.06 0.18 0.62 0.37 0.62 0.36 0.60 0.38
0.01 0.71 0.31 0.66 0.34 0.06 0.20 0.60 0.36 0.60 0.36 0.58 0.38
0.05 0.70 0.30 0.64 0.33 0.03 0.08 0.56 0.35 0.54 0.35 0.54 0.36
0.1 0.70 0.28 0.62 0.31 0.01 0.02 0.52 0.34 0.49 0.33 0.48 0.35
0.2 0.70 0.25 0.60 0.29 0.00 0.01 0.45 0.32 0.42 0.32 0.42 0.33
0.3 0.71 0.23 0.59 0.28 0.00 0.01 0.40 0.30 0.36 0.3 0.36 0.31
0.5 0 0.68 0.32 0.63 0.35 0.03 0.11 0.58 0.37 0.6 0.36 0.59 0.37
0.01 0.67 0.32 0.62 0.35 0.05 0.16 0.57 0.37 0.58 0.36 0.58 0.37
0.05 0.67 0.30 0.60 0.33 0.03 0.08 0.53 0.35 0.53 0.34 0.53 0.35
0.1 0.67 0.29 0.58 0.32 0.01 0.02 0.50 0.34 0.48 0.33 0.48 0.34
0.2 0.68 0.26 0.56 0.30 0.00 0.00 0.43 0.32 0.41 0.32 0.41 0.32
0.3 0.68 0.24 0.55 0.29 0.00 0.00 0.39 0.30 0.36 0.30 0.36 0.30
1 0 0.62 0.33 0.55 0.36 0.01 0.02 0.52 0.37 0.56 0.36 0.56 0.36
0.01 0.62 0.33 0.55 0.36 0.02 0.07 0.51 0.37 0.55 0.36 0.55 0.36
0.05 0.62 0.32 0.51 0.34 0.02 0.08 0.49 0.36 0.51 0.34 0.51 0.34
0.1 0.62 0.3 0.48 0.33 0.01 0.02 0.45 0.34 0.46 0.33 0.46 0.33
0.2 0.64 0.28 0.46 0.32 0.00 0.00 0.41 0.32 0.40 0.32 0.40 0.32
0.3 0.64 0.25 0.46 0.30 0.00 0.00 0.37 0.3 0.36 0.30 0.36 0.30
2 0 0.54 0.34 0.22 0.29 0.00 0.00 0.44 0.36 0.50 0.35 0.50 0.35
0.01 0.54 0.33 0.22 0.29 0.00 0.00 0.44 0.36 0.49 0.35 0.50 0.34
0.05 0.54 0.32 0.22 0.29 0.01 0.04 0.42 0.35 0.47 0.34 0.47 0.33
0.1 0.55 0.31 0.21 0.28 0.01 0.02 0.40 0.34 0.44 0.33 0.43 0.32
0.2 0.57 0.29 0.22 0.28 0.00 0.00 0.37 0.32 0.39 0.31 0.38 0.30
0.3 0.59 0.27 0.25 0.27 0.00 0.00 0.34 0.29 0.35 0.29 0.35 0.28
4 0 0.43 0.32 0.02 0.04 0.00 0.00 0.34 0.33 0.40 0.33 0.42 0.32
0.01 0.43 0.31 0.02 0.04 0.00 0.00 0.34 0.33 0.40 0.33 0.41 0.32
0.05 0.44 0.31 0.02 0.04 0.00 0.00 0.33 0.32 0.40 0.32 0.39 0.31
0.1 0.45 0.31 0.02 0.05 0.00 0.01 0.33 0.32 0.39 0.31 0.37 0.30
0.2 0.48 0.29 0.04 0.07 0.00 0.00 0.31 0.30 0.36 0.29 0.34 0.28
0.3 0.50 0.28 0.05 0.10 0.00 0.00 0.30 0.28 0.33 0.28 0.32 0.27
243
A.2 Stata simulation code for partially nested trials analysis
The following Stata code was used for the simulation study in chapter 4. Code was going to be
written in R initially, until it became apparent that the heteroscedastic model with Satterthwaite
degrees of freedom correction was not available in R packages at the time of the study. Models 2,
3 and 4 were run for imposed clustering of different types, however, only cluster type 1 (singleton
clusters in control group) are shown in simulation code below.
/* Simulation Parameters */
*Simulation for Yij = alpha +theta*tij + ujtij+(1-tij)rij + tijeij
*normally distributed continuous outcome with cluster (j) and
*residual (i) variability
/* Function parameters */
*theta*: difference in outcome between treatment and control
*gam*: ratio of individual varaince between control and treatment arm
*rho*: ICC in clustered treatment arm
*clusterSize*: Size of each cluster
*nClusters*: Number of clusters in treatment arm
*total trial sample size = 2*nClusters*clusterSize
*nIterations*: number of iterations for simulation
/* Variable Specification */
*y*: is the dependent variable;
*cluster* is one of the following clustering options
*cluster1* is the cluster indicator and treats the control group as clusters of
size 1;
*cluster2* is the cluster indicator and treats the control group as one cluster
;
*cluster3* is the cluster indicator and treats the control group as random
clusters;






/* 1_simulation.do takes args simul_No nIterations theta rho gam clusterSize nClusters
.
Use a master file to run 1_simulation.do file with various scenarios given by args
for example, do do\1_simulation.do 1 1000 0.2 0 1 5 12 */
/* args assigns the first command line argument to the local macro simula_No, second
argument to nIterations and so on.*/
args simul_No nIterations theta rho gam clusterSize nClusters
/* Set working directory */
cd "working directory"
local initial_seed = c(seed)
/* Log file */
log using log\simulation‘simul_No’.smcl, smcl replace
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/*Set up file for output*/
* Create a temporary file that will store the output from the simulations
tempname memhold
tempfile results
qui postfile ‘memhold’ Theta gam rho clusterSize nClusters Model Treat SE P_value
CI_ll CI_ul Cover Ind_cont_var Ind_clust_var Btw_clust_var ICC Converge using ‘
results’, replace
forvalues sim = 1/‘nIterations’{
* monitor iterative process of simulations by displaying a dot after every 100
simulations
if int(‘sim’/100) ==‘sim’/100{
di as text "." _cont
}
* quietly performs command but suppress terminal output
quietly{
* Create an empty dataset where the number of observations are number of clusters x 2
local n2 = ‘nClusters’*2
set obs ‘n2’
gen cluster = _n
gen clustZ = rnormal(0,1)
* Expand so have ’clusterSize’ observations per cluster
expand ‘clusterSize’
bysort cluster: generate clustID = _n
* Generate treatment indicator
gen tx = 0
replace tx = 1 if _n< = _N/2
* Generate clustering in control arm
bysort tx: gene txID=_n
*cluster1 = singletone clusters in control arm
gen cluster1 = .
replace cluster1 = (txID + ‘nClusters’) if (tx == 0)
replace cluster1 = cluster if (tx == 1)
* cluster2 = one large cluster in control arm
gen cluster2 = .
replace cluster2 = 0 if (tx == 0)
replace cluster2 = cluster if (tx == 1)
* cluster3 = pseudo clusters in control arm
gen cluster3 = cluster
* Generate random variables
gen indZ = rnormal(0,1)
* Generate individual and cluster residuals
gen ClustRes_j = clustZ*sqrt(‘rho’)
gen ClustInd_ij = indZ*sqrt(1-‘rho’)
gen ContInd_ij = indZ*sqrt(‘gam’)*sqrt(1-‘rho’)
drop clustZ indZ txID
* Generate outcome
gen y = ‘theta’*tx + tx*ClustRes_j + tx*ClustInd_ij + (1-tx)*ContInd_ij
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/* Fit models */
* Model 1: ignoring clustering
capture {
regress y tx
*define model number as first column
if _rc == 0 local converge = 1
local m 1
* retrieve the contents of the outputs (estimates)
mat define M1 = r(table)
local b M1[1,1] //estimate of the treatment effect
local se M1[2,1] //standard error of the treatment effect
local p M1[4,1] //p value
local ll M1[5,1] //ll 95%CI
local ul M1[6,1] //ul 95%CI
local cv inrange(‘theta’,‘ll’,‘ul’) //coverage indicator
local ind_var = e(rmse)
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (‘b’) (‘se’) (‘p’) (‘ll’) (‘ul’) (‘cv’) (‘
ind_var’) (.) (.) (.) (‘converge’)
}
if _rc != 0 {
local converge = 0
local m 1
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (.) (.) (.) (.) (.) (.) (.) (.) (.) (.) (‘
converge’)
}
* Model 2: fully clustered random effects
* Cluster 1
capture{
mixed y tx || cluster1: , reml nolog dfmethod(sat) emiterate(10)
if _rc == 0 local converge = 1
local m 2.1 //define model number
* retrieve the contents of the outputs (estimates)
mat define M21 = r(table)
mat list M21
local b M21[1,1] //estimate of the treatment effect
local se M21[2,1] //standard error of the treatment effect
local p M21[4,1] //p value
local ll M21[5,1] //ll 95%CI
local ul M21[6,1] //ul 95%CI
local cv inrange(‘theta’,‘ll’,‘ul’) //coverage indicator
local ind_var = exp(M21[1,4])^2 //individual variance
local btw_clust_var = exp(M21[1,3])^2 //between cluster variance
(clustered arm)
estat icc
local estrho r(icc2) //ICC
*post the results of each model output from each simulation
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (‘b’) (‘se’) (‘p’) (‘ll’) (‘ul’) (‘cv’) (‘
ind_var’) (‘ind_var’) (‘btw_clust_var’) (‘estrho’) (‘converge
’)
}
if _rc != 0 {
local converge = 0
local m 2.1
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post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (.) (.) (.) (.) (.) (.) (.) (.) (.) (.) (‘
converge’)
}
* Model 3: partial clustering homoscedastic
* Cluster 1
capture {
mixed y tx || cluster1: tx , nocons reml nolog dfmethod(sat) emiterate
(20)
if _rc == 0 local converge = 1
*define model number
local m 3.1
* retrieve the contents of the outputs (estimates)
mat define M31 = r(table)
local b M31[1,1] //estimate of the treatment effect
local se M31[2,1] //standard error of the treatment effect
local p M31[4,1] //p value
local ll M31[5,1] //ll 95%CI
local ul M31[6,1] //ul 95%CI
local cv inrange(‘theta’,‘ll’,‘ul’) //coverage indicator
local btw_clust_var = exp(M31[1,3])^2 //between cluster variance
(clustered arm)
local ind_var = exp(M31[1,4])^2 //individual variance (clustered
arm)
local estrho ‘btw_clust_var’/(‘btw_clust_var’+‘ind_var’) // ICC
*post the results of each model output from each simulation
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (‘b’) (‘se’) (‘p’) (‘ll’) (‘ul’) (‘cv’) (‘
ind_var’) (‘ind_var’) (‘btw_clust_var’) (‘estrho’) (‘converge
’)
}
if _rc != 0 {
local converge = 0
local m 3.1
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (.) (.) (.) (.) (.) (.) (.) (.) (.) (.) (‘
converge’)
}
* Model 4: partial clustering heteroskedastic
* Cluster 1
capture {
mixed y tx || cluster1:tx, nocons reml nolog residuals(independent, by(
tx)) dfmethod(sat) emiterate(10)
if _rc == 0 local converge = 1
*define model number
local m 4.1
* retrieve the contents of the outputs (estimates)
mat define M41 = r(table)
local b M41[1,1] //estimate of the treatment effect
local se M41[2,1] //standard error of the treatment effect
local p M41[4,1] //p value
local ll M41[5,1] //ll 95%CI
local ul M41[6,1] //ul 95%CI
local cv inrange(‘theta’,‘ll’,‘ul’) //coverage indicator
local btw_clust_var = exp(M41[1,3])^2 //between cluster variance
(clustered arm)
local ind_clust_var = (exp(M41[1,4]+ M41[1,5]))^2 //individual
variance (clustered arm)
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local ind_cont_var = (exp(M41[1,4]))^2 //individual variance (
control arm)
local estrho ‘btw_clust_var’/(‘btw_clust_var’+‘ind_clust_var’) //
ICC
*post the results of each model output from each simulation
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘
nClusters’) (‘m’) (‘b’) (‘se’) (‘p’) (‘ll’) (‘ul’) (‘cv’) (‘
ind_cont_var’) (‘ind_clust_var’) (‘btw_clust_var’) (‘estrho’)
(‘converge’)
}
if _rc != 0 {
local converge = 0
local m 4.1
post ‘memhold’ (‘theta’) (‘gam’) (‘rho’) (‘clusterSize’) (‘







qui use ‘results’, clear
/* After all all simulations are run and the N-obsrvation dataset of results is
created, code ends with */
note: File results‘simul_No’
note: Ran simluation ‘0’
note: Time taken (minutes) ‘tmins’
note: Seed was ‘initial_seed’
save dta\results‘simul_No’, replace
/* Closed and convert log to html */
log close
translate log\simulation‘simul_No’.smcl log\simulation‘simul_No’.log, replace
A.3 Publication
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Randomised controlled trials (RCTs) are often categorised
into two types: individually randomised controlled trials
(iRCTs) where participants are individually randomised to
treatment arms to receive one of the investigative treat-
ments; and cluster randomised controlled trials (cRCTs)
where groups of participants (clusters) are randomised to
treatment arms. We may expect outcomes for participants
within the same cluster to be more similar than those from
different clusters. The similarity can arise due to partici-
pants in the same cluster receiving care from the same
health provider or interacting with one another [1]. The im-
plications of clustering in cRCTs are widely acknowledged
[1, 2]. Clustering results in a reduction in statistical effi-
ciency in cRCTs and if ignored standard errors and p-values
for intervention effects are typically underestimated.
Clustering can also occur in iRCTs. For instance, clus-
tering of participants outcomes due to receiving treat-
ment as part of a group-based parenting intervention
[3], treatment in specialist clinics for the treatment of
venous leg ulcers [4], or participants under the care of a
surgeon for comparison for hemostasis in elective
benign thyroid surgery [5]. The care provider or group
dynamics may play a role in the causal pathway of the
intervention effect. We might expect correlated out-
comes between individuals either in the same group or
receiving treatment from the same care provider.
Standard sample size and analysis methods for iRCTs
rely on the assumption of independence between partici-
pants, which is violated when clustering is present. The
‘clustering effect’ is commonly quantified using the
intracluster correlation coefficient (ICC). The ICC mea-
sures the extent to which outcomes from participants
within the same cluster are correlated to one another
[1]. When designing and analysing iRCTs with cluster-
ing we need to consider implications of the potential
lack of independence. Ignoring clustering in the ana-
lysis can lead to over precise results and consequently
incorrect conclusions [1]. Clustering of any form re-
sults in a reduction in the effective sample size,
hence, there is a reduction in the power to detect an
intervention effect if it truly exists.
In addition to obtaining sufficient power and accurate
results, accounting for clustering enables us to estimate
the ICC. ICCs are often important for the interpretation
of trial results; we may be directly interested in the inter-
vention group or care provider effects. ICCs are also key
when calculating sample sizes for RCTs with clustering,
in order to maintain power [1].
An increasingly applied design in healthcare and educa-
tion research is a partially nested randomised controlled
trial (pnRCT) [6], where participants are individually ran-
domised to trial arms and clustering of outcomes occurs
in only one arm of the trial [7] (also termed partially
clustered trials). The STEPWISE trial is an example of a
pnRCT, assessing a structured lifestyle education
programme aimed at supporting weight loss for adults
with schizophrenia and first episode psychosis in a
community mental health setting. Individuals were rando-
mised to either an intervention arm of group-based life-
style education sessions or a control arm receiving usual
care at the individual level [8].
Specific statistical methods need to be used for analys-
ing pnRCTs. Consequently, there has been a consider-
able growth in the methodology literature (particularly
in the fields of psychotherapy and educational research)
in the past few decades both proposing and reviewing
statistical methods for pnRCTs.
Table 1 presents a summary of relevant literature
on the analysis of pnRCTs. This expands on the lit-
erature search by Flight et al. [9] summarising models
for the analysis of pnRCTs. Sample size calculations
for pnRCTs have been addressed elsewhere [10–14].
Analysis methods for pnRCTs have mainly focussed on
using mixed-effects models, individual-level models
which account for the hierarchical structure of the data
[6, 7, 9, 15–19]. These models allow us to control for
baseline covariates and represent the different levels in the
data, including cluster, individual, and repeated measures
(where applicable). In addition to accounting for the
clustering, we may expect the variance of the individ-
ual errors to differ between trial arms in pnRCTs,
termed heteroscedastic variance [7]. When a clustered
intervention arm is compared to a non-clustered control
arm the between-cluster variation in the intervention arm
is not present in the control arm. The clustered interven-
tion may result in a decrease or increase of the individual
level variability.
In this study, we use a series of simulations to evaluate
the statistical analysis models for two-arm parallel
pnRCTs with continuous outcomes, assessing a range of
scenarios including the effect of cluster size and the
number of clusters. In theory, the mixed-effects models
can be formulated so that they do not model clustering
in the control arm, however, when running these models
in statistical software packages it is necessary to impose
some form of clustering in the control arm. The litera-
ture identified in Table 1 highlighted that research to
date is lacking in addressing the best way to treat the
non-clustered control arm when fitting the models in
statistical software, using scenarios of relevance in the
field of public health with small clusters and small ICCs
[9], and evaluating the effect of the variance ratio of the
residuals on the model fit. In pnRCTs we may have small
numbers of clusters [9], thus we evaluate the impact of
the number of clusters on statistical inference and if
statistical inference remains valid using mixed-effects
models.
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Table 1 Summary of relevant literature on analysis of pnRCTs
Paper Relevant themes Range of valuesa Findings
Schweig &
Pane [16]
Describe and compare models for
pnRCTs with non-compliance using
a simulation study.
Simulation for two levels of clustering,
exact cluster sizes (m) unclear in paper,
cschool = 37, cclass = 177, λB = 2, 8,
ρschool = 0.005, 0.05, 0.15, ρclass = 0.0004,
0.10, 0.25, and θ = 0.087.
Clustering and non-compliance may have
a substantial impact on statistical inference
about intention-to-treat effects. Provide
methods that may accommodate pnRCT
with non-compliance, recommend using
complier average causal effect estimate
(CACE) and scaling by the proportion of
compliers. No mention of degrees of
freedom, we have assumed they used
default degrees of freedom method
available in R lme packages.
Flight et al. [9] Compare models applied to four
examples of pnRCTs. Compare
three different methods for classifying
the non-clustered control arm in
pnRCTs, including: singleton clusters,
one large cluster and pseudo clusters.
Examples with {m, c} = {36, 8; 24, 7; 14,
8; 5, 6}, and estimated ρ = < 0.0001, 0.02,
0.007.
Recommend use of the heteroscedastic
model, recommendations based only on
re-analysis of case studies. Methods for
classifying the non-clustered control arm
in pnRCTs had a large impact in fully
clustered mixed effects models and no
measurable impact in partially nested
mixed-effects models. ICCs in four
examples were small.
Sterba [27] Review of modelling developments
for pnRCTs, focused on those particularly
relevant to psychotherapy trials.
Recommend the inclusion of cluster
variability in analysis model as it provides
insight into treatment process (rather than





Report presenting a guide to design
and analysis issues for pnRCTs in education
research, using example trials. Discussion
of degrees of freedom issue in Appendix.
Guidance document, defines pnRCT in
context of education research and show
methods to analyse these using SAS.




Compare models for pnRCTs using
simulation study, investigate
mis-specification for the estimation
of the parameters and their standard
errors.
Simulation study with m = 5, c = 10, 30,
50, 100, ρ = 0.05, 0.1, 0.2, λA = 1, d = 0.3.
All models perform comparably with
respect to fixed effect estimates.
Recommend use of partially nested
mixed-effects model. Simulations were
under null and ICC always greater than
zero. No mention of degrees of freedom,
we have we assumed default degrees of
freedom used from MLwiN software, and
homoscedasticity was assumed for
ndividual variances between the two
arms.
Sanders [17] Compare models for pnRCTs using
simulation study in terms of Type
I error and power
Simulation study with {m, c} = {2, 10; 4,
4; 5, 4; 10, 2}, ρ = 0, 0.1, 0.2, 0.3, 0.4, 0.5,
λA = 1, and ω2 = 0, 0.01, 0.059, 0.138.
Type I error rate increased as ICC increased,
Satterthwaite degrees of freedom had
better control than Kenward-Roger degrees
of freedom. Found using mixed-effects
model for pnRCT when ICC is zero likely
leads to never detecting intervention
effects, observed Type I error rates nearly
non-existent under all scenarios with ICC
equal to zero. Recommend to evaluate if
ICC is significantly different from zero prior
to selecting analysis method. Homoscedas
ticity was assumed for individual variances
between the two arms.
Baldwin
et al. [15]
Compare analysis models for pnRCT
simulation study, comparing three
degrees of freedom calculations,
and a pnRCT example.
Simulation for m = 5, 15, 30, c = 2, 4, 8,
16, ρ = 0, 0.05, 0.1, 0.15, 0.3, λB = 0.25,
1, 4, and d = 0, 0.5.
Recommend pnRCTs take account of
heteroscedasticity. Satterthwaite and
Kenward-Roger degrees of freedom
control Type I error rate. The heteroscedas
tic model provides an unbiased estimate
and little reduction in power compared to
the homoscedastic model. Argue that using
a partially nested mixed-effects model only
a problem for statistical inference when the
number of clusters is small. The number of
clusters has greater impact on power in
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We evaluate and provide recommendations for the
most appropriate analysis methods for pnRCTs,
including:
1) where mixed-effects models are necessary,
2) methods of specifying the clusters in the non-
clustered arm when fitting a model and the impact
these have on the analysis,
3) the impact of cluster sizes and the number of
clusters on statistical inference and,
4) the impact of heteroscedastic individual variance
between trial arms on statistical inference.
Methods
Methods for analysis of partially nested trials
In this section, we present the main modelling ap-
proaches currently available and used for pnRCTs, in-
cluding ignoring clustering altogether, imposing
clustering in the non-clustered control arm, and expli-
citly modelling the partially nested design by modelling
clustering only in the intervention arm.
It is possible to account for clustering by including each
cluster as a fixed effect in a standard regression model, in
addition to a fixed effect representing the intervention ef-
fect. Although this method is simple to implement, it is
not recommended. Firstly, it does not reflect the study de-
sign of a pnRCT and may require a large number of fixed
effects to be fitted lowering the degrees of freedom [9].
Secondly, if clusters are of size one there is insufficient in-
formation to estimate both the intervention effect and the
cluster effect for each cluster. Finally, it will generally
underestimate the intervention effect variability as the
cluster level variability is removed.
Table 2 presents a summary of the models for the ana-
lysis of pnRCTs using findings from the literature search
by Flight et al. [9]. We define: y as a continuous out-
come, i is the individual participant indicator, j is the
cluster indicator, t is the intervention indicator (0 = con-
trol, 1 = intervention), θ is the intervention effect, β0 is
an intercept term. Error terms are defined depending on
the model procedure, represented using ϵ, u, and r,
where u represents the between cluster variation and ϵ
and r represent individual level variation.
Model 1 (Table 2) is the linear regression model which ig-
nores the clustering and uses analysis for non-clustered tri-
als, assuming independence between individuals regardless
of whether they are in the same cluster. This infers that the
conditional variance of y in both the intervention and con-
trol arms is equal. If the outcomes of individuals in the
same cluster are correlated, the independence assumption
Table 1 Summary of relevant literature on analysis of pnRCTs (Continued)
Paper Relevant themes Range of valuesa Findings
pnRCTs. At least eight, preferably 16 clusters,
to maintain Type I error rate.
Bauer
et al. [6]
Review of RCTs to ascertain the prevalence
of pnRCTS in four public health and clinical
research journals. Analysis models for pnRCTs
extended to include pre-test measures as
covariates, individual and group level
covariates, and example of pnRCT
Example with clustering in one arm
c = 41, m = 9, and estimated ρ = 0.02.
Out of 94 RCTs, 32% were pnRCTs, 40%
iRCTs and 27% cRCT. None used methods
specific to pnRCTs. Example pnRCT data
could be analysed using mixed-effects
models. Argue pnRCTs “often increase




Examine the case of pnRCTs, heterogeneity,
comparison of analysis methods for
simulation study and present an example.
Simulation for m = 6, c = 8, ρ = 0, 0.1, 0.2,
0.3, λA = 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2
and d = 0.
Recommend pnRCTs take account of
heteroscedasticity. Satterthwaite unequal
variances t-test gave robust to heterosce
dasticity. The heteroscedastic model gives
slightly inflated test size for large ρ: suggest





Describe analysis models for iRCTs with
clustering and apply to two examples
(using Bayesian approach)
Show that ignoring clustering may




Statistical tests for RCTs with clustering
that differ across trial arms.
Example with clustering in both
arms with m = 7 − 12, c = 3.
Provide an adjustment for the independent
samples t-test for pnRCTs. Statistical impact
of heterogeneity effect increases as the
cluster size increases, and as heterogeneity
increases. The test does not allow for the
inclusion of covariates, multiple treatments,
baseline measures, or non-normally
distributed outcomes.
am = cluster size, c = number of clusters, ρ= ICC, d = standardised effect size, ω2= Omega Squared effect size percent of variability accounted for by treatment
condition, λA= ratio of total variance in control arm compared to clustered, λB= ratio of individual variance in control arm compared to clustered arm. Ordered by
year of publication
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is violated and we underestimate uncertainty around inter-
vention effects when using the linear regression model
above.
Model 2 (Table 2) is the fully clustered mixed-effects
model which includes the cluster as a random effect; this
includes variability at both the individual and cluster level.
The mixed-effects model with imposed clustering of the
control arm requires the estimation of a random cluster
effect for both intervention and control groups. Some op-
tions for the imposed clustering in the control arm are
given in Table 3. The variance of the control arm and
intervention arm are assumed to be the same (homoscedas-
tic). When the variance is believed to differ between control
and intervention arm model 2 is not appropriate as it does
not account for heteroscedasticity. Models 3 and 4
(Table 2) apply the cluster effect to the clustered arm only
[7, 10, 11, 14], we term these the partially nested models.
Individuals in the non-clustered control arm are as-
sumed independent. This accurately reflects the design
of the study with clustering only in one arm. In the par-
tially nested homoscedastic model, we apply the random
effect uj to the clustered intervention arm only;
between-cluster variability is only present for the inter-
vention arm. Model 3 is homoscedastic as the variance
of the individual errors, ϵij, between arms is the same. In
practice, the variance of the individual errors may differ
between trial arms [7]. Therefore, model 3 is extended
to a partially nested heteroscedastic model, model 4,
this allows for differing individual errors between
intervention and control arms but does not constrain
the form of heteroscedasticity.
Imposed clustering in the control arm
Regardless of whether or not the model assumes cluste-
ring in one (models 3 and 4) or both arms (model 2),
within the statistical software package a decision must
be made about how to code the cluster indicators in the
control arm. One method is to impose clusters for all in-
dividuals, including those in the control arm, and use
analysis for cRCTs with clustering in both arms.
Table 3 represents the different options for imposing
clustering, j, in the control arm, l is the number of indi-
viduals in the control arm and k is the number of arbi-
trary clusters in the control group. Option one treats the
control group as one single cluster; option two treats
each individual in the control arm as their own cluster
of size one (singleton clusters) giving j=l clusters in the
control arm. ICC estimation can be problematic with
options one and two, in theory, it is not possible to
estimate between-cluster variability in option one, or es-
timate within cluster variability in the control group
using option two [20]. Option three imposes artificial
pseudo-random clusters in the control group to
overcome the problem of estimating within or between-
cluster variability. The number of arbitrary clusters, k,
needs to be considered. We chose it to be equal across
treatment arms. In addition, option three will likely
result in a lower ICC estimation due to the assumed
independence of control participants.
In our simulation study, the fully clustered model 2 is
parametrised using the imposed clustering from Table 3.
The models are:
 Model 2.1 fully clustered mixed-effects model with
singleton clusters in the control arm;
Table 2 Models for the analysis of pnRCTs
Model description Statistical model Heteroscedastic
residuals
Model 1 Linear regression
(ignore clustering)
yi = β0 + θti + ϵi
• ϵ i  Nð0; σ2ϵ Þ the individual level variation
No
Model 2 Fully clustered
(impose clustering)
yij = β0 + θtij + uj + ϵij
• u j  Nð0; σ2uÞ a random effects term representing between cluster
variation
• ϵ i j  Nð0; σ2ϵÞ the individual level variation
No
Model 3 Partially nested
homoscedastic
yij = β0 + θtij + ujtij + ϵij
• u j  Nð0; σ2uÞ a random effects term representing between-cluster variation
in clustered arm
• ϵ i j  Nð0; σ2ϵÞ the individual level variation
No
Model 4 Partially nested
heteroscedastic
yij = β0 + θtij + ujtij + rij(1 − tij) + ϵijtij
• u j  Nð0; σ2uÞ a random effects term representing between cluster-variation
in clustered arm
• rij  Nð0; σ2r Þ the individual level variation in the non-clustered control arm.
• ϵ i j  Nð0; σ2ϵÞ the individual level variation in the clustered arm
Yes
Table 3 Options for imposing clustering in the non-clustered
control arm
Option Cluster Intervention
1 j = 0 j = 1, …, c
2 j = 1, …, l j = l + 1, …, c
3 j = 1, …, k j = k + 1, …, c
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 Model 2.2 fully clustered mixed-effects model with
one large cluster in the control arm;
 Model 2.3 fully clustered mixed-effects model with
pseudo clusters in the control arm.
Flight et al. [9] investigated the effect of the different
methods of imposing clustering in the control arm
presented in Table 3 in four pnRCT case-studies. The four
case-studies covered trials evaluating the effect of: specialist
leg ulcer clinics (clustered by clinic), acupuncture for low
back pain (clustered by acupuncturist), postnatal support in
the community (clustered by community support worker),
and telephone befriending for maintaining quality of life in
older people (clustered by volunteer facilitator). Little differ-
ence was found between the different methods for the fully
clustered mixed-effects models and there was no difference
between the different methods for the partially nested
mixed-effects models.
We anticipated that the method of imposing the clus-
tering in the control arm does not affect the results of
the methods which model clustering in only one arm,
however, this evaluated in the simulation study.
Degrees of freedom for fixed effect estimates
In the mixed-effects models above we wish to carry out
significance tests for the intervention effect. In addition
to the correct choice of model, the test statistics and
degrees of freedom in mixed-effects models also need to
be considered. For large sample sizes in mixed-effects
models, the test statistics for fixed effects can be as-
sumed Normally distributed. However, for small samples,
the t-distribution is generally used as an approximation of
the distribution of the test statistic. Estimating the degrees
of freedom for the t-distribution is unclear for pnRCTs
and will affect both the significance test and the confi-
dence intervals of the intervention effect estimate.
Comparison of degrees of freedom correction methods
has been undertaken for cRCTs and pnRCTs with small
numbers of clusters [15, 21]. The Satterthwaite
small-sample degrees of freedom correction takes into
account the variance structure of the data, for pnRCTs,
it has been shown to be superior to the between-within
method for maintaining Type I error rates (and compa-
rable to the Kenward-Roger method) [15]. Following
these results, the Satterthwaite approximation was used
to calculate degrees of freedom (using dfmethod() option
for mixed, available in Stata 14 onwards [22]).
Simulation study
Overview
We performed a simulation study to evaluate the statis-
tical analysis models for pnRCTs presented in Table 2,
and the imposed clustering of the control arm in Table 3
[23]. All models were fitted using a restricted maximum
likelihood procedure (REML). All simulations were done
in Stata [22], graphs produced using ggplot2 [24] in R
[25]. See Additional file 1 for simulation code.
Data-generating mechanism
We simulated data to replicate a two-arm parallel
pnRCT trial with a non-clustered control arm and a
clustered intervention arm (randomised 1:1) and a con-
tinuous outcome. We simulated data under various de-
sign scenarios and under both the null (θ = 0) and
alternative hypothesis (θ =A, where A ≠ 0).
Data were simulated from the following model with
the intercept set to zero and group allocation denoted
by t (t = 0 for control, t = 1 for intervention arm):
 For the intervention arm ðt ¼ 1Þ yi j ¼ θ þ uj
ffiffiffi
ρ




 For the control arm ðt ¼ 0Þ yi j ¼ zi j
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
γð1−ρÞp
Where uj~N(0, 1) and zij~N(0, 1). This simulates an ICC
of ρ and a ratio of individual level variance between the
non-clustered control arm and the clustered intervention
arm of γ. If γ = 1, there is homoscedasticity between the
individual level variance in the control and intervention
arms. Full simulation study steps, including the data
generation process and modelling, are presented in Fig. 1.
Simulation scenarios are presented in Table 4. We var-
ied: the intervention effect, ICC, cluster size, number of
clusters, and ratio of individual variance between the
trial arms. If γ = 0.25 then individual variance in the con-
trol arm is one quarter that in the intervention arm and
if γ = 4 then individual variance in the control arm is
four times that in the intervention arm.
Simulation values were chosen based on literature on
pnRCTs [7, 9, 15, 17, 18, 26–28], as well as extending
these to more extreme cases of γ and ρ that may occur
in rare instances. Reporting of ICCs in iRCTs with clus-
tering is limited at present and it is plausible that ICCs
in pnRCTs differ from those of cRCTs. Current evidence
suggests ICCs in iRCTs with clustering in either one or
both arms are generally small and often less than 0.05
[7–9, 29], hence the choice to include a small ICC ρ =
0.01 in the simulations with ICCs of 0.2 or more occur-
ring only in rare instances. We were unaware of specific
literature on the evidence of heteroscedasticity, however,
from the authors experience of working on trials it was
expected γ to typically stay within the range of 0.5–2.
The number of clusters in the intervention group was 3,
6, 12 or 24. These figures reflect the small numbers of
clusters recruited in many pnRCTs and, coupled with
the cluster sizes of 5, 10, 20 or 30, they allowed alterna-
tive combinations of cluster size and number of clusters
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to be investigated for a given total trial sample size.
Figure 2 provides a graphical example of the simulated
partially nested trial data.
Methods
Each simulated dataset was analysed using the models
described in Table 2.
Estimand
Our estimands of interest are the REML estimate of
the intervention effect θ and the model estimate of
the ICC ρ.
Performance measures
We used the following performance measures: bias,
mean square error (MSE), and coverage of 95% confi-
dence intervals for θ̂, Type I error rate and power (calcu-
lated as the proportion of simulated results with a
statistically significant intervention effect at the 5% level
when the null or alternative hypothesis were true, for
Type I error and power respectively) and where appli-
cable, model estimated ICC. See Additional file 2 for
more detail on performance measures. For each of the
1440 scenarios 1000 datasets were generated; a 5%
significance level and 95% confidence interval based on
1000 simulations has a Monte Carlo error of 0.7%.
Results
Model convergence was generally satisfactory for all
models with models converging 95–100% of the time
across the different scenarios.
Imposed clustering in the control arm
Methods for imposing clustering in the control arm, pre-
sented in Table 3, had a negligible impact on the per-
formance measures of the partially nested mixed-effects
models (models 3 and 4). Under the simulation scenar-
ios, the differences in the p-value, confidence intervals
Fig. 1 Flowchart representing the simulation study steps
Table 4 Simulation input scenario values (total 1440 scenarios)
Variable Notation Values
Number of clusters c 3, 6, 12, 24
Cluster size m 5, 10, 20, 30
Intervention effect θ 0, 0.2, 0.5
ICC ρ 0, 0.01, 0.05, 0.1, 0.2a, 0.3a
Ratio of individual variance
between control and cluster
trial arms
γ 0.25a, 0.5, 1, 2, 4a
aConsidered extreme values to occur in rare scenarios
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and estimated ICC between the methods were only
present at four decimal places. Model fitting was consid-
erably faster (around four to five times faster) using ei-
ther one large cluster or the pseudo clusters compared
to the singleton clusters, however, this will likely be im-
material when fitting only a small number of models.
Methods for imposing clustering in the control arm
had a large impact on the performance measures of the
fully clustered mixed-effects models (models 2.1, 2.2,
and 2.3). Specific results for each performance measure
are presented in the following sections.
Results are reported only for the partially nested
mixed-effects models (models 3 and 4) with the
non-clustered controls classified as one large cluster, as
other methods were comparable. All three methods for
classifying the non-clustered control arms for the fully
clustered mixed-effects model (models 2.1, 2.2, and 2.3)
are reported.
Bias
The bias of the intervention effect estimate was not af-
fected by the analysis model used, individual variances
(γ) or the ICC (ρ). The maximum absolute bias of the
intervention effect was |0.057|, |0.043|, and |0.053| for
θ = 0, 0.2 and 0.5, respectively.
Mean square error
The models produced unbiased estimators with no dif-
ference in the observed MSE between the different
models. The MSE of the intervention effect estimate had
a mean of 0.051 (standard deviation (SD) 0.056) and
maximum of 0.346.
Type I error
Plots of the mean Type I error rates split by model, the
ratio of individual variances (γ) and the ICC (ρ) are pre-
sented in Fig. 3. As would be expected the linear regres-
sion model which ignores clustering had inflated Type I
error rates, with Type I error rate affected by ICC (ρ),
the ratio of individual variances (γ), number of clusters
(c), and cluster size (m). Although the inflation was
minimal when ICC ρ = 0.01, the mean Type I error
was 0.061 (SD 0.010). When cluster size m ≤ 10 and
ICC ρ = 0.01 the mean Type I error rate was 0.056
(SD 0.007).
Model 2, the fully clustered models with imposed clus-
tering in the control arm resulted in biased Type I error
rates. Imposing clustering as singleton clusters (model
2.1) led to Type I error rates which were largely affected
by the ratio of individual variances (γ) and ICC (ρ). Im-
posing one large cluster in the control arm (model 2.2)
resulted in Type I error rates of zero (due to the
Satterthwaite degrees of freedom correction resulting in
large degrees of freedom when imposing one large clus-
ter in the control arm). Imposing pseudo clusters in the
control arm of the same size as the intervention arm
(model 2.3) provided relatively good control of Type I
error rates, mean Type I error of 0.039 (SD 0.018), but
was affected slightly by both the ratio of individual
variances (γ) and ICC (ρ).
Both the homoscedastic and heteroscedastic partially
nested models (models 3 and 4) provided good control of
Type I error rates (model 3: mean Type I error 0.045 (SD
0.016) and model 4: mean Type I error 0.044 (SD 0.014))
with little difference present between the two models.
For more detailed comparison Fig. 4 presents the Type
I error rates for the linear regression model (model 1),
the homoscedastic (model 3) and the heteroscedastic
(model 4) partially nested models by ICC (ρ), the ratio
of individual variances (γ), number of clusters (c), and
cluster size (m). Higher ICC values resulted in higher
Type I error rates in each model. The impact of ignoring
clustering (model 1) depends on both ICC (ρ), cluster
size (m), and number of clusters (c). Larger number of
clusters (c) resulted in better control of Type I error
rates for the partially nested models. When ICC ρ = 0,
the Type I error rates of the partially nested models
(models 3 and 4) were reduced from the nominal level.
This is due to the cluster variance components being es-
timated when they are not actually present in the data.
When the ICC was small (ρ ≤ 0.05) and the individual
variance in the control arm smaller than that in the
intervention arm (γ < 1), the Type I error rates of par-
tially nested models were reduced from the nominal 5%
level. When ICC was large (ρ = 0.3) the partially nested
models generally resulted in inflated Type I error rates.


































































Fig. 2 Example of simulated partially nested trial dataset, ρ = 0.1,
γ = 1, c = 12, and m = 10
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partially nested models 3 and 4 only reaching above the
nominal Type I error rate of 5% on average when ICC
ρ ≥ 0.2.
The Satterthwaite correction used in Stata mixed
(dfmethod(sat)) did not fully correct the Type I error
rates to the nominal 5% level, even with the use of the
heteroscedastic model 4. The heteroscedastic model 4
did have slightly improved control of Type I error rates
than the homoscedastic model 3.
Coverage
Plots of the mean coverage of the 95% confidence inter-
vals of the intervention effect estimate split by model,
ICC (ρ) and the ratio of individual variances (γ) are pre-
sented in Fig. 5 under the alterative hypothesis. The lin-
ear regression model (model 1) resulted in under
coverage when ICC was small (ρ ≤ 0.05) and the cover-
age rates decrease as ICC (ρ) increases. The fully clus-
tered models with imposed clustering in the control arm
resulted in both over and under coverage dependent on
the direction of the variance ratio and the method of im-
posed clustering. Imposing clustering as singleton clus-
ters (model 2.1) resulted in coverage rates largely
affected by ratio of individual variances (γ). Imposing
one large cluster in the control arm (model 2.2) resulted
in over coverage, due to the reduced Type I error rates
of zero caused by the Satterthwaite degrees of freedom
correction. Imposing pseudo clusters in the control arm
(model 2.3) provided mean coverage rates of 0.961 (SD
0.018).
Both the homoscedastic and heteroscedastic partially
nested models (models 3 and 4) provided good control
of coverage rates of 95% confidence intervals (model 3:
mean coverage rate 0.956 (SD 0.014) and model 4: mean
coverage rate 0.956 (SD 0.014)) with little difference be-
tween the two models. In the simulations over coverage
of the 95% confidence intervals for the heteroscedastic
model 4 occurred when ICC ρ ≤ 0.05, except when the
Fig. 3 Mean Type I error rate by γ and ρ over all scenarios, for each model
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ratio of individual variances γ = 4. Hence, the results
were generally conservative when ICC was small. Under
coverage of the 95% confidence intervals for the hetero-
scedastic model 4 only occurred for large ICC (ρ) and
ratio of individual variances (γ).
Power
Increasing the number of clusters as opposed to increas-
ing the cluster size had a bigger impact on power with a
fixed total sample size. Fig. 6 shows the power of the lin-
ear regression model (model 1), the homoscedastic
(model 3) and the heteroscedastic (model 4) partially
nested models when intervention effect θ = 0.5 by ICC
(ρ), the ratio of individual variances (γ), number of
clusters (c), and cluster size (m) (see Additional file 2 for
when θ = 0.2). Under the simulation scenarios con-
ducted, 12 or more clusters and cluster sizes of ten or
more were generally needed for a power greater than
80%. Using three or six clusters rarely gave power over
80%, only for ICC ρ ≤ 0.05 and relatively large cluster
sizes m ≥ 20, did power go over 80%.
For ICC ρ ≤ 0.05, which is commonly assumed when
planning complex intervention trials in healthcare,
power of 80% was generally achieved with: 24 clusters of
any size, 12 clusters of size ten or more, and six clusters
of size 20 or more (120 in each arm).
Under a ratio of individual variances γ = 1 the total
residual variance in both trial arms is equal to one,
hence, the intervention effect (θ) we simulated is the
standardised intervention effect. Figure 7 shows the
power of models 1, 3 and 4 under homoscedastic indi-
vidual variances (γ = 1). The heteroscedastic model 4 is
over-parameterised in the case of the ratio of individual
variances γ = 1, however, it did not result in a substan-
tially lower power than the homoscedastic model.
Table 5 presents the power of model 4 and model 1
under ICC ρ = 0, model 4 is over-parametrised here.
There is a loss in mean statistical power which ranged
between 1.7 to 6.3%.
ICC
Figure 8 presents the mean estimated ICC across the
fully clustered and partially nested mixed effect models,
Fig. 4 Type I error rate of models 1, 3 and 4, by ρ, γ, c, and m
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by the ratio of individual variances (γ) and ICC (ρ). ICC
estimation was consistent under the heteroscedastic par-
tially nested model (model 4). The homoscedastic par-
tially nested model (model 3) resulted in biased ICC,
with the direction of bias dependent upon the ratio of
individual variances (γ).
Figure 9 presents the ICC for the homoscedastic
(model 3) and heteroscedastic (model 4) partially nested
models by the ratio of individual variances (γ), ICC (ρ),
number of clusters (c), and cluster size (m). The ICC es-
timation from the homoscedastic model was highly af-
fected by γ. The ICC estimation from the
heteroscedastic model was not affected by γ. Using the
heteroscedastic model, there was a slight positive bias in
the ICC estimation when ICC ρ ≤ 0.05, and when ICC
ρ ≥ 0.2 there was slight negative bias in the ICC estima-
tion. For example, when ICC ρ = 0.0 the mean ICC esti-
mation was 0.028 (SD 0.018), and when ICC ρ = 0.05 the
mean estimation was 0.060 (SD 0.014). As expected ICC
estimation improved as sample size increased. The ICC
estimation was only consistent across all values of ICC
(ρ) when there were 24 clusters, regardless of cluster
size. For an accurate estimate of ICC when true ICC ρ =
0.05, under the simulation scenarios we required cluster
sizes (m) of 20 or 30 or at least six clusters of size ten or
24 clusters of size five.
Summary of results
Simulation results are summarised in Table 6 presenting
the performance of the simple linear regression model
(model 1), homoscedastic partially nested mixed effects
model (model 3) and heteroscedastic partially nested
mixed effects model (model 4) under different design
scenarios. Results from the fully clustered mixed-effects
models (model 2) are excluded from Table 6 as we do
not recommend these in any scenario regardless of the
method used to impose clustering in the control arm.
None of the fully clustered mixed-effects models pro-
vided full control of the Type I error rates and the par-
tially nested mixed effects models always outperformed
them.
Discussion
In this study, we have investigated six modelling strat-
egies for the analysis of pnRCTs with a continuous out-
come. Our simulation study showed that when analysing
pnRCTs the use of the heteroscedastic partially nested
mixed-effects model for normally distributed outcome
Fig. 5 Mean coverage of 95% confidence interval, by ρ and γ over all scenarios
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Fig. 6 Power when θ = 0.5, by ρ, γ, c, and m
Fig. 7 Power with standardised intervention effect of 0.5 (θ = 0.5 and γ = 1)
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data (using Satterthwaite degrees of freedom) in general
provides: unbiased effect estimates; maintains relatively
good control of Type I error rates; and did not noticeably
cause a reduction in power even with homoscedastic indi-
vidual variances across arms. The heteroscedastic partially
nested model takes account of the between-cluster
variance (if present) and therefore provides valid infer-
ences for the intervention effect. Additional file 2 presents
model-fitting code for R, Stata and SAS. When using the
partially nested mixed-effects model, the method of classi-
fying the non-clustered controls had a negligible impact
on statistical inference under the simulation scenarios,
agreeing with findings from analysis of four example
pnRCTs by Flight et al. [9].
Our findings were broadly similar to those of Bald-
win et al. [15]. However, they did not assess the
method of classifying the non-clustered controls or
performance of models under small ICC (ρ = 0.01,
lowest value used in our study) which commonly
occur in pnRCTs [7–9, 26, 29]. Unlike findings from
Baldwin et al. [15], the Satterthwaite degrees of freedom
correction did not fully control the Type I error rate in
our simulations. The largest discrepancy from the nominal
level occurred when the ICC was small, ratio of individual
variances <1, and under small sample sizes.
Table 5 Mean and SD of power of model 4 versus model 1





0 1 0.050 (0.007)
4 0.033 (0.014)
0.2 1 0.388 (0.276)
4 0.327 (0.286)
0.5 1 0.803 (0.254)
4 0.740 (0.298)
Fig. 8 Mean estimated ICC by γ and ρ over all scenarios, for each model
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We have illustrated that using a naïve linear regression
model, which ignores clustering in pnRCTs, gave inflated
Type I error rates and resulted in under coverage of
confidence intervals when clustering of outcomes was
present. When ICC 0.01 ≤ ρ ≤ 0.05, which we believe is
common in pnRCTs [9], ignoring clustering led to
largely inflated Type I error rates using the linear regres-
sion model. A low ICC may still have a large impact,
particularly when cluster sizes are large.
When ICC was small and/or with very few clusters
and small cluster sizes using the partially nested
mixed-effects models 3 and 4 resulted in underestimated
Type I error rates. These models correctly reflect the de-
sign of the trials; however, they can result in conservati-
vism regarding the precision of estimates due to the bias
in estimating the variance estimates when we have a
small number of clusters. Consequently, using the par-
tially nested mixed effects models with small ICC may
make it difficult to detect differences between the trial
arms when present.
Sanders [17] recommend evaluating whether ICC is sig-
nificantly different from zero prior to selecting an analysis
method. We caution such significance testing for ICC,
and similarly testing for heteroscedasticity [7]. These tests
will generally lack power in a pnRCT and it is not the
statistical significance of the ICC that matters but impact
of the magnitude on inference. In general, we recommend
the use of the partially nested models when analysing
pnRCT trials, particularly if conservatism and an ICC esti-
mate are desired. However, the choice of model and the
requirement or not for conservatism needs to be consi-
dered in the context of the specific trial setting.
Similar to cRCTs [1], in a pnRCT increasing the number
of clusters rather than increasing the cluster size has a
greater increase in power for a fixed total sample size. Our
simulation results showed that this will also provide a more
accurate estimation of the ICC. When the number of clus-
ters is small, for example, three clusters in the intervention
arm, the ICC estimation will likely be upwardly biased.
With six clusters in the intervention arm, the ICC estimate
was relatively unbiased once the true ICC ≥0.1. The ICC
estimation became consistent regardless of cluster size or
true ICC only once there were 24 clusters in the simulation
scenarios. This reflects findings from previous research that
to reliably estimate the size of clustering effects a large
number of clusters are required [30].
This study investigated the case of analysing partially
nested trials under complete compliance. Non-compliance
in the clustered arm of a pnRCT may occur when some
participants randomised to a particular treatment group or
Fig. 9 ICC estimation of heteroscedastic partially nested model, by γ, ρ, m and c
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care provider do not attend any sessions or receive treat-
ment as part of different treatment group or care provider
intended at randomisation. Consequently, non-complier
outcomes may be assumed independent if they do not
receive the clustered intervention. Schweig and Pane [16]
describe and compare models for pnRCTs with non-com-
pliance using a simulation study. They argue that an un-
biased intention-to-treat (ITT) estimate under non-
compliance on a pnRCT may be obtained using a Complier
Average Causal Effects (CACE) model. This method in-
volves estimating the treatment effect for compliers and
scaling this CACE effect estimate by the proportion of
compliers to provide an ITT effect estimate. The issues
posed by non-compliance warrant further investigation,
considering a broader range of scenarios and investigating
the degrees of freedom corrections for valid statistical
inferences.
The design and analysis of trials with clustering in one
arm needs to take account of heterogeneity and ICC to
have a sufficiently powered sample size and accurate
intervention effect. We strongly recommend the reporting
of ICCs in trials results papers. The framework developed
for cRCTs is also broadly applicable in iRCTs with cluster-
ing, identifying three dimensions to consider when report-
ing an ICC: a description of the dataset (including
characteristics of the outcome and the intervention); how
the ICC was calculated; and the precision of the ICC [31].
This has the potential to improve the assumptions about
ICCs in iRCTs, adhere to CONSORT reporting guidelines
for RCTs of nonpharmacological interventions [32], and
raise awareness of the need to account for clustering in
both the sample size and analysis in iRCTs with clustering.
A wide variety of terminology are used in iRCTs with
clustering in one arm, including partially nested, partially
clustered, multi-level, and individually randomized group
intervention. A more consistent use of terminology would
reduce confusion, improve reporting and make finding
relevant ICCs from previous trials easier. We suggest the
terminology partially nested randomised trial (pnRCT) to
describe an iRCT with clustering in one arm.
Limitations
All the mixed-effects models assume that the cluster
level means follow a Normal distribution. This may not
be a valid assumption, for example, when we have a
small number of clusters.
In the simulations, we have used fixed cluster sizes. In
practice, cluster size may vary, causing a loss in efficiency
when estimating the intervention effect. A simulation
study by Candel and Van Breukelen [10] found the effi-
ciency loss in the intervention effect estimate was rarely
more than 10%, requiring recruitment of 11% more
Table 6 Summary of simulation results by different models split by ρ, m, and c averaged over all γ
*Model 1: simple linear regression; Model 3: homoscedastic partially nested mixed effects model; Model 4: heteroscedastic partially nested mixed effects model.
Green highlighted ≤ than expected, red highlighted > than expected
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clusters for the intervention arm and 11% more individ-
uals for the control arm. The loss of efficiency in the inter-
cept variance reached to 15%, requiring 19% more clusters
in the clustered arm, and no additional recruitment in the
control arm. Additionally, it has been shown in cluster tri-
als if the coefficient of variation in cluster size is small, less
than 0.23, then the correction on sample size is negligible
[33]. It should be noted that cluster sizes are likely to be
more similar in group administered interventions com-
pared to trials which impose clustering by being treated
by the same care provider [7].
Throughout the simulations we assumed there was no
effect of clustering in the control arm, this may not strictly
be true in practice. In healthcare intervention trials, a
commonly used control intervention is ‘care as usual’. This
type of control may induce some form of low-level clus-
tering, for instance, treatment by a healthcare practitioner.
If the same practitioner treats numerous individuals, we
can assume, in the same sense as we have done for the
intervention arm that these individuals are clustered and
include this in the modelling procedure. However, this in-
formation is often not available in trial data and is not
unique to pnRCTs.
Partially nested trials pose a number of challenges, in
particular, the issue of internal validity [6]. The grouping
of individuals as part of the delivery of a treatment may
affect the outcome. However, taking a pragmatic view-
point, we consider the grouping as part of the treatment
as a whole if this is reflective of treatment delivery in
real-world practice. In addition, if the ungrouped con-
trols are the true comparison in real life a pnRCT design
will provide external validity.
Conclusion
Partially nested RCTs are increasingly used in complex
intervention research. Ignoring clustering can lead to infla-
tions of the Type I error rates, even for small ICCs. When
analysing a pnRCT with continuous outcomes we recom-
mend the use of a heteroscedastic partially nested
mixed-effects model with corrected degrees of freedoms
such as using the Satterhwaite method, for outcomes similar
to those generated under the scenarios of our simulations
study. The method used for classifying the non-clustered
controls had a negligible impact on the results using the par-
tially nested mixed-effects model. The model is easy to im-
plement in standard statistical software and does not cause a
notable reduction in power under homoscedastic variances.
With few clusters, small cluster sizes and small ICC, the par-
tially nested model underestimated Type I error rates and
gave largely inflated ICC estimates, hence, for such designs
there is no optimal model and we need to be cautious in
model interpretation. Finally, to aid the design and prior
selection of an appropriate analysis plan for pnRCTs, we
strongly recommend the reporting of estimated ICC when
publishing trials results.
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randomised trials (chapter 5)
B.1 Supplementary results, figures and tables
B.1.1 Linear regression models (OLS, cluster robust and cluster bootstrap)
Table B.1: Type 1 error mean and standard deviation by ρ
ICC
Model: linear regression with
OLS SEs Cluster robust SEs Cluster bootstrap SEs
Mean SD Mean SD Mean SD
0.01 0.051 0.005 0.006 0.006 0.076 0.010
0.05 0.057 0.008 0.006 0.008 0.080 0.009
0.1 0.064 0.009 0.007 0.007 0.080 0.009
0.2 0.077 0.021 0.009 0.009 0.080 0.008
Table B.2: Coverage rates of 95% confidence intervals mean and standard deviation by ρ
ICC
Model: linear regression with
OLS SEs Cluster robust SEs Cluster bootstrap SEs
Mean SD Mean SD Mean SD
0.01 0.951 0.007 0.989 0.009 0.935 0.009
0.05 0.947 0.005 0.988 0.009 0.936 0.006
0.1 0.937 0.010 0.985 0.011 0.935 0.010
0.2 0.920 0.019 0.981 0.010 0.931 0.009
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B.2 Stata simulation code for within-arm partially nested trials
analysis
The following Stata code was used for the simulation study in chapter 5.
/* Simulation Parameters */
*Simulation for Yij = alpha + theta1*tij + theta2*t2ij + ujt2ij + eij
*normally distributed continuous outcome with cluster (j) and
*residual (i) variability
/* Function parameters */
*theta1*: stage one intervention effect
*theta2*: stage two intervention effect
*rho*: ICC in clustered stage two
*clusterSize*: Size of each cluster
*nClusters*: Number of clusters in stage two
*nIterations*: number of iterations for simulation
/* Variable Specification */
*y*: is the dependent variable;
*cluster* is one of the following clustering options







/* Value of parameters: args assigns the first command line argument to the local
macro simula_No, the second argument to nIterations and so on. */
args simulNo nIterations theta1 theta2 sigmau sigmae rho clusterSize nClusters
/* Set working directory */
cd "working directory"
local initial_seed = c(seed)
/* Log file for debugging and working out where mistakes are*/
log using log\simulation‘simulNo’.smcl, smcl replace
tempname memhold
tempfile results
qui postfile ‘memhold’ simICC theta1 theta2 sigmau sigmar sigmae rho clusterSize
nClusters Model TreatEst SE p_value NormalCI_ll NormalCI_ul NormalCI_cv BCCI_ll
BCCI_ul BCCI_cv ind_var converge using ‘results’, replace
forvalues sim = 1/‘nIterations’{
* monitor iterative process of simulations by displaying a dot after every 100
simulations
if int(‘sim’/100) ==‘sim’/100{




local n2 = round((‘nClusters’*‘clusterSize’)/.5,2)*2
set obs ‘n2’
di ‘n2’
local n2 = _N
local sigmar = 1-‘sigmau’
* Generate treatment indicator
gen treat1 = 0
replace treat1 = 1 if _n< = _N/2
* Generate unique patient ID
gen patID = _n
* generate individual residuals control arm
gen e = rnormal(0,sqrt(‘sigmae’))
* generate individual residuals int arm
gen r = rnormal(0,sqrt(‘sigmar’))
* generate outcome after follow-up 1
gen y1 = ‘theta1’*treat1 + r*treat1 + e*(1-treat1)
* generate treat2
gen treat2 = 0
replace treat2 = 1 if y1<‘theta1’ & treat1 ==1
* generate cluster ID for those who get treat2 and singleton cluster ID for others
bysort treat2: egen cluster1 = seq(), b(‘clusterSize’)
summarize cluster1 if treat2 == 1
scal nClusters_treat2 = r(max)
*Number of clusters who receive intervention treat2-
replace cluster1 = (_n + nClusters_treat2) if (treat2==0)
* Generate cluster residual
sort cluster1
by cluster1: gen _rcl = rnormal(0,sqrt(‘sigmau’)) if _n==1
by cluster1: egen u = max(_rcl)
* generate follow-up 2
gen y2 = y1 + ‘theta2’*treat2 + u*treat2
* Calculate ICC of simulated data
tabstat u, by(treat2) stat(v) save
mat define I1 = r(Stat2)
local ClustRes_var I1[1,1]
tabstat r, by(treat2) stat(v) save




/* FIT MODELS */
*--------------------------
/* Notes on standard errors in regress: vce(vcetype) specifies the type of standard
error reported, which includes types that are derived from asymptotic theory (ols)
, that are robust to some kinds of misspecification (robust), that allow for
intragroup correlation (cluster clustvar), and that use bootstrap or jackknife
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methods (bootstrap, jackknife); see [R] vce option */
* Model: Simple linear regression model ignoring clustering for follow-up 1 outcome
capture {
regress y2 treat1
*define model number as first column
if _rc == 0 local converge = 1
local m 1.0
* retrieve the contents of the outputs (estimates)
mat define M10 = r(table)
local b M10[1,1] //estimate of the treatment effect
local se M10[2,1] //standard error of the treatment effect
local p M10[4,1] //p value
local ll M10[5,1] //ll 95%CI
local ul M10[6,1] //ul 95%CI
local cv inrange(‘theta1’,‘ll’,‘ul’) //coverage indicator
local ind_var = e(rmse)
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m
’) (‘b’) (‘se’) (‘p’) (‘ll’) (‘ul’) (‘cv’) (.) (.) (.) (‘
ind_var’) (‘converge’)
}
if _rc != 0 {
local converge = 0
local m 1.0
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m
’) (.) (.) (.) (.) (.) (.) (.) (.) (.) (.) (‘converge’)
}
* Model: Simple linear regression model with cluster robust Std errors
* cluster() indicates that observations are clustered into groups and that
observations may be
* correlated within these clusters, but independent between the clusters. By including
the cluster
* option we also imply the robust option. The standard errors now take account that
observations within
* clusters are correlated. Using this procedure, clusters are bootstrapped and the
resampled clusters
* are kept intact.
capture {
regress y2 treat1, cluster(cluster1)
*define model number as first column
if _rc == 0 local converge = 1
local m 2
* retrieve the contents of the outputs (estimates)
mat define M21 = r(table)
local b M21[1,1] //estimate of the treatment effect
local se M21[2,1] //standard error of the treatment effect
local p M21[4,1] //p value
local ll M21[5,1] //ll 95%CI
local ul M21[6,1] //ul 95%CI
local cv inrange(‘theta1’,‘ll’,‘ul’) //coverage indicator
local ind_var = e(rmse)
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m




if _rc != 0 {
local converge = 0
local m 2
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m
’) (.) (.) (.) (.) (.) (.) (.) (.) (.) (.) (‘converge’)
}
* Model: boostrap SEs, cluster1, strata treat2
capture {
bootstrap _b[treat1], cluster(cluster1) strata(treat2) reps(1000): regress y2
treat1
*define model number as first column
if _rc == 0 local converge = 1
local m 3
mat define M3 = r(table)
local b M3[1,1] //estimate of the treatment effect
local se M3[2,1] //standard error of the treatment effect
local p M3[4,1] //p value
estat bootstrap, all
mat define N3 = e(ci_normal)
local n_ll N3[1,1] //normal ll 95%CI
local n_ul N3[2,1] //normal ul 95%CI
mat define B3 = e(ci_bc)
local bc_ll B3[1,1] //bias-corrected confidence interval ll 95%CI
local bc_ul B3[2,1] //bias-corrected confidence interval ul 95%CI
local n_cv inrange(‘theta1’,‘n_ll’,‘n_ul’) //coverage indicator
local bc_cv inrange(‘theta1’,‘bc_ll’,‘bc_ul’) //coverage
indicator
mat define V3 =e(V)
local ind_var = V3[1,1]
di ‘b’ ‘se’ ‘p’
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m
’) (‘b’) (‘se’) (‘p’) (‘n_ll’) (‘n_ul’) (‘n_cv’) (‘bc_ll’) (‘
bc_ul’) (‘bc_cv’) (‘ind_var’) (‘converge’)
}
if _rc != 0 {
local converge = 0
local m 3
post ‘memhold’ (‘simICC’) (‘theta1’) (‘theta2’) (‘sigmau’) (‘
sigmar’) (‘sigmae’) (‘rho’) (‘clusterSize’) (‘nClusters’) (‘m






qui use ‘results’, clear
/*
After all all simulations are run and the N-obsrvation
dataset of results is created, the code ends with
*/
note: File results‘simul_No’
note: Ran simluation ‘0’
note: Seed was ‘initial_seed’
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save dta\results‘simulNo’, replace
/* Closed and convert log to html */
log close
translate log\simulation‘simulNo’.smcl log\simulation‘simul_No’.log, replace
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Appendix C
Sample size methods for partially
nested trials (chapter 6)
C.1 List of included papers
Turner, E. L., Li, F., Gallis, J. A., Prague, M., and Murray, D. M. (2017). Review of recent
methodological developments in group-randomized trials: part 1-design. American journal of
public health, 107(6), 907-915.
Candel, M. J., and Van Breukelen, G. J. (2015). Sample size calculation for treatment effects in
randomized trials with fixed cluster sizes and heterogeneous intraclass correlations and variances.
Statistical methods in medical research, 24(5), 557-573.
Moerbeek, M. and Teerenstra, S. (2015). Power analysis of trials with multilevel data. Chap-
man and Hall/CRC.
Batistatou, E., Roberts, C., and Roberts, S. (2014). Sample size and power calculations for
trials and quasi-experimental studies with clustering. The Stata Journal, 1, 159-75.
Heo, M., Litwin, A. H., Blackstock, O., Kim, N., and Arnsten, J. H. (2017). Sample size
determinations for group-based randomized clinical trials with different levels of data hierarchy
between experimental and control arms. Statistical methods in medical research, 26(1), 399-413.
Lohr, S., Schochet, P. Z., and Sanders, E. (2014). Partially Nested Randomized Controlled
Trials in Education Research: A Guide to Design and Analysis. NCER 2014-2000. National
Center for Education Research.
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Roberts, C., and Walwyn, R. (2013). Design and analysis of non-pharmacological treatment
trials with multiple therapists per patient. Statistics in medicine, 32(1), 81-98.
Korendijk, E. (2012). Robustness and optimal design issues for cluster randomized trials
(Doctoral dissertation, Utrecht University).
Baldwin, S. A., Murray, D. M., Shadish, W. R., Pals, S. L., Holland, J. M., Abramowitz, J. S.,
... and Christensen, A. (2011). Intraclass correlation associated with therapists: estimates and
applications in planning psychotherapy research. Cognitive Behaviour Therapy, 40(1), 15-33.
Baldwin, S. A., Bauer, D. J., Stice, E., and Rohde, P. (2011). Evaluating models for partially
clustered designs. Psychological Methods, 16(2), 149.
Walwyn, R. E. (2010). Therapist variation within meta-analyses of psychotherapy trials.
Manchester, UK: University of Manchester.
Candel, M. J., and Van Breukelen, G. J. (2009). Varying cluster sizes in trials with clusters in
one treatment arm: sample size adjustments when testing treatment effects with linear mixed
models. Statistics in medicine, 28(18), 2307-2324.
Moerbeek, M., and Wong, W. K. (2008). Sample size formulae for trials comparing group and
individual treatments in a multilevel model. Statistics in Medicine, 27(15), 2850-2864.
Pals, S. L., Murray, D. M., Alfano, C. M., Shadish, W. R., Hannan, P. J., and Baker, W. L.
(2008). Individually randomized group treatment trials: a critical appraisal of frequently used
design and analytic approaches. American journal of public health, 98(8), 1418-1424.
Roberts, C., and Roberts, S. A. (2005). Design and analysis of clinical trials with clustering
effects due to treatment. Clinical Trials, 2(2), 152-162.
Hoover, D. R. (2002). Clinical trials of behavioural interventions with heterogeneous teaching
subgroup effects. Statistics in medicine, 21(10), 1351-1364.
C.2 Sample size comparison
Table C.1 provides a comparison of empirical sample size calculated using respective formulae
from Heo et al. [137] and Moerbeek and Wong [131].
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Table C.1: Comparison of pnRCT sample size methods from Heo et al. [137] and [131]. Assuming
a standardised intervention effect δs = 0.5 and homoscedastic variances γ = 1.
ICC m
Heo [137] method Moerbeek [131] method
k mk npn Total k mk npn Total
0.01 10 7 70 70 140 7 70 65 135
0.05 10 8 80 80 160 9 90 70 160
0.1 10 9 90 90 180 11 110 75 185
0.01 5 13 65 65 130 14 70 64 134
0.05 5 14 70 70 140 15 75 66 141
0.1 5 15 75 75 150 17 85 69 154
0.2 10 12 120 120 240 15 150 84 234
0.4 10 17 170 170 340 22 220 99 319
0.6 10 22 220 220 440 29 290 111 401
0.2 5 17 85 85 170 20 100 74 174
0.4 5 21 105 105 210 27 135 83 218
0.6 5 24 120 120 240 34 170 90 260
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Appendix D
Information on empirical ICCs and
data extraction (chapter 7)
D.1 ICC estimates from other studies
Links to ICC estimates from other studies that may be used alongside those presented in this
Appendix:
 Baldwin et al. [57] contact author for ICC estimates from psychotherapy trials (therapist
ICCs) (on-line link from paper is no longer in use);
 Cook et al. [46] database of ICC estimates in surgery trials (centre and surgeon) avail-
able via downloadable excel spreadsheet from webpage https://www.abdn.ac.uk/hsru/
what-we-do/tools/index.php#panel177;
 Stuart et al. [171] database of ICCs from primary care trials (GP centre ICCs), at the time
of this thesis submission the paper was still under revisions .
D.2 Data extraction variables
The extraction variables included for the purpose of the HTA audit in chapter 7 are listed below.




 Data extraction date
 Auditor





 Trial type and design
 Number of arms
 Clinical area
 Setting















 Treatment induced clustering recognised
 Centre clustering recognised
 Sample size accounted for clustering?
 Sample size ICC treatment induced
 Sample size ICC centre
 Is sample size inflated in all arms?
 Evidence source for ICC
 Information on number of treatment clusters overall (if not reported per arm)
 Information on number of treatment clusters per arm (average, SD, range)
 Free text column regarding notes on clustering analysis and ICC
CONSORT adherence relating to items:
 CONSORT-NPT 4a, 7a, 12a, 13a (participant flow and diagram recorded separately), 15
 CONSORT-cluster 17a
 Free text column regarding whether and for what item it could be used for an exemplar.
D.3 Empirical ICC estimates
Table D.1 shows ICC values from the HTA iRCT identified in chapter 7. An extended table
including further information such as sample size, cluster information and status of outcome
and follow-up (primary/secondary) has been collected into an Excel sheet It was not possible to
include all this in the Appendix. I aim to include the excel file as an online supplementary file
to be submitted alongside a publication based on findings from chapter 7. For the purpose of
this thesis submission it is presently stored using ORDA - The University of Sheffield Research
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Data Catalogue and Repository which is hosted on Figshare via https://figshare.com/s/
d2645eb91b3ea9b65e0d.
Table D.1: ICC values from HTA studies





1 AESOPS Average drinks per
day (ADD) 12m
GP Practice 0.0570 NR NR Primary care
3 Body Therapy for Schizophrenia Calgary 10w Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia MANSA 10w Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Positive 6m Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Positive 10w Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia SAS 10w Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia SIX 6m Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia SIX 10w Physio 0.0010 NR NR Mental health
3 Body Therapy for Schizophrenia SAS 6m Physio 0.0070 NR NR Mental health
3 Body Therapy for Schizophrenia CAINS Expression
10w
Physio 0.0220 NR NR Mental health
3 Body Therapy for Schizophrenia CAINS Expression
6m
Physio 0.0230 NR NR Mental health
3 Body Therapy for Schizophrenia CAINS Experience
10w
Physio 0.0370 NR NR Mental health
3 Body Therapy for Schizophrenia CAINS Experience
6m
Physio 0.0410 NR NR Mental health
3 Body Therapy for Schizophrenia MANSA 6m Physio 0.0500 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Marder 6m Physio 0.0750 NR NR Mental health
3 Body Therapy for Schizophrenia Calgary 6m Physio 0.0860 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS General 10w Physio 0.0960 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Negative 10w Physio 0.0990 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Negative 6m Physio 0.1370 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS General 6m Physio 0.2050 NR NR Mental health
3 Body Therapy for Schizophrenia PANSS Marder 10w Physio 0.6780 NR NR Mental health
6 CASPER PHQ-9 4 m Case manager 0.0069 0.0000 0.0644 Mental health
6 CASPER PHQ-9 12m Case manager 0.0072 0.0000 0.0676 Mental health
7 CASPER Plus PHQ-9 4 m Case manager 0.0001 0.0000 0.0644 Mental health
10 COBRA PHQ-9 12m NR 0.0400 NR NR Mental health
12 Families for Health BMI z-score 12m Family-level 0.4713 0.3170 0.0396 Obesity
12 Families for Health BMI z-score 12m Families for Health
delivery group
0.0000 NR NR Obesity
13 Getting out of the house NEADL 12m Occupational
therapist/Physio
0.0012 NR NR Stroke
13 Getting out of the house SF36-v2 12m Occupational
therapist/Physio
0.0025 NR NR Stroke




0.0028 NR NR Stroke
13 Getting out of the house GHQ-12 (participant)
6m
NHS stroke services 0.0035 NR NR Stroke
13 Getting out of the house GHQ-12 (participant)
12m
NHS stroke services 0.0043 NR NR Stroke
13 Getting out of the house SF36-v2 6m Occupational
therapist/Physio
0.0051 NR NR Stroke
13 Getting out of the house NEADL 6m Occupational
therapist/Physio
0.0052 NR NR Stroke
13 Getting out of the house RMI 12m NHS stroke services 0.0057 NR NR Stroke
13 Getting out of the house RMI 6m NHS stroke services 0.0060 NR NR Stroke
13 Getting out of the house GHQ-12 (carer) 12m NHS stroke services 0.0066 NR NR Stroke




0.0075 NR NR Stroke
13 Getting out of the house SWOM 12m NHS stroke services 0.0093 NR NR Stroke
13 Getting out of the house SF36-v2 6m NHS stroke services 0.0099 NR NR Stroke
13 Getting out of the house RMI 6m Occupational
therapist/Physio
0.0111 NR NR Stroke
13 Getting out of the house SWOM 6m NHS stroke services 0.0123 NR NR Stroke
13 Getting out of the house RMI 12m Occupational
therapist/Physio
0.0134 NR NR Stroke
13 Getting out of the house GHQ-12 (carer) 12m Occupational
therapist/Physio
0.0136 NR NR Stroke
13 Getting out of the house NEADL 6m NHS stroke services 0.0155 NR NR Stroke
13 Getting out of the house NEADL 12m NHS stroke services 0.0171 NR NR Stroke
13 Getting out of the house GHQ-12 (carer) 6m Occupational
therapist/Physio
0.0176 NR NR Stroke
13 Getting out of the house GHQ-12 (carer) 6m NHS stroke services 0.0234 NR NR Stroke
13 Getting out of the house SWOM 6m Occupational
therapist/Physio
0.0289 NR NR Stroke
13 Getting out of the house SWOM 12m Occupational
therapist/Physio
0.0315 NR NR Stroke
13 Getting out of the house SF36-v2 12m NHS stroke services 0.0597 NR NR Stroke
14 IMPACT MFQ centred time
variable in model
Orthopaedic surgeon 0.0001 NR NR Mental health
15 KATMETAL EQ-5D 12m Orthopaedic surgeon 0.0000 0.0000 0.0250 O/R/MSK
15 KATMETAL EQ-5D 12m NHS Hospital 0.0060 0.0000 0.0700 O/R/MSK
15 KATMETAL EQ-5D 3m NHS Hospital 0.0000 0.0000 0.000* O/R/MSK
15 KATMETAL EQ-5D 3m Orthopaedic surgeon 0.0140 0.0000 0.1040 O/R/MSK
15 KATMETAL EQ-5D 60m Orthopaedic surgeon 0.0000 0.0000 0.000* O/R/MSK
15 KATMETAL EQ-5D 60m NHS Hospital 0.0000 0.0000 0.000* O/R/MSK
15 KATMETAL Operating time (min) NHS Hospital 0.4490 0.1720 0.7260 O/R/MSK
15 KATMETAL Operating time (min) Orthopaedic surgeon 0.5140 0.2780 0.7270 O/R/MSK
15 KATMETAL Oxford knee score
12m
NHS Hospital 0.0210 0.0000 0.0420 O/R/MSK
15 KATMETAL Oxford knee score
12m
Orthopaedic surgeon 0.0560 0.0000 0.1300 O/R/MSK
15 KATMETAL Oxford knee score 3m NHS Hospital 0.0000 0.0000 0.000* O/R/MSK
15 KATMETAL Oxford knee score 3m Orthopaedic surgeon 0.0070 0.0000 0.0570 O/R/MSK
15 KATMETAL Oxford knee score
60m
NHS Hospital 0.0000 0.0000 0.000* O/R/MSK
15 KATMETAL Oxford knee score
60m
Orthopaedic surgeon 0.0020 0.0000 0.0210 O/R/MSK
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15 KATMOBILE EQ-5D 60m NHS Hospital 0.0150 0.0000 0.0800 O/R/MSK
15 KATMOBILE EQ-5D 12m Orthopaedic surgeon 0.0240 0.0000 0.0800 O/R/MSK
15 KATMOBILE EQ-5D 3m Orthopaedic surgeon 0.0710 0.0210 0.1490 O/R/MSK
15 KATMOBILE EQ-5D 12m NHS Hospital 0.0400 0.0040 0.1030 O/R/MSK
15 KATMOBILE Oxford knee score
60m
NHS Hospital 0.0440 0.0000 0.1230 O/R/MSK
15 KATMOBILE EQ-5D 60m Orthopaedic surgeon 0.0190 0.0000 0.0650 O/R/MSK
15 KATMOBILE Operating time (min) Orthopaedic surgeon 0.1990 0.0730 0.3900 O/R/MSK
15 KATMOBILE EQ-5D 3m NHS Hospital 0.0600 0.0050 0.1330 O/R/MSK
15 KATMOBILE Oxford knee score
12m
NHS Hospital 0.0630 0.0230 0.1340 O/R/MSK
15 KATMOBILE Oxford knee score
12m
Orthopaedic surgeon 0.0590 0.0120 0.1340 O/R/MSK
15 KATMOBILE Oxford knee score 3m Orthopaedic surgeon 0.0680 0.0180 0.1300 O/R/MSK
15 KATMOBILE Oxford knee score 3m NHS Hospital 0.0730 0.0160 0.1580 O/R/MSK
15 KATMOBILE Operating time (min) NHS Hospital 0.1670 0.0920 0.2940 O/R/MSK
15 KATMOBILE Oxford knee score
60m
Orthopaedic surgeon 0.0510 0.0000 0.1210 O/R/MSK
15 KATPATELLA EQ-5D 60m NHS Hospital 0.0020 0.0000 0.0210 O/R/MSK
15 KATPATELLA EQ-5D 12m Orthopaedic surgeon 0.0400 0.0110 0.0760 O/R/MSK
15 KATPATELLA EQ-5D 3m NHS Hospital 0.0080 0.0000 0.0410 O/R/MSK
15 KATPATELLA EQ-5D 3m Orthopaedic surgeon 0.0050 0.0000 0.0320 O/R/MSK
15 KATPATELLA EQ-5D 12m NHS Hospital 0.0170 0.0000 0.0520 O/R/MSK
15 KATPATELLA Oxford knee score
12m
NHS Hospital 0.0270 0.0040 0.0710 O/R/MSK
15 KATPATELLA EQ-5D 60m Orthopaedic surgeon 0.0090 0.0000 0.0470 O/R/MSK
15 KATPATELLA Operating time (min) Orthopaedic surgeon 0.4450 0.3600 0.5240 O/R/MSK
15 KATPATELLA Oxford knee score 3m NHS Hospital 0.0410 0.0140 0.0870 O/R/MSK
15 KATPATELLA Oxford knee score
60m
NHS Hospital 0.0450 0.0160 0.0860 O/R/MSK
15 KATPATELLA Oxford knee score
12m
Orthopaedic surgeon 0.0470 0.0150 0.0940 O/R/MSK
15 KATPATELLA Oxford knee score 3m Orthopaedic surgeon 0.0500 0.0210 0.0870 O/R/MSK
15 KATPATELLA Operating time (min) NHS Hospital 0.3700 0.2540 0.4700 O/R/MSK
15 KATPATELLA Oxford knee score
60m
Orthopaedic surgeon 0.0370 0.0030 0.0740 O/R/MSK
16 OCTET Guided self-help Y-BOCS-OR 12m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help Y-BOCS-OR 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help Y-BOCS-OR 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help CORE-OM 12m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help CORE-OM 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help CSQ-8 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help GAD-7 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help PHQ-9 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help PHQ-9 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 MCS 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help WSAS 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help WSAS 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 PCS 12m Psychological
wellbeing practitioner
0.0020 NR NR Mental health
16 OCTET Guided self-help CORE-OM 3m Psychological
wellbeing practitioner
0.0030 NR NR Mental health
16 OCTET Guided self-help Y-BOCS-SR 12m Psychological
wellbeing practitioner
0.0040 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 PCS 6m Psychological
wellbeing practitioner
0.0040 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 MCS 12m Psychological
wellbeing practitioner
0.0070 NR NR Mental health
16 OCTET Guided self-help Y-BOCS-SR 3m Psychological
wellbeing practitioner
0.0090 NR NR Mental health
16 OCTET Guided self-help PHQ-9 12m Psychological
wellbeing practitioner
0.0110 NR NR Mental health
16 OCTET Guided self-help WSAS 12m Psychological
wellbeing practitioner
0.0120 NR NR Mental health
16 OCTET Guided self-help GAD-7 3m Psychological
wellbeing practitioner
0.0300 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 MCS 6m Psychological
wellbeing practitioner
0.0480 NR NR Mental health
16 OCTET Guided self-help Y-BOCS-SR 6m Psychological
wellbeing practitioner
0.0780 NR NR Mental health
16 OCTET Guided self-help GAD-7 12m Psychological
wellbeing practitioner
0.0820 NR NR Mental health
16 OCTET Guided self-help CSQ-8 6m Psychological
wellbeing practitioner
0.0970 NR NR Mental health
16 OCTET Guided self-help SF-36 v2 PCS 3m Psychological
wellbeing practitioner
0.1780 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-OR 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-SR 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT CORE-OM 12m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT CORE-OM 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT CSQ-8 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT GAD-7 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT PHQ-9 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
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16 OCTET Supported cCBT WSAS 3m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT WSAS 6m Psychological
wellbeing practitioner
0.0010 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-SR 3m Psychological
wellbeing practitioner
0.0030 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 PCS 12m Psychological
wellbeing practitioner
0.0110 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 MCS 6m Psychological
wellbeing practitioner
0.0180 NR NR Mental health
16 OCTET Supported cCBT PHQ-9 6m Psychological
wellbeing practitioner
0.0190 NR NR Mental health
16 OCTET Supported cCBT CORE-OM 3m Psychological
wellbeing practitioner
0.0260 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-OR 3m Psychological
wellbeing practitioner
0.0270 NR NR Mental health
16 OCTET Supported cCBT GAD-7 3m Psychological
wellbeing practitioner
0.0280 NR NR Mental health
16 OCTET Supported cCBT CSQ-8 6m Psychological
wellbeing practitioner
0.0410 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 MCS 12m Psychological
wellbeing practitioner
0.0900 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-SR 12m Psychological
wellbeing practitioner
0.0980 NR NR Mental health
16 OCTET Supported cCBT Y-BOCS-OR 12m Psychological
wellbeing practitioner
0.1090 NR NR Mental health
16 OCTET Supported cCBT GAD-7 12m Psychological
wellbeing practitioner
0.1510 NR NR Mental health
16 OCTET Supported cCBT WSAS 12m Psychological
wellbeing practitioner
0.1580 NR NR Mental health
16 OCTET Supported cCBT PHQ-9 12m Psychological
wellbeing practitioner
0.1600 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 PCS 6m Psychological
wellbeing practitioner
0.1640 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 PCS 3m Psychological
wellbeing practitioner
0.1820 NR NR Mental health
16 OCTET Supported cCBT SF-36 v2 MCS 3m Psychological
wellbeing practitioner
0.2250 NR NR Mental health
18 PEPS SPSI-R 72 w Problem-solving
therapy groupgroup
0.0100 0.0100 0.1700 Mental health





0.0100 0.0100 0.1500 Mental health
18 PEPS SFQ 72 w Problem-solving
therapy groupgroup
0.0700 0.0000 0.2900 Mental health
18 PEPS HADS-T 72 w Problem-solving
therapy groupgroup
0.1100 0.0000 0.2900 Mental health
19 PhysioDirect SF-36 v2 PCS 6m NHS Primary Care
Trust
0.0050 NR NR O/R/MSK
19 PhysioDirect SF-36 v2 PCS 6m GP Practice 0.0050 NR NR O/R/MSK
20 POWER+ EQ5-D 12m GP Practice 0.0140 0.0000 0.3600 Obesity
20 POWER+ Mean weight
reduction 12m
GP Practice 0.0150 0.0000 0.0900 Obesity
20 POWER+ Clinically important
weight reduction 12m
GP Practice 0.0180 0.0000 0.1600 Obesity
22 SARAH MHQ overall hand
function 12m
Hand therapist 0.0000 NR NR O/R/MSK
23 SHEAR Form 90: Alcohol
6mconsumption in
last 90 days
Clinician 0.0120 0.0001 0.6486 Mental health
24 START HADS-T 12m Psychology graduate 0.0000 0.0000 0.0700 Mental health
24 START HADS-T 18 m Psychology graduate 0.0000 0.0000 0.0700 Mental health
24 START HADS-T 8 m Psychology graduate 0.0000 0.0000 0.0800 Mental health
24 START HADS-T 4 m Psychology graduate 0.0200 0.0000 0.0900 Mental health
26 SWAP Group (intervention) Weight 6m Weight management
group
0.0130 0.0000 0.1050 Obesity
26 SWAP Group (intervention) Weight 12m Weight management
group
0.0010 0.0000 0.0760 Obesity
26 SWAP Group (intervention) Waist 6m Weight management
group
0.1170 0.0000 0.2650 Obesity
26 SWAP Group (intervention) Waist 12m Weight management
group
0.0800 0.0000 0.2030 Obesity
26 SWAP Group (intervention) SBP 6m Weight management
group
0.0320 0.0000 0.1350 Obesity
26 SWAP Group (intervention) SBP 12m Weight management
group
0.0200 0.0000 0.1080 Obesity
26 SWAP Group (intervention) DBP 6m Weight management
group
0.1560 0.0000 0.3220 Obesity
26 SWAP Group (intervention) DBP 12m Weight management
group
0.0570 0.0000 0.1690 Obesity
26 SWAP Group (intervention) BMI 6m Weight management
group
0.0280 0.0000 0.1290 Obesity
26 SWAP Group (intervention) BMI 12m Weight management
group
0.0010 0.0000 0.0760 Obesity




0.0010 0.0000 0.0840 Obesity




0.0010 0.0000 0.0760 Obesity




0.0010 0.0000 0.0840 Obesity




0.0010 0.0000 0.0760 Obesity




0.0010 0.0000 0.0840 Obesity




0.0460 0.0000 0.1510 Obesity




0.0390 0.0000 0.1460 Obesity





0.0010 0.0000 0.0770 Obesity




0.0190 0.0000 0.1150 Obesity
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0.0010 0.0000 0.0780 Obesity





0.0010 0.0000 0.0850 Obesity





0.0010 0.0000 0.0780 Obesity





0.0810 0.0000 0.2130 Obesity





0.0350 0.0000 0.1350 Obesity





0.0650 0.0000 0.1870 Obesity





0.0630 0.0000 0.1790 Obesity





0.0010 0.0000 0.1010 Obesity





0.0500 0.0000 0.1730 Obesity




0.0280 0.0000 0.1470 Obesity




0.0010 0.0000 0.1020 Obesity
26 SWAP Nurse (control) Weight 6m Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) Weight 12m Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) Waist 6m Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) Waist 12m Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) SBP 6m Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) SBP 12m Nurse 0.0550 0.0000 0.2220 Obesity
26 SWAP Nurse (control) DBP 6m Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) DBP 12m Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) BMI 6m Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) BMI 12m Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) Lost 5% of body
weight 6m
Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) Lost 5% of body
weight 12m
Nurse 0.0140 0.0000 0.1210 Obesity
26 SWAP Nurse (control) Lost 10% of body
weight 6m
Nurse 0.0010 0.0000 0.1020 Obesity
26 SWAP Nurse (control) Lost 10% of body
weight12m
Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) Food knowledge
assessment 6m
Nurse 0.0010 0.0000 0.1010 Obesity
26 SWAP Nurse (control) Food knowledge
assessment 12m
Nurse 0.0010 0.0000 0.0860 Obesity
26 SWAP Nurse (control) Food craving index –
frequency domain 6m
Nurse 0.0500 0.0000 0.2220 Obesity
26 SWAP Nurse (control) Food craving index –
frequency domain
12m
Nurse 0.0800 0.0000 0.2800 Obesity
26 SWAP Nurse (control) Food craving index –
strength domain 6m
Nurse 0.0930 0.0000 0.3190 Obesity
26 SWAP Nurse (control) Food craving index –
strength domain 12m
Nurse 0.0170 0.0000 0.1300 Obesity
26 SWAP Nurse (control) Three factor eating –
cognitive restraint
domain 6m
Nurse 0.0160 0.0000 0.1430 Obesity
26 SWAP Nurse (control) Three factor eating –
cognitive restraint
domain 12m
Nurse 0.0970 0.0000 0.3190 Obesity
26 SWAP Nurse (control) Three factor eating –
uncontrolled eating
domain 6m
Nurse 0.2370 0.0000 0.6070 Obesity
26 SWAP Nurse (control) Three factor eating –
uncontrolled eating
domain 12m
Nurse 0.1070 0.0000 0.3460 Obesity
26 SWAP Nurse (control) Three factor eating –
emotional eating
domain 6m
Nurse 0.1150 0.0000 0.3680 Obesity
26 SWAP Nurse (control) Three factor eating –
emotional eating
domain 12m
Nurse 0.1830 0.0000 0.5010 Obesity
26 SWAP Nurse (control) IPAQ – METS
minutes/week domain
6m
Nurse 0.0010 0.0000 0.1240 Obesity
26 SWAP Nurse (control) IPAQ – METS
minutes/week domain
12m
Nurse 0.0010 0.0000 0.1000 Obesity
26 SWAP Nurse (control) IPAQ – sitting
domain domain 6m
Nurse 0.0010 0.0000 0.1210 Obesity
*NR:Not reported; O/R/MSK: Orthopedics/ Rheumatology/ Musculoskeletal (including back pain)
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